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ZUSAMMENFASSUNG 
Staphylococcus aureus ist nicht nur ein häufiger Besiedler des Vestibulum nasi aller Säugetiere, sondern auch Verursacher vielfältiger Infektionen in Krankenhäu-sern und der nicht hospitalisierten Bevölkerung. Beim Menschen reicht das weite In-fektionsspektrum von Infektionen der Haut bis hin zur lebensbedrohlichen Endokar-ditis. Besonders besorgniserregend sind, auf Grund der begrenzten Möglichkeiten der antibiotischen Therapie, Infektionen mit Methicillin-resistenten S. aureus (MRSA). Seit 2004 wurden MRSA des klonalen Komplexes CC398 weltweit als Besiedler und Infektionserreger bei Nutz- und Haustieren nachgewiesen. Seit dieser Zeit wächst die Besorgnis um damit verbundene gesundheitliche Risiken für den Menschen.  In der vorliegenden Arbeit wurde die Populationsstruktur des klonalen Kom-plexes CC398 durch Analyse von Mutationen in 97 chromosomal lokalisierten Haus-haltsgenen bei 195 Isolaten untersucht. Diese stammen von 11 verschiedenen Wirtsspezies aus mehreren Ländern. Des Weiteren wurden bei ausgewählten Isola-ten einer bestimmten Subpopulation die Fähigkeit an Fibronectin zu binden und die Phagozytoserate durch Granulozyten von verschiedenen Wirtsspezies untersucht. Um tiefere Einblicke in die genetische Ausstattung dieser Subpopulation zu erhalten, wurden Ganzgenomsequenzierungen für repräsentative Isolate durchgeführt. Die vorliegende Arbeit erweitert unsere Kenntnisse zur Populationsstruktur des klonalen Komplexes CC398. Insbesondere zeigte sich, dass es eine speziell in Pferde-Kliniken verbreitete Subpopulation gibt, die als Besiedler und Infektionserre-ger bei Pferden und auch als nasaler Besiedler bei Menschen mit engem Kontakt zu diesen Tieren auftritt. Bisher wurden Isolate dieser Subpopulation nur sehr selten als Infektionserreger beim Menschen nachgewiesen. Offenbar kann diese Subpopulation Menschen und Pferde effizient besiedeln, ist aber nicht gegen die Wirtsimmunität ge-schützt. Die vergleichende Genomanalyse zeigte das Auftreten einer neuen Pathoge-nitätsinsel, sowie zweier bisher noch nicht beschriebener Prophagen bei Isolaten die-ser Subpopulation. 
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SUMMARY 
Staphylococcus aureus is not only a frequent nasal coloniser of all mammals and birds, but also is a common cause of a wide range of infections in both hospitals and the community. In humans, S. aureus is associated with a wide spectrum of dis-eases from skin infections to life-threatening endocarditis. Infections caused by methicillin-resistant S. aureus (MRSA) are of particular concern due to limited treat-ment opportunities. Since the early 2000s, a particular MRSA clonal complex (CC398) was widely disseminated as a coloniser and pathogen in economically important live-stock and companion animals worldwide. Since then, CC398 is of increasing concern to pose a risk to public health. In this study, we investigated the population structure of CC398 through mu-tation discovery at 97 genetic housekeeping loci, which are distributed along the S. 
aureus chromosome within 195 CC398 isolates, collected from 11 different host spe-cies and various countries. Furthermore, we investigated the phenotypic characters of a certain sub-clone within CC398 by studying its ability to adhere to fibronectin and to invade neutrophils from various host species. To gain a better insight into the genetic determinants of this CC398 sub-clone, we have applied whole genome se-quencing approach on eight representative CC398 isolates. This study provided a novel insight into the phylogeny of CC398 concerning the spread of a specific MRSA-CC398 sub-clone within equine settings, which causes infections in horses and nasal colonisation of humans that are in close contact with these horses. Of note, it remained extremely rare among S. aureus isolates from hu-man infections. Furthermore, this MRSA-CC398 sub-clone can initiate colonisation in both human and horse efficiently; however, it was not generally protected from the host immune system response. Lastly, the comparative genomic analysis of CC398 revealed a novel pathogenicity island and two prophages that were harboured by cer-tain CC398 isolates.  
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1 INTRODUCTION 
1.1 Staphylococci 
In earlier times, several scientists had observed cocci shaped bacteria in clini-cal specimens such as pus and wound secretions. Although cocci bacteria exhibited different morphological characters under the microscope, the German surgeon Bill-roth believed that all cocci represented different life cycle stages of the same micro-organism. It was the merit of the British surgeon Alexander Ogston to introduce the discrimination between streptococci and staphylococci in 1881. As staphylococci ap-pear as grape-like clusters under the microscope, he deduced the name from Staphy-
lococcus, Greek for “bunch of grapes” [1]. Staphylococci belong to the family Staphylo-
coccaceae and are Gram-positive cocci, non-motile, non-spore forming, and faculta-tive anaerobic bacteria that produce catalase enzyme. 
1.2 Staphylococcus aureus  
In 1884 Anton J. Rosenbach (1842-1923), a German surgeon, isolated two strains of staphylococci, which he named according to the pigmented appearance of their colonies: Staphylococcus aureus (Latin aurum, “gold”) (Figure 1.1), and Staphy-
lococcus albus (Latin albus, “white”) (later called epidermidis). The genus Staphylo-
coccus contains 71 identified species (http://www.bacterio.cict.fr/), which includes pathogens and non-pathogens. Rosenbach showed that S. aureus caused wound infec-tions and furunculosis, while S. epidermidis was a natural part of the skin flora [2]. S. 
aureus produces coagulase, an enzyme that coagulates the host’s plasma by activating prothrombin, which is diagnostically important for differentiating S. aureus from oth-er coagulase-negative staphylococci.     
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S. aureus colonises the anterior nares of approximately 25 - 30% of the healthy human population [3]. Although a large number of humans are colonised with S. au-
reus, only a little fraction of them develop an infection. Hence, S. aureus is compara-tively harmless commensal bacteria (facultative pathogen) unless it enters the body through a cut in the skin, and then overcomes the host’s immune system. Neverthe-less, S. aureus is a common cause of skin and soft tissue infections such as abscesses, folliculitis and post-operative wound infections [4]. Previous studies reported that persistent carriers of S. aureus are at higher risk for developing endogenous bacte-raemia compared with the non-carriers [5]. 
1.3 Staphylococcus aureus and the waves of antibiotic resistance 
The development of antibiotics was one of the greatest medical advances for all humankind. Antibiotics were considered as miracle drugs, which eradicated the fear of death due to bacterial infections. In the early 1940s, the introduction of peni-cillin (a β-lactam antibiotic) into clinical use brought the major infections under con-trol; however, penicillin-resistant Staphylococci isolates were reported two years lat-er [6]. This resistance to penicillin is mediated by penicillinase (β-lactamase) enzyme encoded by the blaZ gene, which cleaves the β-lactam ring of the penicillin molecule leading to its ineffectiveness. By the late 1960s, reports showed that more than 80% of staphylococcal isolates were resistant to penicillin [7]. To overcome the effect of 
Figure ‎1.1. Staphylococcus aureus (yellow) and human 
neutrophil cell (red). Courtesy: National Institute of Al-lergy and Infectious Diseases. 
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penicillinase, a semisynthetic antibiotic, methicillin, was introduced into clinical prac-tice. Similarly, the launch of methicillin was rapidly followed by reports of methicil-lin-resistant S. aureus (MRSA) isolates [8–10]. Since then, the numbers of MRSA iso-lates have frequently increased worldwide [11,12]. Hence, new antibiotics, such as gentamicin, vancomycin and ceftaroline were developed and used to treat MRSA in-fections [13]. However, a similar path of bacterial resistance events has occurred with the introduction of novel antibiotics in clinical practice (Figure ‎1.2; [14]). 
1.4 Staphylococcus aureus genome structure  
The first S. aureus genome was sequenced and reported in 2001 (Kuroda M, 2001). The S. aureus genome is approximately 2.8 Mega-base (Mb) pairs in size with nearly 2,600 open reading frames and has a G+C content of approximately 33% [15]. To date, approximately 4175 S. aureus genomes are available on the National Centre for Biotechnology Information (NCBI). The comparison of this huge sequence data revealed that the S. aureus genome structure could be divided into two main compo-nents: core genome (genetic backbone), and the accessory genome. 
1.4.1 Core genome The core genome is the genetic backbone for all S. aureus strains. This core ge-
nome constitutes ≈ 75% of the S. aureus genome, and encodes housekeeping genes that are highly conserved among all S. aureus strains and essential for the growth and 
Figure ‎1.2. The timeline of antibiotic discovery, introduction and overuse. Figure adapted by the author from Hede, 2014 [14]. 
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survival of S. aureus [15–17]. In contrast to the core genome, the core variable ge-nome is a lineage specific and carries more than 700 variable genes. These genes en-code surface binding proteins, virulence factors and toxins, which are known to in-teract with the hosts’ immune system [15,17]. The sequence variation in the core ge-nome is due to either single nucleotide polymorphisms (SNPs) or large variation that range from few nucleotides to several kilo-base (kb) pairs (insertions or deletions of repetitive elements) [15]. 
1.4.2 Accessory genome  The accessory genome constitutes ≈ 25% of the S. aureus genome and is com-posed mainly of mobile genetic elements (MGEs) that vary among the different S. au-
reus strains. These MGEs are DNA fragments that can be moved between different bacteria [16,17]. MGEs are known to carry genes encoded for antimicrobial resistant, heavy metal resistance, virulence determinants and host adaptation factors [18]. The MGEs have G+C content comparable to the chromosomal DNA, suggesting that the various S. aureus lineages acquired the MGEs via horizontal gene transfer [19,20]. S. 
aureus can comprise several types of MGEs, including the staphylococcal cassette chromosome elements, plasmids, transposons, bacteriophages, and pathogenicity is-lands. 
1.4.2.1 Staphylococcal cassette chromosome mec The characteristic feature of MRSA strains is the acquisition of a mobile genet-ic element called the staphylococcal cassette chromosome mec (SCCmec). This SCC-
mec element consists of two essential components; the mec gene complex, which is considered as the essential determinant for broad-spectrum β-lactam antibiotics re-sistance; and the cassette chromosome recombinase (ccr) gene complex, which is in-volved in the mobilization and integration of SCCmec element into the S. aureus chromosome [21]. The mec gene complex carries mecA gene and genes that regulate its expression (mecR1 (promoter) and mecI (repressor)). The mecA gene (2.1 kb) en-codes the penicillin-binding protein (PBP2a or PBP2’) that has low affinity for penicil-lin and other β-lactam antibiotics [22,23]. The ccr gene complex comprises of seven to eight open reading frames (ORFs) and the ccr gene is placed in the core of this gene complex. Up to the present time, three different ccr genes have been reported (ccrA, 
ccrB, and ccrC) [24]. In contrast to the high similarity of the mecA genes, the ccr genes 
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are greatly diverse among staphylococcal species. In addition to the mec and ccr genes complexes, SCCmec element contains so-called joining regions (J-regions), which were classified into J1, J2, and J3. These J-regions may carry additional antimi-crobial resistance or virulence determinants [24,25]. J1-3 regions are highly diverse, and their sequences are used for the subtyping of various SCCmec types [24,25].  SCCmec elements have been classified into distinct types and subtypes based on the combination of the ccr gene complex type and the class of the mec gene com-plex. To date, eleven different SCCmec types were identified (Figure ‎1.3) [21,26–33]. The size of SCCmec types IV and V (≈24 kb and ≈28 kb, respectively) is comparable, and they are the smallest among the remaining SCCmec types [27,28]. However, SCCmec IV carries only the recombinase, regulatory, and structural genes for the methicillin resistance, and it lacks the restriction-modification system compared to SCCmec V [34]. Hence, SCCmec IV may have a lower cost on fitness; therefore, it is frequently acquired by various S. aureus lineages such as ST22, which is a major cause of healthcare-associated infections worldwide [27,28,34,35].   
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Figure ‎1.3. The structures of the eleven identified SCCmec element types. The pink and blue belts indicate the location of mec- and ccr-gene complexes, respectively. Fig-ure adapted by the author from Hiramatsu et al., 2013 [24]. 
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1.4.2.2 Plasmids Plasmids are typically circular DNA molecules, which often carry genes that are beneficial for bacterial survival, including genes that confer resistance to various antibiotic classes such as aminoglycosides, β-lactam and macrolides. In addition, genes encoded for heavy metal resistance and virulence factors such as exfoliative toxin B are frequently found on plasmids [36,37]. S. aureus strains can carry up to several plasmids that vary in their gene content and functions.  
1.4.2.3 Bacteriophages Bacteriophages (or so-called phages for short) are viruses that infect bacteria. They have a narrow host range, and their global population was estimated to be on the order of 1031 [38]. Bacteriophages attach to specific receptors on the surface of bacteria and inject their phage DNA into the host cell. They are classified into two main distinctive groups: virulent (lytic) and temperate. Virulent (lytic) phages drive the host cell to produce and assemble new phage particles, followed by bacterial cell lyses due to the release of progeny phages. The majority of the phage population is temperate phages, which typically establish a long-term relationship with the host cell. Temperate phages DNA were found to integrate into specific sites of the S. aureus genome as prophage and play a significant role in its diversity and evolution [39]. Prophages can affect the pathogenicity of S. aureus either by carrying additional viru-lence factors or by interfering chromosomal virulence genes [39]. Several virulence factors encoded by prophages have been previously characterized, such as the im-mune evasion cluster (IEC), which encodes the immune-modulating proteins staphy-lokinase (sak), the chemotaxis inhibitory protein (chip), the staphylococcal comple-ment inhibitor (scin) [40–46]. Furthermore, other prophages encode virulence mole-cules that have a destructive effect on the human white blood cells, such as enterotox-ins and Panton-Valentine leukocidin (PVL) [47]. 
1.4.2.4 Pathogenicity islands The S. aureus pathogenicity islands (SaPIs) are type of MGEs, which are ≈ 14-17 kb in size and encode additional superantigens and virulence genes [48]. In S. au-
reus, several SaPIs were detected and have been sequenced [48,49]. Integrase, repli-cation and terminase genes are the common features among all detected SaPIs [49,50]. The dissemination of SaPIs among various S. aureus lineages occurs via a 
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helper phage and horizontal gene transfers [51]. Certain S. aureus strains have adapted to their ruminant niche by encoding coagulation factor, which was carried by a certain SaPI family [52].  
1.5 Staphylococcus aureus virulence factors  
S. aureus has a broad range of virulence factors that enhance its pathogenicity. 
S. aureus carries several surface proteins that are covalently attached to the pepti-doglycan layer (Figure ‎1.4). These surface proteins, or so-called microbial surface components recognizing adhesive matrix molecules (MSCRAMMs), mediate the ad-herence of S. aureus to the host tissue; therefore, they play an important role in the colonization and infection process [53–56]. For instance, (1) staphylococcus protein A binds the fragment crystallisable region of the host’s immunoglobulin G (IgG) anti-bodies and prevents the opsonisation; (2) fibronectin-binding proteins are common adhesins of S. aureus strains that contribute to the adherence of S. aureus to the host plasma clots; (3) the collagen-binding protein arbitrates bacterial adherence to colla-gen substrates and collagenous tissues; (4) clumping factors that mediate adherence of bacteria to immobilized fibrinogen and blood clots [54–56].  As soon as S. aureus adheres to the host tissues, it is able to escape the host de-fence mechanisms in several ways, such as biofilm and capsule formation [57–59]. In addition, S. aureus can form small-colony variants that hide in the host cells and are relatively protected from antibiotics [60–62]. During infection, S. aureus strains pro-duce various numbers of enzymes, such as lipases, proteases, and elastases, which are able to destroy the host tissues [63–66]. Furthermore, some S. aureus strains se-crete toxins (exfoliative toxins, α-toxins) that facilitate their spread among host tis-sues (Figure ‎1.4).    
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Figure ‎1.4. Virulence determinants of Staphylococcus aureus. TSST-1, toxic shock syndrome toxin 1; chip, chemotaxis inhibitory protein; sak, immune-modulating proteins staphylokinase; scin, staphy-lococcal complement inhibitor. Figure created by author and adapted from Gordon et al., 2008 [55]. 
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1.6 Staphylococcus aureus and the host’s innate immune system  
Humans and animals are frequently exposed to the invasion of pathogens and have developed systems of immune defence to eliminate infective pathogens in their body. The immune system is comprised of two main parts: innate and acquired im-munity. The innate immune system is the first line of host defence against pathogens and is mediated by phagocytes including neutrophils and macrophages [67,68]. Ac-quired immunity is involved in the eradication of pathogens in the late phase of infec-tion, and the generation of immunological memory. Neutrophils are the first cells re-cruited from the bloodstream to sites of infection [69–72]. In healthy adult humans, the bone marrow produces, in the steady state, approximately 1 to 2 x 1011 neutro-phils daily [72].  When S. aureus breach the host’s skin and mucous surfaces, it is challenged by 
the host’s innate immune system. The S. aureus infection stimulates a strong inflam-matory response, comprising the migration of neutrophils to the site of infection. Hence, S. aureus has evolved mechanisms to resist this frontline of host’s neutrophils such as hiding from recognition by neutrophils, blocking the phagocyte receptors or lysing the phagocytes (Figure ‎1.5). Some of these mechanisms are mentioned in the previous section (‎1.5), including the capsule and biofilm formation. Additionally, some S. aureus strains acquired a prophage, by horizontal gene transfer, that encodes PVL toxin [73]. PVL is known to lyse neutrophils, which are attempting to engulf and kill S. aureus, by forming pores in its cell membranes (Figure ‎1.5) [74–77]. Another important mobile genetic element that could be acquired by S. aureus, is the phage 
φSa3 that carries genes encoding human specific immune-modulating proteins (chip, 
scin and sak) [40,41,43,78]. These inhibitory proteins help S. aureus to prevent the human neutrophils response and phagocytosis [79].  
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1.7 Molecular typing of Staphylococcus aureus 
Typing refers to the identification of different bacterial strain within a certain species. S. aureus typing is the essential key for epidemiological studies, outbreak analysis and infection control. S. aureus can be typed either by phenotypic or molecu-lar methods. For several years, phenotypic typing methods such as observing the col-ony morphology, biochemical reactions, toxin production, antibiotic susceptibility (antibiogram) and bacteriophage typing have been used. However, the poor discrim-inatory power, the lack of reproducibility, time consuming and the high proportion of non-typable isolates are the main disadvantages of phenotypic typing of S. aureus. Therefore, these phenotyping methods were either replaced by or combined with molecular genotyping typing methods. Genotyping classifies the bacterial strains 
based on distinctive genetic “fingerprints” patterns [80].  
Figure ‎1.5. Staphylococcus aureus (yellow) escaping phagocytosis by lysing the human 
neutrophils (red). Courtesy: National Institute of Allergy and Infectious Diseases. 
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1.7.1 Pulsed-field gel electrophoresis Pulsed-field gel electrophoresis (PFGE) was developed in 1984 for the karyo-typing and separation of yeast DNA [81]. PFGE is based on digestion of bacterial DNA using rare-cutting restriction enzymes (macro-restriction) that recognize certain en-donuclease cleavage sites, which are distributed over the bacterial genome. In 1987, PFGE approach was used for the genotyping of Escherichia coli [82,83]. In the 1990s, 
PFGE has been considered as the “gold standard” among the molecular typing meth-ods for S. aureus typing [84,85]. The DNA fragments resulting from the digestion of S. 
aureus genome with rare-cutting enzymes are 10-800 kb in length and can be sepa-rated on agarose gels under “pulsed-field” electrophoresis condition in which the po-larity of the electric field varies periodically. Subsequently, the separated DNA frag-ments form a particular band pattern for each S. aureus lineage. In contrast to phage typing, PFGE provides improved reproducibility and high discriminatory power, al-lowing successful investigations of different S. aureus outbreaks. However, results in-consistency between different laboratories and interpretation struggles are the main disadvantage of PFGE [86,87].  
1.7.2 Multilocus sequence typing Multilocus sequence typing (MLST) is a sequence based genotyping method, which was introduced, in 2000, for the unambiguous characterisation of S. aureus [88]. MLST involves the amplification and sequencing of seven housekeeping genes (each locus ≈ 450–500 bp in length) in the S. aureus genome [88]. For each locus, the sequences are compared to previously identified alleles via the MLST website (http://www.mlst.net) and hence a discriminatory allelic profile (seven integers), so-called the sequence type (ST), for each bacterial isolate can be described. Using the Based Upon Related Sequence Types (BURST) algorithm, related S. aureus strains could be grouped to distinct clonal complex (CC) [89]. The major advantage of the MLST typing approach is the ability to compare results obtained from various studies through web-based database. However, the lack of sub-typing within the distinct clones, the high cost and the time consumed for analysis are considered the main dis-advantages of the MLST approach.  
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1.7.3 Staphylococcal protein A typing Staphylococcal protein A (spa) is a S. aureus surface protein, which plays a sig-nificant role in the evasion of host immune responses by binding to the hosts’ immu-noglobulin G (IgG) [90]. The spa gene contains the conserved fragment crystallisable (Fc) binding domain and the X-region (Figure ‎1.6). This X-region consists of poly-morphic tandem repeat sequences (≈ 24 bp per each repeat). Spa typing is based up-on sequence analysis of these variable number tandem repeats. The repeat sequences are assigned to certain numeric code. Strains with different repeat sequences are as-signed definite spa types based on the comparison to an international database (http://spaserver.ridom.de). Similar to MLST typing, spa typing provides proper dis-criminatory power that enables the national and international investigation of S. au-
reus outbreaks [91–93]. However, the most important advantages of spa typing over MLST are its cost-effectiveness and simplicity, since it requires sequencing only a sin-gle locus. Nevertheless, it was shown that infrequently spa typing could provide mis-leading information, which might be due to recombination events concerning the spa locus [92,94].  
 
Figure ‎1.6. Structure of the staphylococcal protein A gene. The fragment crystallisable (Fc) binding domain is represented in yellow colour, while the repeats-region is represented in red colour. Red ar-rows indicate the annealing sites for the forward 1113F and the reverse 1517R primers.  
1.7.4 SCCmec typing The type of the SCCmec element can be identified based on the determination of the mec complex structure and the different types of ccr genes using polymerase chain reaction (PCR)-based approaches. Several approaches were developed till now, however, two PCR methods are commonly used for this determination, either the 
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multiplex PCR developed by Oliveira et al. that differentiates SCCmec type I to IV or the method developed by Ito et al. that involves several PCR assays [26,34,95]. How-ever, both methods showed discrepancies in the results for the same MRSA isolate [96,97]. Hence, another multiplex PCR assay was established to determine the struc-ture of SCCmec type I to V [98,99]. In addition, the multiplex PCR assay from Oliveira et al. has been updated to include type V and to improve the detection discriminatory power of SCCmec type I to IV [100]. Kondo et al developed a convenient system for SCCmec typing based on six multiplex PCRs that identify the ccr gene complex, the 
mec gene complex and the specific structures in the J regions [101]. However, this method is practicable for routine applications, since the large numbers of required PCR reactions are time consuming [101]. These entire methods share one disad-vantages in common that they determine different structural properties of SCCmec [102,103]. Hence, a single standardised assay for the determination of the SCCmec structure and type need to be developed.  
1.8 Population structure of methicillin-resistant Staphylococcus aureus 
In the 1960s, MRSA was first identified as a healthcare-associated (HA-MRSA) pathogen, which caused nosocomial infections [11]. However, community-associated MRSA (CA-MRSA) infections were detected in human with no prior health care expo-sure [104].  Previously, the population structure of S. aureus, especially MRSA, has been studied using several well-established typing methods, including PFGE [105], MLST combined with SCCmec typing [12], single nucleotide polymorphisms (SNPs) analysis [94,106,107] and whole genome sequencing approach [108]. The main findings of these studies could be summarized in as followed (i) the population structure of S. 
aureus is highly clonal [12,89], (ii) the MRSA strains could be assigned to five distinct genotypic lineages [12], and (iii) the SCCmec element was introduced on several oc-casions into different phylogenetic lineages of S. aureus [12,20,94,109]. However, in sections 1.8.1 and 1.8.2, below, we review the evolutionary history of both HA-MRSA and CA-MRSA in more details.  
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1.8.1 Healthcare-associated MRSA HA-MRSA is highly disseminated in hospitals worldwide [110]. However, the prevalence rate of HA-MRSA varies among the different countries. For instance, the Netherlands and Scandinavia have low HA-MRSA prevalence rates (≤ 1%), while the highest rates (> 50%) were reported in North and South America, Asia and Malta [111–114]. HA-MRSA describes the epidemiological behaviour of certain MRSA strains that are very successful, transfer at higher frequency between patients, and cause epidemic levels of infections in hospitals [115,116].  PFGE technique had been useful for detecting newly emerging MRSA clones only at a local level [117]. Enright et al. applied both MLST and SCCmec typing meth-ods on a large international collection of S. aureus (912 MSSA and MRSA isolates), and demonstrated that only five CCs (CC5, CC8, CC22, CC30 and CC45) were observed among the MRSA strains [12]. Another study has shown that a predominant epidemic MSSA genotype shared a common MLST allelic profile (ST250) with the first MRSA strains from England, hence, it was suggested that MSSA ST250 is the ancestral geno-type of the first MRSA [118]. Later, Robinson et al. demonstrated the multiple emer-gences of MRSA by proposing that the two MRSA clones (ST247 and ST257) have emerged from the MRSA clone ST250 by stepwise evolution, while the MRSA clone ST254 has emerged independently [119]. Previous studies have reported the impact of recombination events on the evolution of MRSA. For instance, the MRSA ST239 has originated through the acquisition of ≈557 kb and ≈2220 kb chromosomal fragments from ST30 and ST8, respectively [120–122]. The successful dissemination of ST239 in several countries [122,123] may emphasise the influence of recombination events on the emergence of new pandemic clones [121]. Since MLST methods indexes variation at seven housekeeping genes only, it delivers a limited resolution and discriminatory power to elucidate the evolution of different MRSA lineages [106].  Previous studies based on genome-wide SNPs discovery from international MRSA isolate collections demonstrated that the MRSA genomes evolve much faster than previously known (one point mutation every six to eight weeks) [106,108]. An-other study based on SNPs analysis revealed that MRSA CC5 lineage has evolved sev-eral times through the acquisition of multiple SCCmec elements repeatedly into MSSA-CC5 strains [94]. Holden et al. demonstrated that the successful epidemic 
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spread of EMRSA-15 strains, a HA-MRSA in United Kingdom, is due to mutations that were associated with the evolution of resistance to fluoroquinolones [35]. Similarly, based on whole genome sequencing of a large set of CC30 isolates, McAdam et al. identified the existence of four independent sub-lineages of CC30 [124]. In addition, based on phylogeographic analysis, the authors demonstrated that transmission of CC30 from hospitals in London and Glasgow to regional health-care settings was due to patient transfers [124].  Another study has shown a frequent transmission of the HA-MRSA ST225 clone that had been emerging since two decades in Central Europe [106]. The inter-continental spread and the hospital transmission of MRSA ST239 were demonstrated based on whole genome sequencing approach [108].  
1.8.2 Community-associated MRSA The earliest reported infection cases of community-associated MRSA (CA-MRSA) were caused by a USA400 strain [125]. CA-MRSA clones differ from HA-MRSA by being resistant to a limited number of antibiotics, usually harbour SCCmec IV, V or VII and Panton-Valentine leukocidin (PVL) genes [27,110]. The frequent acquisition of the PVL toxin is associated with the tendency for CA-MRSA strains to cause skin, soft tissue and necrotising pneumonia infections [126–128].  Several CA-MRSA clones with different genetic background have emerged in certain parts of the world. For instance, CA-MRSA clone USA300 is the predominant cause of infections in the United States community [129,130]. In addition, this CA-MRSA clone has replaced HA-MRSA strains in North America [131]. In Europe, the PVL positive ST80- SCCmec IV (CC80) is the most frequent and widely disseminated CA-MRSA strain [132–134]. The CA-MRSA lineages ST1, ST5, ST9, ST22, ST30 and ST59 were reported in Germany in 2005; however, they have not widely spread in the German community [132].  A previous study based on SNPs analysis revealed that MRSA CC8 has accumu-lated an increasing number of antibiotic resistances over time [135]. It was suggested that the emergence of CA-MRSA lineages ST8, ST30, ST59 and ST80 is due to inter-continental transmission between the North and South America, Europe, North Africa and East Asia. In addition, it was claimed that ST8 has been spread from the USA to 
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Europe, while ST80 was transmitted from the Middle East to Europe and then to Asia [136]. A recent study, based on whole genome sequencing revealed that ST80 isolates from Denmark have acquired a novel type SCCmec IV with an integrated fractional plasmid, and three integrated prophages encoding PVL and immunomodulatory genes (sak and scn) [137].  Another study based on comparative genomic analysis of multi-drug resistant ST59 strains, a clone that predominant in Taiwan, has detected truncated hsdM and 
hsdS genes that encode the restriction-modification system. Such deficiency in the re-striction-modification system may have contributed to the acquisition of mobile ge-netic elements from enterococci, which confer multi-drug resistance [138]. A recent study, based on genome-wide SNPs discovery has demonstrated that certain sub-lineages within CC121, a S. aureus clone that commonly found as MSSA, were associ-ated with specific clinical phenotypes [107]. 
1.9 MRSA in animals 
In addition to being a human pathogen, S. aureus causes a wide spectrum of in-fections in economically essential livestock and companion animals [139–141]. In 1972, MRSA was reported from cases of bovine mastitis [142]. Since then, reports of MRSA from animals have increased dramatically [141,143–148]. Similar to human, MRSA can colonize the skin and nasal mucosa of healthy animals. Several studies sug-gested that the animals might act as a potential source of zoonotic MRSA infections in human [149–155].  The population genetic studies have identified genotypes that are associated with specific host species (Figure ‎1.7). For instance, the MRSA CC1, CC5, CC8 and CC398 were found among ruminants [156,157], while CC1, CC30 and CC398 are fre-quently found in pigs [141,158]. The MRSA lineages isolated from companion animals tend to reflect the genetic backgrounds of the human MRSA strains [150,159–161], such as CC5, CC8 and CC22 in dogs and cats [152,162] (Figure ‎1.7). A previous study based on SNPs analysis have revealed that the MRSA CC5 poultry strains have origi-nated in humans and transmitted to poultry, where it subsequently acquired avian- specific MGEs [163]. In contrast, the human pandemic MRSA CC97 strains are de-
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scended from bacteria that recently made bovine-to-human jump [164]. Recently, a novel homolog of the mecA gene, called mecC, has been found among MRSA isolates from bovine mastitis [33]. Afterward, mecC have been detected in MRSA strains iso-lated from livestock, wildlife, and companion animals that originated from several European countries [165–167]. Overall, these studies demonstrated that S. aureus clones undergo frequent hosts jumps, and they are able to adapt to novel hosts.    
Figure ‎1.7. The most dominant Staphylococcus aureus clonal complexes (CCs) detected in vari-
ous host species. 
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1.10 Clonal complex 398 
In the early 2000s, MRSA CC398 strains were first detected in France [168], and then in pig farms and farmers in the Netherlands [169]. Since then, MRSA CC398 has been found in pig farms and among their workers in several European countries, North and South America, and Asia [141,145,149,158,170–176]. Hence, the term live-stock-associated MRSA (LA-MRSA) was applied to CC398. Although CC398 has been mainly associated with pigs, it has also been found to colonise and cause infections among other host species, including poultry, cattle, and rabbits [141,157,177–179]. Furthermore, CC398 was isolated from horses and small companion animals (cats and dogs) [159,162,180–182]. Although livestock workers are mainly colonised with CC398, transmission from farmers to their family members is infrequent, and decolo-nisation occurs rapidly after removal of the infection source [149,151,183,184]. However, it was reported that CC398 colonise and cause infections in humans lacking contact with livestock or livestock workers [149,154,155]. MRSA CC398 strains have key genotypic and phenotypic features: first, they are non-typable by PFGE using SmaI [185]; second, they harbour SCCmec type IVa or V that differ from those carried by other HA-MRSA and CA-MRSA [186]; third, they are resistant to tetracycline macrolides, lincosamides and aminoglycosides antibiot-ics [187,188]; fourth, they mainly lack toxins such as PVL and enterotoxins [189]; and fifth, they are represented by a large number of spa types such as t011, t034, t108, t571, t567, t899, t119, t1451, and t6867 [141].  A Previous study, based on the whole genome sequencing approach, demon-strated that CC398 likely originated in human as MSSA and was transmitted to live-stock, where it then acquired methicillin resistance [190]. Furthermore, the same study suggested that CC398 acquired SCCmec element in multiple independent events; emphasising the antibiotic selective pressure that occurs in the livestock in-dustry [190]. The descent human MSSA CC398 strains were characterized by spa type t571 and they carried the φSa3 prophage (involved in human-specific innate immune 
evasion), whereas the φSa3 prophage was detected in only one animal isolate [190]. 
Hence, it was suggested that the φSa3 prophage plays a role in the adaptation of CC398 to the human niche, and its loss was part of the adaptation to non-human 
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hosts [16,190,191]. Another study revealed that the ancestral CC398 strains (human MSSA CC398 with spa type t571) adhere more avidly to human keratinocytes com-pared with the LA-MRSA CC398 strains, reflecting their wider spread among humans rather than animals [192]. 
1.11 Aim of this study 
This study aimed to the following: 
x Elucidating the population structure and the evolution of the S. aureus clonal complex CC398. 
x To evaluate the adhesion ability of certain CC398 sub-clone to the human and equine fibronectin. 
x To investigate the extent to which the innate immune systems of various hosts response to the CC398 infection. 
x To determine whether the acquisition of the immune evasion cluster by CC398 leads to its protection from the human’s innate immune system response.   
x To assess the genomic content of various CC398 strains from different host species based on comparative genomic analysis.  
1.12 Study design 
This study included CC398 isolates that were partially provided by the Ger-man National Reference Centre for Staphylococci and Enterococci at Robert Koch In-
stitute (part of the institute’s preserved S. aureus isolates collection). Whereas, the remaining CC398 isolates were received from collaborating microbiologists.  The population structure of CC398 was investigated based on mutation dis-covery using the denaturing high-performance liquid chromatography (dHPLC) ap-proach. Previously, 112 CC398 isolates were analysed using the dHPLC approach by Anne Wittenberg (Table ‎A.1), a former member of Robert Koch Institute, as a part of her doctoral degree in veterinary medicine that was submitted to the Free University of Berlin in January 2014 [193]. To assess whether a certain CC398 sub-lineage had emerged among horses, we extended this isolates collection by including further 83 
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CC398 isolates that were analysed, in the present study, using the same method (dHPLC) (Table ‎A.1). Furthermore, the association of this CC398 sub-lineage with eq-uine origin was investigated based on in vitro characterisation of host specificity properties and whole genome sequencing approach of representative CC398 isolates.   
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Staphylococcus aureus CC398 isolate collection In this study, a collection of 195 S. aureus CC398 isolates was investigated and summarized in Table ‎2.1. Most of the investigated CC398 isolates were submitted to the German National Reference Centre for Staphylococci and Enterococci at the Rob-ert Koch Institute (RKI), Wernigerode branch, while the remaining isolates were re-ceived from international cooperation partner. This CC398 isolate collection was col-lected between 1993 and 2011; from ten different countries, and 11 various host species. Hence, this collection represented a broad population of CC398. All the inves-tigated isolates details are listed in Table ‎A.1. 
Table ‎2.1. Summary of the S. aureus CC398 isolate collection investigated in this study. 
Country of origin Host species Isolation year Colonisation/Infection Austria (n = 17) Bovine (n = 6) 1993 (n = 1) Colonisation (n = 29) Belgium (n = 6) Cat (n = 1) 2001 (n = 1) Infection (n = 72) Canada (n = 1) Chicken (n = 7) 2002 (n = 2) Information not available (n = 94) Denmark (n = 31) Dog (n = 5) 2003 (n = 3)  Germany (n = 110) Environment (n = 1) 2004 (n = 7)  Italy (n = 3) Goat (n = 1) 2005 (n = 5)  The Netherland (n = 15) Goose (n = 2) 2006 (n = 11)  Thailand (n = 1) Horse (n = 53) 2007 (n = 53)  UK (n = 5) Human (n = 80) 2008 (n = 31)  USA (n = 6) Pig (n = 35) 2009 (n = 33)   Turkey (n = 4) 2010 (n = 12)    2011 (n = 38)    
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2.1.2 Chemicals, enzymes and proteins All chemicals, enzymes, proteins and DNA markers used in this study are listed below in Table ‎2.2 and Table ‎2.3. 
Table ‎2.2. Chemicals, enzymes and proteins used in this study. 
Chemicals/Enzymes Manufacturer Agarose Sigma-Aldrich GmbH Agarose Life Technologies Corporation Big Dye® Terminator v3.1 Cycle Seq. Kit Applied Biosystems® bisBenzimide H 33342 trihydrochloride Sigma-Aldrich GmbH Bovine serum albumin Sigma-Aldrich GmbH Bromphenol blue (loading buffer) Sigma-Aldrich GmbH Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Sigma-Aldrich GmbH Distilled water Sigma-Aldrich GmbH EDTA (Ethylenediaminetetraacetic acid) Serva Electrophoresis GmbH Ethanol (96%) Merck KGaA Ethidium Bromide (10mg/mL) Carl Roth GmbH & Co. KG. FACSClean BD Biosciences FACSFlow BD Biosciences FACS Lysing Solution BD Biosciences FACSRinse BD Biosciences Heparin Sigma-Aldrich GmbH HCl (37%) Carl Roth GmbH & Co. KG. Horse fibronectin Biopur AG, Bubendorf, Switzerland Human fibronectin Biopur AG, Bubendorf, Switzerland Lysostaphin Sigma-Aldrich GmbH Magnesium chloride (MgCl2) Carl Roth GmbH & Co. KG. Optimase Polymerase Transgenomic, Inc. Proteinase K Qiagen GmbH Sodium chloride (NaCl) Carl Roth GmbH & Co. KG. Sodium hydroxide (NaOH) Carl Roth GmbH & Co. KG. RNaseI Sigma-Aldrich GmbH Taq-Polymerase Invitrogen, Karlsruhe Tris Transgenomic, Inc. Tris-HCl Transgenomic, Inc. Triton X-100 Sigma-Aldrich GmbH WAVE Puffer A Transgenomic, Inc. WAVE Buffer B Transgenomic, Inc. 
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WAVE Wash Solution Transgenomic, Inc. WAVE Buffer D Transgenomic, Inc.  
Table ‎2.3. DNA molecular size markers used in this study. 
DNA Molecular size markers Manufacturer GeneRuler 100bp DNA-Ladder Plus  Thermo Fisher Scientific Inc.  GeneRuler 1kb DNA-Ladder Plus  Thermo Fisher Scientific Inc.   
2.1.3 Equipment  All instruments used in this study are listed in Table ‎2.4. 
Table ‎2.4. Instruments used in this study. 
Equipment Manufacturer Analytical Balance Sartorius AG  Autoclave Biomedis Laborservice GmbH  Biological Safety Cabinet Thermo Scientific Heraeus® ChemiDocXR Bio-Rad Laboratories, Inc Capillary Sequencer, 3130xl Genetic Analyser Applied Biosystems, Darmstadt Centrifuge, Centrifuge 5804R Eppendorf AG Centrifuge, Centrifuge 5417R Eppendorf AG Centrifuge, MiniSpin® plus Eppendorf AG dHPLC WAVETM - System Transgenomic Inc. Electrophoresis chamber Sub-Cell GT BioRad Bio-Rad Laboratories, Inc. Electrophoresis chamber Power Pac 300 BioRad Bio-Rad Laboratories, Inc ELISA plate reader Infinite® M1000 PRO Tecan Group Ltd.; Männedorf, Switzerland FACSCalibur BD Biosciences Freezer -20. , LIEBHERR comfort Liebherr-holding GmbH Fridge + 4., Liebherr Comfort Liebherr Group Gel Documentation System GelDoc XR BioRad Bio-Rad Laboratories, Inc. Incubator B 6760 Thermo Scientific Heraeus® Incubator Shakers Innova® 42/42R New Brunswick Scientific Company, Inc. Microwave, MW81W Samsung Group Multichannel-pipette (8 canals), Research Eppendorf AG 
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Pipettes, Reference, variable Eppendorf AG Pipettes, Research, variable Eppendorf AG Power supply, Power Pack Basic Bio-Rad Laboratories, Inc. Pyrosequencer, 454 GS FLX System Roche Diagnostics GmbH Spectrophotometer, Biophotometer plus Eppendorf AG Thermocycler, GeneAmp PCR System 9700 Applied Biosystems, Darmstadt Thermocycler, PTC-200 DNA Engine Bio-Rad Laboratories, Inc. UV/Vis Spectrophotometer, BioPhotometer plus Eppendorf AG Vacuum Centrifuge, Concentrator 5301 Eppendorf AG Vortex Genie 2 Scientific Industries Water bath GFL GmbH Water purification system SG Reinstwasser GmbH  
2.1.4 Nutrient media The media used for the cultivation and growth of S. aureus isolates are listed in the Table ‎2.5. The nutrient broths (Becton, Dickinson & Co.) were prepared in the RKI laboratory, Wernigerode branch, while the nutrient agar plates were purchased from Oxoid GmbH. 
Table ‎2.5. Nutrient media used for the cultivation and growth of S. aureus isolate collection. 
Nutrient media Reagents Manufacturer  Mueller Hinton agar (MH) with sheep blood Tryptone 2%, yeast extract 0.5%, NaCl 10 mM, glucose 20 mM, MgCl2 10 mM, MgSO4 10 mM, sheep blood 5% Oxoid GmbH Tryptic Soy Broth (TSB)  
Bacto™ Tryptone (Pancreatic Digest of Casein) 1%, yeast extract 0.5%, NaCl 0.5%, glycine (C2H5NO2) 1%, MgCl2 10 mM, pH 7.4 BD Diagnostic Systems Luria Bertani broth (LB) with 1% glycine  Tryptone 10 g/L, yeast extract 5 g/l, NaCl 0.5 g/L, gly-cine (C2H5NO2) 1%, pH7.0 Robert Koch In-stitute   
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2.1.5 Commercial kits Commercial kits used in this study are listed below in Table ‎2.6. 
Table ‎2.6. Commercial kits used in this study. 
Kit Name Usage Manufacturer Big Dye® Terminator v3.1 Cycle Seq. Kit Sequencing the PCR products Applied Biosystems® DNAeasy Blood and Tissue kit DNA extraction Qiagen GmbH PCR Master Mix  PCR Thermo Fisher Scientific Inc.  QIAquick PCR Purification Kit Purification the PCR prod-ucts  Qiagen GmbH  
2.1.6 Standard solutions All the standard solutions listed below were prepared in the RKI laboratory, Wernigerode branch. 
Phosphate buffered saline (PBS)  NaCl 137 mM KCl 2.7 mM Na2HPO4.2 H2O 10 mM KH2PO4 2 mM pH 7.4   
Tris-EDTA (TE) buffer  Tris-HCl 200 mM EDTA 20 mM pH 7.5      
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Tris-Borat-EDTA (TBE) buffer  Tris-HCl 10.78 g Sodium EDTA (Celaplex III) 0.1 g Boric acid 5.4 g pH 8.0  
2.1.7 Software and Internet tools Table ‎2.7 represents the software and the web-based tools used for the analy-sis, manipulation and representation of data. 
Table ‎2.7. Software and web based tools used for the data analysis. 
Program Description Source 
Adobe Suite CS6 Graphic design and photo-editing © 2014 Adobe Systems Software Ireland Ltd, license Robert Koch Institute Artemis Release 13.0 Genome browser and an-notation tool http://www.sanger.ac.uk/ Bayesian Tip-Significance testing (BaTs v1.3) 
Analysis of phenotype and genotype association with phylogeny  http://evolve.zoo.ox.ac.uk/ BEAST v1.7.5 Bayesian MCMC analysis of molecular sequences http://beast.bio.ed.ac.uk/ BEAUTi 1.7.5 Generating XML as input data files for BEAST http://beast.bio.ed.ac.uk/ BioNumerics v6.5 Creating database of loci sequences Applied Maths, Sint-Martens-Latem, Belgium. License Robert Koch Institute BRIG v2.3.2 Visualisation of genome comparisons http://sourceforge.net/projects/brig/  CorelDraw v.12.0.0.536 Graphic design and photo-editing © 2003 Corel Corporation, license Robert Koch Institute DnaSP v5.10.01 Analysis of DNA polymor-phism http://www.ub.edu/ EndNote® X5 Reference manager Thomas Reuters, license Robert Koch Institute FaBox Fasta sequences toolbox http://users-birc.au.dk/biopv/php/fabox/ FigTree v.1.3.1 Graphical viewer of phylo-genetic trees http://tree.bio.ed.ac.uk/ Image Reader v1.5E Documentation of Agarose gel Fuji Photo Film 
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iTOL v2.1 Visualization and manipu-lation of phylogenetic trees http://itol.embl.de/  Kodon v3.6.1 Genome alignments and comparisons  Applied Maths, Sint-Martens-Latem, Belgium Microsoft office pack-age Office suite Microsoft  MrBayes v3.1.2 Bayesian analysis http://mrbayes.sourceforge.net NavigatorTM software v3.0.0 dHPLC data analysis Transgenomic Inc., license Robert Koch Insti-tute NCBI BLAST Alignment search tool http://blast.ncbi.nlm.nih.gov/Blast.cgi PHAST Identification of prophages http://phast.wishartlab.com/ R Statistical computing and graphics http://www.r-project.org RAST Server Genome annotation http://rast.nmpdr.org Reverse Complemen-tary Converting the DNA se-quences templates to their complementary http://www.bioinformatics.org 
SeaView v4.2.3 DNA sequence alignment and establishment of ML tree  http://pbil.univ-lypn1.fr/ SeqMan Pro v8.1.5(3), 418 Assembling DNA sequence  DNASTAR Lasergene 8, license Robert-Koch-Institut Tracer v1.5 Visualizing the BEAST re-sults http://beast.bio.ed.ac.uk/    
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2.2 Microbiological methods 
2.2.1 Bacterial growth All the S. aureus isolates investigated in this study were streaked onto Mueller-Hinton-Blood agar plates (Oxoid, Cambridge, UK) and cultured overnight at 37 °C. For long-term storage, colonies of each S. aureus isolate were inoculated into the cryo-preservative vial, which kept at -80 °C as part of the strains collection of RKI, Wer-nigerode branch, Germany. 
2.2.2 Antimicrobial susceptibility testing The antimicrobial resistance profile for each S. aureus isolate was determined using the broth dilution method according to the European Committee on Antimicro-bial Susceptibility Testing (EUCAST) DIN 58940 guidelines (http://www.eucast.org). The minimum inhibitory concentration (MIC) for the following antibiotics were test-ed; penicillin G (PEN), oxacillin (OXA), teicoplanin (TPL), vancomycin (VAN), gen-tamicin (GEN), tetracycline (TET), ciprofloxacin (CIP), moxifloxacin (MFL), trime-thoprim / sulfamethoxazole (SXT; cotrimoxazole, and intermediate resistance to SXTi), erythromycin (ERY), clindamycin (CLI), rifampicin (RAM), daptomycin (DAP), mupirocin (MUP), linezolid (LNZ) and tigecycline (TGC). This test was performed as standard procedure in the National Reference Cen-tre for Staphylococci and Enterococci in RKI, Wernigerode branch, Germany. 
2.2.3 Extraction of the chromosomal DNA  For each of the investigated isolates, the chromosomal DNA was extracted us-ing the DNeasy Blood and Tissue kit following the manufacturer instructions, and us-ing 100 µg/ml lysostaphin instate of 20 mg/ml lysozyme. Briefly, single colony of each S. aureus isolate was inoculated in TSB nutrient broth and incubated overnight at 37 °C, with shaking at 150 rpm. From the overnight culture, 1 ml was centrifuged for 5 min at 8,000 rpm and the supernatant was de-canted. The pellet was re-suspended in 200 µl lysis buffer (2 mM EDTA, 20 mM Tris-HCl, 1.2% Triton-X-100, 100 µg/ml lysostaphin at pH 8.0) and incubated for 30 min at 37 °C. Subsequently, 25 µl of Proteinase K solution (20 mg/ml) and 200 µl AL buff-
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er were added and incubated for another 90 min at 56 °C. To stop the reaction, 200 µl of 96% ethanol were added and the mixture was transferred into DNeasy spin col-umn and centrifuged for 1 min at 8,000 rpm. The spin column was transferred into a new tube and 500 µl AW1 buffer were added, followed by centrifugation at 8,000 rpm for 1 min. Once more, the upper aqueous phase was transferred into a new tube and 500 µl AW2 buffer were added, followed by centrifugation for 3 min at 14,000 rpm. The DNA was eluted from the spin column by adding 100 µl deionized double-distilled water and incubating for 2 min at room temperature, followed by centrifuga-tion at 8,000 rpm for 1 min. The extracted chromosomal DNA was stored at -20 °C.  
2.2.4 Quantification of the extracted chromosomal DNA The concentration and purity of the extracted chromosomal DNA were deter-mined by measuring its absorbance at 260 nm using Biophotometer plus (Eppendorf AG). The DNA concentration of 50 µg/ml was represented by OD260 = 1. The purity of the DNA was determined based on the ratio of absorbance at 260 nm and 280 nm. A ratio of ≈1.8 is usually accepted as “pure” DNA. The presence of protein, RNA or other impurities was indicated with ratio lower than 1.8 and they were absorbed at 280 nm.  
2.2.5 Molecular typing of S. aureus 
2.2.5.1 Spa typing 
Spa typing is considered as one of the standardised typing methods for S. au-
reus. Spa typing is based on the sequence analysis of the highly polymorphic X region of the spa (staphylococcal protein A) locus, which compose of succession of short se-quence-variable number of tandem repeats (VNTR) [194]. This VNTR are subjected to point mutations, insertions or deletions that lead to the occurrence of different spa types. The spa typing method represents a high discriminatory power for outbreak investigations.  Polymerase chain reaction (PCR) was performed to amplify the spa repeat re-gion using the forward primer spa-1113f (5'- TAA AGA CGA TCC TTC GGT GAG C -3') and the reverse primer spa-1514r (5'- CAG CAG TAG TGC CGT TTG CTT -3') [91]. PCR products were sequenced in RKI, sequencing lab using Sanger sequencing method as 
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described later in paragraph ‎2.3.2. The software  idom StaphType™ ( idom GmbH, 
 u rzburg, Germany) was used for analysing the spa sequences of each isolate as de-scribed previously [91]. Although spa typing does not reach the discriminatory power of SmaI-generated macrorestriction patterns, it is widely used for epidemiological typing of S. aureus due to comparability and portability of the results. 
2.2.5.2 Multi-locus sequence typing Multi-locus sequence typing (MLST) is an excellent method to investigate the clonal evolution and population structure of S. aureus. MLST is based on the sequence analysis of seven relatively conserved housekeeping genes (≈ 500 bp); including car-bamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol kinase (glpF), guanylate kinase (gmk), phosphatase acetyltransferase (pta), triosephonate isomer-ase (tpi) and acetyl coenzyme A acetyltransferase (ygiL) [88]. The diverse sequences of each housekeeping gene are assigned as distinct alleles, and these alleles of the seven housekeeping genes form an allelic profile or sequence type (ST). The Based Upon Related Sequence Types (BURST) algorithm groups S. aureus strains to defined clonal complex (CC) based on sharing at least five identical loci in common [119,195]. Primers used for amplifying and sequencing these seven housekeeping genes are listed in Table ‎A.2, while the PCR and sequencing conditions are described in par-agraphs ‎2.2.7 and ‎2.3.2, respectively. For certain isolates, the sequences of the seven loci were assigned and compared with those from all S. aureus isolates maintained by the MLST online database (http://saureus.mlst.net/). The disadvantages of MLST typing are that the method remains expensive, laborious and time-consuming. 
2.2.5.3 Staphylococcal cassette chromosome mec typing The mecA gene is responsible for transmission of the methicillin and other ß-lactam antibiotic resistance of S. aureus and it is located on the mobile genetic ele-ment SCCmec. Eleven different SCCmec types have been described for S. aureus based on the type of cassette chromosome recombinases (ccr) gene and the class of the mec gene complex. SCCmec types I to V were typed through a multiplex PCR, while for SCCmec IV subtypes an additional simplex PCR was performed as previously de-scribed [95]. The primers used for amplifying the ccr gene complexes are listed in Table ‎A.3. 
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2.2.6 Detection of various mobile genetic elements The PCR approach was used for the screening of certain genes encoded by mobile genetic elements (MGEs) carried by the S. aureus isolates. These genes includ-ed Panton-Valentine leukocidin (PVL) and the integrase genes (int) for the bacterio-
phages φSa2, φSa3, φSa6 and φAVβ. The PCR primers used for this screening are listed in Table ‎A.4.  
2.2.7 Polymerase chain reaction approach PCR was performed for spa, MLST, SCCmec typing, and the screening of certain MGEs. A total volume of 50 µl PCR reaction contained 200 µM deoxynucleoside tri-phosphates (dATP, dCTP, dGTP, and dTTP), 10 pmol of each of the forward and re-verse primers, 5 µl 10x PCR reaction buffer (PeqLab, Erlangen), MgCl2 1.5 mM, and 1.25 U of AmpliTaq DNA polymerase (Applied Biosystems). The amplification reac-tion was performed in Gene Amp® PCR System 9700 Thermocycler (Applied Biosys-tems) using the following PCR program: an initial denaturation for 5 min at 80°C, fol-lowed by 35 cycles of denaturation for 45 s at 94°C, annealing for 45 s at 60°C, and an extension for 90 s at 72°C, followed by a single final extension step for 10 min at 72°C.     
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2.3 Mutation discovery  
Denaturing high-performance liquid chromatography (dHPLC) is a technique developed for the experimental discovery of single-nucleotide polymorphisms (SNPs) [196–200], and was previously used to elucidate the evolutionary history and popu-lation structure of various clonal complexes (CCs) of S. aureus [94,106,107,135,163]. The dHPLC allows the automated detection of single base substitutions besides small insertions and deletions, by comparing two or more chromosomal DNA fragments as a mixture of denatured and re-annealed PCR amplicons. The principles behind the SNPs detection through dHPLC is that the heteroduplexes DNA fragments at raised temperature start to melt at the mismatched region and are less thermo stable in comparison with their homoduplexes counterparts. Hence, heteroduplexes elute ear-lier than homoduplexes and the difference in their retention times indicate the pres-ence of SNP. In this study, the population structure of S. aureus CC398 was investigated based on the mutation discovery at 97 genetic housekeeping loci (≈ 400 bp per locus) in a collection of 195 isolates (112 isolates were analysed previously by Anne Wit-tenberg, a former member of Robert Koch Institute, while 83 isolates were analysed by the author) (Table ‎A.1). These 97 housekeeping loci were mainly metabolic genes and their polymorphisms provided the most reliable phylogenetic markers for S. au-reus [94]. In addition, they were scattered over the core genome of CC398, and con-stituted 1.4% (40,230 bp) of the CC398 whole genome. In order to reduce the costs and the time consumed for analysis, pools of DNA was created by mixing the DNA from eight to ten different isolates (referred to multiplex DNA), which then used as template to amplify each loci as described below (see paragraph ‎2.3.1). The PCR products of each locus from these multiplex DNA were compared to their counter-parts from the reference strain (08-00301) using dHPLC to detect the heteroduplex. When the chromatographic profile yielded the presence of heteroduplex, then the mutant isolate was identified by simplex test against the reference strain (08-00301).  Directly prior to the dHPLC analysis, the PCR products were denatured by heating at 96 °C for 5 min and then gradually cooled down to 12 °C over a period of 12 min. 5 µl of the PCR products were automatically loaded on the DNAsep HT col-
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umn (Transgenomic, Inc., Omaha, USA) and eluted on a linear gradient in WAVE buff-er A (0.1M diethylamine acetate, pH 7.0) and WAVE buffer B (0.1 M TEAA, 25% ace-tonitrile) with a constant flow rate of 0.9 ml/min. The start and end points of the gra-dient depended on the size of each PCR product. The temperature required for suc-cessful resolution of the PCR products was determined for each primer pairs and are listed in Table ‎A.5. Subsequently, UV detector at 254 nm detected the eluted PCR 
products, and the Navigator™ software was used to analyse the chromatographic pro-file. The identified SNPs were confirmed by sequencing the PCR products from both ends through capillary Sanger sequencing method using the primers listed in ble ‎A.5.   
2.3.1 PCR conditions for the mutation discovery analysis PCR is considered as the main technique for all high throughput mutational analysis methods. Reliable PCR quality was reached by careful primer design, exclu-sion of pre-PCR artefacts using “hot-start” methods, optimisation of Mg2+ concentra-tion, and prevention of excessive cycle number. In addition, low error rate was achieved by using thermo-stable proofreading polymerases. The PCR for the dHPLC analysis was performed using a particular Tag poly-merase enzyme (Optimase Polymerase) with an efficient 3’Æ5’ exonuclease activity to maximize data reproducibility and to deliver the highest reliability. A total volume of 25 µl PCR reaction contained 2.5 µl 10 x reaction buffer (PeqLab, Erlangen), 16.5 µl deionized double-distilled water, 1 µl forward primer (10 mM), 1 µl reverse primer (10 mM), 2.5 µl dNTP-Mix (each 2 mM dATP, dCTP, dTTP), 1 µl of template DNA (15 ng/µl) and 0.5 µl Optimase Polymerase (2.5 U). The PCR reactions were performed using Gene Amp® PCR System 9700 Thermocycler (Applied Biosystems) with the fol-lowing program: denaturation at 95 °C for 5 min, followed by 30 cycles of denatura-tion at 96 °C for 30 s, annealing at 55 °C for 45 s and extension at 72 °C for 60 s. Sub-sequently, a final extension step for 5 min at 72 °C, which was followed by cooling at 8 °C. 
2.3.2 Capillary-based Sanger sequencing  The Sanger sequencing method was used for the spa typing graph ‎2.2.5.1), MLST typing (paragraph ‎2.2.5.2) and the confirmation of the SNPs de-
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tected by the dHPLC approach. The Sanger method (also referred to as dideoxy se-quencing or chain termination) is based on the use of dideoxynucleotide triphos-phates (ddNTPs) as DNA chain terminators [201]. Dideoxynucleotides contain a hy-
drogen group on the 3’ carbon instead of a hydroxyl group (OH). hen these modi-fied nucleotides integrate into a sequence, then they prevent the addition of further nucleotides and thus the DNA chain is terminated. The PCR products to be sequenced were purified using the QIAquick PCR Puri-fication Kit (QIAGEN, Crawley, UK), and then amplified using BigDye® Terminator v3.1 cycle sequencing kit (Applied Biosystems, Darmstadt) following the manufactur-er instructions. The 10 µl of PCR reaction mixtures were consisted of 8.25 µl nucle-ase-free water, 1 µl BigDye v3.1; forward and reverse primers 0.5 µl each and 0.25µl of the PCR product. The amplification reaction was performed in Gene Amp® PCR System 9700 Thermocycler (Applied Biosystems) using the following PCR program: denaturation at 96 °C for 5 min, followed by 30 cycles of denaturation at 96 °C for 30 s, annealing at 55 °C for 45 s and extension at 72 °C for 60 s. Finally, an extension step at 72 °C for 5 min and the samples were then cooled to 4 °C. Sequencing process was performed by the sequencing laboratory in RKI, Berlin. 
2.3.3 Single-nucleotide polymorphisms analysis The SNPs discovered by dHPLC were confirmed through the Sanger sequenc-ing method. The software DNASTAR Lasergene 8 (SeqMan Pro) was used for quality assessment and analysing the sequence data. The sequences of the housekeeping loci from each investigated isolate were aligned and compared to their counterparts from the reference strain 08-00301 using SeqMan Pro tool. Subsequently, the identified SNPs by SeqMan Pro were categorised to either ancestral or derived SNPs based on the comparison to previously published S. aureus genomes in the National Centre for Biotechnology Information (NCBI) database via the Basic Local Alignment Search Tool (BLAST) algorithm. Afterward, SNPs positions were assigned in both S. aureus N315 and CC398 (strain S0385) reference genomes (accession numbers BA000018 and AM990992, respectively). Using the BioNumerics software v6.5 (Applied Maths, Sint-Martens-Latem, Belgium), a database was established to include all identified SNPs, their housekeeping loci sequences, isolates number, and the SNPs positions in both N315 and CC398 genomes.  
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Based on the identified SNPs the minimum spanning trees (MSTs) were creat-ed to study the microevolution of the CC398 isolate collection. For the MSTs a distinct database was established by BioNumerics v6.5, which included all investigated iso-lates information and their SNPs. In this database, the SNPs were represented in bi-nary code format (presence of the SNP was assigned to 1, while absence of the SNP was assigned to 0). Using the implemented MST algorithm in BioNumerics software, the MSTs were created for plotting the epidemic divergence of CC398 against other factors such as geographical distribution, spa types, date of sampling, etc.        
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2.3.4 Phylogenetic analysis of CC398 A phylogenetic tree is a graphical representation of the inferred evolutionary relationships among entities called taxa that can be genes, collections of genes, or populations based upon comparisons of their sequence data. Several methods of tree construction are used for the phylogenetic analysis, such as maximum likelihood (ML) method. The ML approach estimates the probability that a chosen evolutionary model is most likely explaining the evolution of the observed data. ML trees are based on examining the isolates sequence positions and attempt to create a tree topology that best fits the observed changes to a particular model of evolution. 
2.3.4.1 Construction of the maximum likelihood tree The ML approach was used to estimate the phylogenetic and evolutionary trees from the sequence data of the CC398 isolates. Prior to the creation of ML tree, all the 97 housekeeping loci sequences were concatenated for each of the 195 CC398 investigated isolates (40,230 bp) and aligned using BioNumerics software v6.5 (Ap-plied Maths, Sint-Martens-Latem, Belgium). Reconstruction of the ML tree was per-formed based on the multiple sequence alignment of concatenated sequences using PhyML software, which is implemented in the multiplatform Seaview v4.2.3 (http://pbil.univ-lypnl.fr/).  Rooting the phylogenetic tree determines its ancestral node and leads to eval-uate the direction of evolution. S. aureus N315 (CC5, accession numbers BA000018) was assigned as outgroup for rooting the CC398 phylogenetic tree. The correspond-ent sequences of the investigated 97 housekeeping loci from the N315 genome were concatenated and compared to the sequences of all 195 CC398 isolates. FigTree Soft-ware v.1.3.1 (http://tree.bio.ed.ac.uk/) and the online tool iTOL v2.1 (http://itol.embl.de/) were used for visualization and manipulation of the phyloge-netic trees. 
2.3.5 Molecular evolution of CC398 DNA sequences Studying the population genetics and molecular evolution of bacteria involve the analysis and comparison of the DNA sequences, to elucidate the diversi-ty/similarity between bacterial populations. Based on this diversity in terms of muta-tion, selection and genetic drift, models for explaining the evolution process can be 
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established. In this context, analysis of the multiple alignment of the concatenated sequences from the investigated loci was performed using DnaSP software package (v 5.0). The DnaSP software implements a number of analytical methods allowing ef-fective analysis of the DNA polymorphism from nucleotide sequence datasets. Nucle-
otide diversity (π), nucleotide variation ( ), synonymous (  ) and nonsynonymous (  ) sites, neutrality (    ⁄ ), and haplotypes diversity (H) were calculated for the concatenated sequences from the investigated housekeeping loci.  The neutral theory states that the majority of molecular evolutionary changes at the DNA level are driven by neutral drift rather than Darwinian selection. Nucleo-tide substitutions in protein coding genes can be either synonymous (do not change amino acid;   ) or nonsynonymous (changes amino acid;   ). Degree of selection can be estimated by calculating the number of synonymous and nonsynonymous sites, and their ratio. Based on Nei and Gojobori method [202], the total numbers of synon-ymous and nonsynonymous, Sd and Nd respectively, were calculated as defined by fol-lowing equations:  
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Where sdj and ndj are the numbers of synonymous and nonsynonymous differ-ences for the codon j, while r is the total number of compared codons. The substitu-tion ratio (    ⁄ ) is expected to be less than unity in case of purifying selection, whereas a ratio exceeds unity only under natural selection. Haplotype diversity (H) is referred to the probability that two random se-quences are different, and is defined as  
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Where n represents the number of sequences, h is the number of haplotypes, while pi is the relative frequency of haplotypes i. Nucleotide diversity (π) is the probability that two random sequences are dif-ferent at a given site, and was given by 
  
 
  Where m is the total number of nucleotide positions and k is the mean number of nucleotide differences. While nucleotide variation ( ) is defined by:      , where N is the effective population size, and µ is the mutation rate per nucleotide and per generation [203,204]. 
2.3.6 Estimating the divergence times based on Bayesian approach Time to most recent common ancestor (TMRCA) of CC398 was estimated us-ing Bayesian evolutionary analysis by sampling trees (BEAST) software (V 1.7.5) [205]. BEAST software is a Bayesian statistical framework, which provides parame-ters estimation and hypothesis testing of evolutionary models from the molecular se-quence data. The Bayesian phylogenetic inference was established by Thomas Bayes, and is based on Markov chain Monte Carlo (MCMC) algorithms. MCMC is a stochastic algorithm, which relies on sampling theory and considered as the state-of-art method for phylogenetic reconstruction. Metropolis-Hastings MCMC [206,207] is implement-ed in BEAST as core algorithm to perform the Bayesian analysis. In addition, BEAST focuses on the calibration of the phylogenies by modelling the rate of molecular evo-lution on each branch in the phylogenetic tree. The molecular clock hypothesis as-sumes that DNA sequences divergence accumulates approximately with a constant rate over time. This means that the difference between DNA sequences of two bacte-rial isolates is in proportional to the time of their divergence from their most recent common ancestor (strict model) [208]. On the other hand, BEAST allows phylogenet-ic inference under relaxed molecular clock models, which do not assume a constant rate across lineages [209,210]. The TMRCA of the investigated CC398 population was estimated using the multiple alignment of the concatenated DNA sequences dataset including the isola-
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tion date of each isolate. BEAST software takes input files only in XML format, which describe the dataset to be analysed, the molecular clock models to be used and the chain length of the MCMC algorithm. Therefore, the XML input file was generated from the multiple alignment file (*.fasta) using the Bayesian Evolutionary Analysis Utility (BEAUti) software v1.7.5. Model parameters values were estimated by com-bining three independent runs, each run with an initial of 5 * 107 MCMC iterations and sampled every 10,000 steps. In addition, the first ten per cent of logged values were discarded as burn-in. Hasegawa-Kishino-Yano (HKY) model was chosen as sub-stitutions model, while strict clock and lognormal relaxed clock were used inde-pendently as molecular clock models with the default settings of Tree Priors. The out-put of the BEAST analysis is a set of tab-delimited text files (*.txt), which included the estimated values and associated effective sample size (ESS) for each model parame-ter. These output files were analysed by Tracer software v1.5 [205], and all ESS val-ues were greater than 500.   
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2.3.7 Correlation between phenotypic traits and the phylogeny Bayesian Tip-association Significance testing (BaTS) software (V 1.0) was used to estimate the correlation between observed phenotypic traits and the phylogeny of CC398. Joe Parker has developed BaTS software to provide a statistical significance test of the null hypothesis that traits are correlated randomly with phylogeny tips [211]. This software is based on three well-established statistics models, the Associa-tion Index (AI) [212], Fitch parsimony score (PS) and the maximum exclusive single-state clade size (MC).  The association index statistic model is the sum across all the internal nodes in the phylogeny, and represented by the following model: 
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Here k is the total number of internal nodes, and for each internal node i, fi represents the frequency of the most common trait value among the tips subtended by that node. mi is the number of tips subtended by node i. Therefore, low AI values indicate strong association of the observed trait with phylogeny [211,212].  The parsimony score (PS) statistic was calculated using the Fitch parsimony algorithm [213]. The PS statistic for a certain trait takes the range         , where   is the number of tips in the phylogenetic tree. As for AI, low PS scores repre-sent strong association of the trait with phylogeny. The third statistic model is the monophyletic clade (MC), which was previous-ly applied by Salemi et al [214]. The stronger associations between phylogeny and trait should produce larger monophyletic clades whose tips all share the identical trait. The MC size of certain trait with value x can be defined as followed: 
  ( )          (    ) Where K represents the number of interior nodes in the phylogeny including the root. mi is the number of tips sharing the node I and Ii is an indicator function, which equal 1 if all tips sharing the node I have trait value x, and equal zero other-
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wise. MC is an integer metric for a single tree and bounded by        , where nx is the tips number that share the trait value x. Association of the phylogeny and trait is positively correlated with MC value.  BaTS integrated the uncertainty arising from phylogenetic error into the anal-ysis using a Bayesian framework. Therefore, the Bayesian MCMC analysis of the se-quence data is a precondition for applying significance testing. To exclude signifi-cance errors by redundant haplotypes, the significance testing of the observed traits was performed on one haplotype from the multiple haplotypes sharing the same trait in the dataset.  
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2.4 Phenotypic characterisation of CC398 
2.4.1 Phagocytosis assay The innate immune system is considered as the first line of host’s defence against pathogens such as S. aureus, which is mediated by phagocytes including mac-rophages and leukocytes. The phagocytic capacities and activity of different hosts (human, pig and horse) leucocytes (granulocytes, monocytes and lymphocytes) to CC398 were compared flow cytometrically. Briefly, representative CC398 isolates were incubated overnight in Luria Bertani broth (LB) at 37 °C. 1 ml bacterial suspen-sion was washed twice with PBS. 5 and 6- carboxyfluorescein diacetate succinimidyl ester (CFSE) was dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 10 mM. Subsequently, bacterial cells were labelled with 1 µl CFSE in 1 ml PBS for 15 min at 37 °C in the dark and then washed three times with PBS before use. Human whole blood was collected from seven different healthy adult donors (females and males), while pig and horse blood were collected from slaughterhouses from 10 different animals before slaughter. All blood samples were collected into lith-ium heparin tubes (SARSTEDT AG, Nuembrecht, Germany) and processed within maximum 45 minutes of venepuncture. 35 µl of CFSE labelled bacterial suspension were added to 700 µl of the hosts’ whole blood, and incubated at 37 °C with shaking at 1000 rpm. At 5, 30 and 60 min of the start point, 200 µl of the infected blood were transferred into FACS tube with 1 ml FACS lysing solution (BD Biosciences, San Jose, CA), and incubated for 15 min at room temperature. This FACS lysing solution is de-signed to lyse red blood cells in whole blood and it contained paraformaldehyde for fixing the bacterial cells. Finally, the cells were centrifuged at 450 g for 5 min, and the pellet was suspended in 200 µl FACSFlowTM (BD Biosciences, San Jose, CA). 
2.4.1.1 Flow cytometery The fluorescently labelled bacterial cells were detected with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) equipped with a 488 nm cooled argon ion laser and 635 nm red-diode laser. Fluorescent bacterial cells were measured at 488 nm (green CFSE), while granulocytes, monocytes and lymphocytes were detected through the side scatter channel (SSC) and assigned as the primary acquisition pa-
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rameter. The diverse physical properties of granulocytes, monocytes and lympho-cytes allow them to be distinguished from each other and from cellular impurities. The lymphocytes, monocytes and granulocytes have been gated as region 1 (R1), re-gion 2 (R2) and region 3 (R3), respectively.  All parameters were set to linear mode, and the flow rate was set to 12 µl / min. Samples were measured at approximately 3,000 events/s, and a total of 10,000 events were recorded for each cell suspension. Data analysis was performed on the mean fluorescence intensities using Cell Quest software. This assay was performed in cooperation with the working group of Dr. M. Bischoff at the Institute of Medical Microbiology and Hygiene, Saarland University 
Hospital; as a part of the BMBF “MedVet-Staph” consortium technical knowledge transfer practices (grant no: D1KI101). 
2.4.2 Adherence assay  
S. aureus is considered primarily as an extracellular pathogen. Colonisation and invasion of S. aureus to different hosts are mediated by the presence of adhesins that bind to components of the extracellular matrix (ECM) of host tissues [54]. Fi-bronectin (FN), collagen and fibrinogen/fibrin are part of the host ECM, which are targeted by S. aureus cell wall anchored surface proteins. Fibronectin is a high-molecular weight glycoprotein, which is involved in cell adhesion, growth, migration and differentiation. Furthermore, it plays a significant role in the mechanism of wound healing. Fibronectin binding proteins (FnBP-A and FnBP-B) were identified as major factors in mediating the uptake of S. aureus into host cells [215], and a double mutant FnBP-A/ FnBP-B S. aureus strain was not able to colonise the lactating gland in an experimental mouse model of mastitis [216,217]. The adhesion capacity of representative CC398 isolates to the human and eq-uine plasma FN (Biopur AG, Bubendorf, Switzerland) was compared using fluores-cence-based approach. High binding black microtiter plates (Greiner Bio-One GmbH, Germany) were coated with 40 µg/ml of either human or equine FN (100 µl/well) di-luted in phosphate buffered saline (PBS, pH 7.4) and, subsequently, incubated over-night at 4 °C. The coated microtiter plates were washed twice with 100 µl PBS. Then, 
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bovine serum albumin (5 mg/ml) was added, and the plates were incubated for 2 h at 37 °C. The plates were washed three times with PBS.  Bacterial isolates were cultured at 37 °C for 3 h in TSB broth. 1 ml of the bacte-rial suspension was centrifuged at 12,000 g for 1 min, and then the pellet was washed twice with PBS. The pellet was re-suspended in 1 µg/ml of the fluorescent dye bisBenzimide H 33342 trihydrochloride (Sigma-Aldrich GmbH, Germany) and incu-bated for 15 min at 37 °C in the dark with shaking at 1,000 rpm. Subsequently, the la-belled bacterial cells were centrifuged at 12,000 g for 1 min, and then washed twice with PBS. 100 µl of the bacterial cell suspension (OD600 = 1.0 in PBS) were added to each well, and the plates were incubated for 1 h at 37 °C. Plates were washed three times with 100 µl PBS and the absorbance was measured at 465 nm in an ELISA plate reader (Infinite® M1000 PRO, Tecan Group Ltd., Männedorf, Switzerland). This ex-periment was performed five times for each isolate.  
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2.5 Whole genome sequencing approach 
2.5.1 454 pyrosequencing The 454 Genome Sequence (GS) platform was the first next generation se-quencing platform presented by 454 Life Sciences, which bought later by Roche. This sequencing platform is based on the pyrosequencing approach, which developed by Pal Nyren and Mostafa Ronaghi at the Royal Institute of Technology Stockholm in 1996 [218]. The principle of this method relies on the release of pyrophosphate when a nucleotide is incorporated into a synthesized DNA strand. The released pyrophos-phate can be detected through enzymatic reactions in which ATP sulfurylase converts adenosine 5’ phosphosulfate (APS) to ATP that enables the second enzyme, luciferase, to react with its substrate (luciferin). This reaction leads to production of visible light, which is measured with a detector (camera). Pyrophosphate will only be released if the DNA synthesis reaction is supplied with the correct dNTP.  The de novo whole genome sequencing was performed through Roche/454 FLX platform for six representatives CC398 isolates (Table ‎A.6). The sequencing pro-cess was performed at RKI, sequencing laboratory. Briefly, the DNA fragments of suitable size are captured on micron-scale beads (28 µm diameter/each) and ampli-fied in water and oil emulsion, in a process referred to emulsion PCR [219]. Subse-quently, the beads containing the coupled DNA fragments are settled into the wells of picotiter plate that contained the enzymatic reagents for the pyrosequencing. The pattern of detected light reveals the nucleotide sequence of each single DNA tem-plate. The raw data is represented as a sequence of images, which are normalised, and then transformed into flowgrams. This flowgram is the preliminary data for the sequence analysis [220].   The advantage of 454/Roche GS FLX platform is production of large sequences (approximately 400 bp in size) and the possibility to sequence roughly 1.5 million beads in a single experiment. However, the errors observed for this method are small insertions or deletions (InDels), due to signal-to-noise thresholding problems [221]. 
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2.5.2 Illumina sequencing Genome sequences of two CC398 isolates recovered from horse infections were received from a cooperation partner at Free University Berlin (FUB) as a part of 
the BMBF “MedVet-Staph” consortium. In addition, 20 further CC398 genomes were included from a previous study (Table ‎A.6) [190]. These 22 genomes were sequenced using Illumina sequencing technology. Illumina Genome Analyzer platform is based on immobilizing linear sequencing library fragments by adding an Illumina-specific adapter to the ends of DNA molecules. These adapters are found on the oligo-derivatized surface of a sealed glass (8-channels) flow cell. This flow cell allows bridge amplification of the DNA fragments on its surface by using DNA polymerase for producing multiple DNA copies or clusters. Each cluster represents the single molecule that initiated the cluster amplification process. Illumina/ Solexa adopts the approach of sequencing-by-synthesis, which uses four fluorescently labelled nucleotides simultaneously and removable blocking group to sequence millions of clusters that present on the flow cell surface. These nucleo-tides carry a base-unique fluorescent label and the 3´-OH group is chemically blocked, which assure the addition of only one base at a time. Therefore, addition of these nu-cleotides to the template DNA fragment is considered as a unique event. The fluores-cent dye released with each nucleotide incorporation event is detected by total inter-nal reflection fluorescence imaging, and then enzymatically cleaved to allow incorpo-ration of the next nucleotide. This series of steps remains for a certain number of cy-cles, as determined by the user, which provide read lengths of 25-35 bp. A base-calling algorithm assigns sequences and their quality based on signal intensity meas-urements during each cycle. 
2.5.3 Genome assembly 
De novo assembly is a method of merging overlapped sequence reads into con-tiguous sequences (contigs) without the aid of any reference genome as a guide. The six CC398 genome sequences generated through the 454 platform were assembled by the sequencing laboratory at RKI with  oche’s GS De Novo Assembler v 2.6 (“New-
bler”) using default parameters [222], while the two isolates sequenced with Illumina approach the were received from the Free University Berlin were de novo assembled 
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using Velvet [223]. The assembled contigs of each isolate were ordered against the CC398 reference genome (strain S0385; accession number AM990992) using Mauve software version 2.3.1 [224]. 
2.5.4 Mapping Mapping refers to comparing and aligning each one of the sequences reads with the reference genome. Prior to the mapping process, the sequences reads files generated by 454 platform were converted from *.Sff to *.Fastq format using an open source tool sff_extract 0.3.0 (http://bioinf.comav.upv.es/sff_extract/download.html). The sequence reads from the 28 genomes in *.FastQ format were mapped against the published CC398 reference genome (strain S0385; accession number AM990992) [225] using the Burrows-Wheeler Alignment tool (BWA), which is implemented in the mapping_pl script developed by Matthias Steglich (RKI member).  Kodon build-in function Repeat and Match Search was used with default set-tings to determine the repetitive sequences. In order to avoid false SNPs calls, the SNPs located in the repetitive sequences regions and the mobile genetic elements were excluded using the Fas_handle (--substitute) script developed by Matthias Steglich (RKI member). SNPs calling were performed using SAM tools, which is im-plemented in the Fas_handle (--snp_filter) script. Based on the SNPs alignment of all 28 CC398 genomes sequences, a maximum likelihood tree was constructed as de-scribed previously in paragraph ‎2.3.4.1. ST36 (accession number BX571856) was previously determined to be the most closely related non-CC398 STs [190]. There-fore, ST36 was used as outgroup for rooting the CC398 phylogenetic tree, and for identifying the most ancestral CC398 clade. 
2.5.5 Genome annotation The annotation is referred to the process of adding information to the nucleo-tides sequences of DNA. For genome annotation a wide range of software solutions and annotation platforms are available. Detection of open reading frames (ORFs) and automated annotation of all genome-sequenced isolates were performed through RAST-Server at CeBiTec in the University of Bielefeld, Germany [226]. RAST is a freely accessible server that delivers initial gene calls, gene functions, and an accurate anno-tation for bacterial genomes. Ordered genome contigs in multi-fasta files format were 
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uploaded to RAST and compared to the previously published CC398 reference ge-nome (strain S0385; accession number AM990992) to identify the ORFs. The ge-nomes annotation files were downloaded in GenBank format, and were examined us-ing Artemis software (http://www.sanger.ac.uk/) (v13.0). 
2.5.6 Comparative genomics Which genes are unique to these particular genomes and which genes do they share with the reference genome? Do these isolates carry specific genes that are known to play a role in host adaptation, virulence, or drug resistance? In order to an-swer these questions the comparative genomes analysis was performed. Eight ge-nomes sequences (six from RKI, two from the Free University Berlin; Table ‎A.6) were compared with the CC398 reference genome (strain S0385; accession number AM990992) using Kodon implemented option (DNA comparative chromosome map-ping).  BLAST Ring Image Generator (BRIG) is a Java based tool, which was used to visualize the comparison of the reference sequence to the eight genomes sequences as previously described [227].  
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3 RESULTS 
3.1 Molecular typing of CC398 isolate collection 
In this study, a collection of 195 S. aureus isolates was investigated. These S. 
aureus isolates were collected between 1993 and 2011, from ten different countries (mainly from Europe), and various hosts (humans: n = 80; animals: n = 115) (Table ‎A.1). Molecular typing techniques such as spa, SCCmec were applied on all iso-lates.  Fourteen different spa types were identified among the 195 CC398, including t011, t034, t108, t571, t799, t899, t1197, t1344, t1451, t2576, t2876, t2974, t5972, and t6867 (Table A.1). The spa types t011 (repeat units pattern; 08-16-02-25-34-24-25) and t034 (repeat units pattern; 08-16-02-25-02-25-34-24-25) were the most predominant, representing ≈ 45% (n = 88) and 41% (n = 80) of the entire isolate col-lection, respectively (Figure ‎3.1). 
  
Figure ‎3.1. Distribution of the various Spa types among the investigated 
CC398 isolates (n = 195). 
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Among the investigated CC398 isolate collection, 37 isolates were MSSA, while the remained 158 isolates were MRSA (Table ‎A.1). The SCCmec typing revealed that ap-proximately 50% of the isolates (n = 99) harboured SCCmec type V, while 27% of the iso-lates (n = 52) acquired SCCmec type IV (Figure ‎3.2). 
      
Figure ‎3.2. Distribution of the different SCCmec types among the investigated 
CC398 isolates (n = 195). 
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3.2 Antimicrobial resistance phenotypes 
Antimicrobial susceptibility testing of the entire CC398 isolate collection (n = 195) displayed 56 different susceptibility patterns (Table A.1). Most of the isolates were resistant to penicillin (n = 187), tetracycline (n = 179) and oxacillin (n =155). All isolates were susceptible to vancomycin, daptomycin, and linezolid.  In total, 18 different antibiotics were included in this susceptibility test. These antibiotics represented the following 12 antibiotic classes penicillins, cephalosporins, carbapenems, monobactams, fluoroquinolones, aminoglycosides, glycopeptides, mac-rolides, lincosamides, streptogramins, clindamycin, tetracyclines, and miscellaneous. 41% of the isolates were resistant to a range of 1 to 3 different antibiotics classes, while 31% of the isolates were resistant to more than 5 antibiotic classes (Figure 3.3).    
Figure ‎3.3. Proportion of resistant isolates to different numbers of 
antibiotic classes. 
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3.3 Phylogenetic analysis of CC398 based on mutation discovery 
The mutation discovery analysis for the CC398 isolate collection was per-formed through the dHPLC approach. SNPs were detected at 97 genetic housekeeping 
loci (≈ 400 bp per locus) that are distributed along the S. aureus chromosome and are known for their metabolic functions. They constituted 1.4% (40,230) of the CC398 chromosome. These 97 housekeeping loci were amplified for each of the 195 CC398 isolates as described in paragraph ‎2.3.1 page 34 using the PCR primers listed in Ta-ble ‎A.5. The PCR amplicons from each isolate were compared to the reference strain (08-00301) for detecting the heteroduplexes that indicated the presence of SNPs. The identified SNPs were confirmed through capillary Sanger sequencing of the PCR products as described in section ‎2.3.2 page 34.  For SNPs confirmation, sequences from the suspected loci were aligned to their reference strain counterparts using the software Lasergene v.8 (Figure ‎3.4). Figure ‎3.4 illustrates the confirmed SNP in locus au301 for the isolate 09-03343. For assigning the confirmed SNPs to either ancestral or derived SNPs, the correspondent loci sequence had been blasted in the NCBI database and compared against the previ-ously published S. aureus genomes. The SNPs positions in both N315 and CC398 (strain S0385) reference genomes (accession numbers BA000018 and AM990992, respectively) were determined as well. 
  Figure ‎3.4. Sequences alignment for the locus au301 from different CC398 isolates against the ref-erence strain (08-00301). The detected SNP (G -> T) is represented in red colour.  
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Based on this analysis, 96 bi-allelic polymorphisms (BiPs) (i.e., polymorphic sites at which two alleles were observed) were detected, which were associated with 63 haplotypes. Among these polymorphisms were 34 synonymous point mutations in the protein coding genes (i.e., substitutions in coding regions that result in the same amino acid), 58 non-synonymous point mutations (i.e., substitutions that lead to change in the amino acid sequence of protein), and 4 insertions or deletions (Indels) ranging in size from 1 to 14 bp (Table ‎A.7). Within these 96 BiPs, 41 polymorphisms were informative for maximum parsimony analysis.  
The nucleotide diversity (π, the average number of nucleotide dissimilarities per site among two isolate sequences) for the coding regions was 0.00008 ± 0.00001, while the estimated mean nucleotide substitution rate was 5.4 x 10-6 substitu-tions/nucleotide site/year (95% confidence interval, 3.5 x 10-6 to 7.5 x 10-6).  
3.3.1 BEAST analysis The concatenated sequences and their isolation date were used to estimate the time to most recent common ancestor (TMRCA) by applying a Bayesian coalescent approach. Based on the estimated mutation rate, the sequences variations and the isolation date (1993 - 2011) of the isolates dataset, the TMRCA of the 195 CC398 iso-lates was estimated to be back to ≈ 1974 (95% confidence interval, 1955 to 1991). 
3.3.2 Minimum spanning tree  Based on the detected 96 polymorphisms, the minimum spanning tree was constructed using BioNumerics software as described in section ‎2.3.4 page 37. The minimum spanning tree composed of 63 haplotypes and showed very limited diversi-ty among the 195 investigated CC398 isolates (Figure ‎3.5). The ancestral node of the phylogenetic tree (*, Root) was determined by comparing the concatenated sequenc-es from the investigated loci of all investigated CC398 isolates with their counterparts of the previously published S. aureus N315 (accession numbers BA000018) as an out-group. The minimum spanning tree revealed six main clades (A to F) within CC398. Each clade is represented by different CC398 isolates that share at least one SNP in common. The SNPs defining each clade are listed below in Table ‎3.1.  
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Table ‎3.1. Point mutation(s) defining each clade. 
Clade SNP-ID Quality Ancestral Derived Position in ST398 genome (strain 
S0385; accession number AM990992) ORF in ST398 genome Product in ST398 genome 
A au251-1 Non- Synony-mous T A 827455 SAPIG0794 Urea amidolyase 
B au209-1 Non- Synony-mous C T 358137 SAPIG0324 Carbohydrate kinase, PfkB family 
C au309-2 Synonymous A T 2533404 SAPIG2453 Nitrite reductase [NAD(P)H], large subunit 
D au200-1 Non- Synony-mous C T 23542 SAPIG0017 Adenylosuccinate synthetase 
 au289-1 Non- Synony-mous T G 813835 SAPIG0778 N-acetylglucosamine-6-phosphate deacetylase 
E au291-1 Non- Synony-mous G A 1074694 SAPIG1020 5' nucleotidase family protein 
F au261-1 Synonymous T C 1929639 SAPIG1818 Proline dehydrogenase   
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Figure ‎3.5. Minimum spanning tree of the investigated 195 CC398 isolates based on the 96 iden-
tified SNPs. Each circle represent a haplotype and the circles size correspond to the number of iso-lates sharing the same haplotype. The position of the ancestral node (*, Root) was determined by com-paring the concatenated sequences from the investigated loci of all investigated CC398 isolates with the concatenated sequences of the previously published S. aureus N315 as an out-group. The minimum spanning tree revealed six main clades (A to F) within CC398. 
 Results 
57  
3.3.3 The Maximum likelihood approach  The maximum likelihood is a tree-building method for inferring the phyloge-netic relationships from sequence data. The ML approach was used to predict the evolutionary dynamics of CC398 and to describe the important trends in the data col-lection without over fitting. The ML model parameters were optimized as described in section ‎2.3.4.1. In this context, all the 97 housekeeping loci sequences were concat-enated for each of the investigated CC398 isolates (40,230 bp), subsequently, a mul-tiple sequence alignment was created, which was used for constructing the ML tree. The phylogenetic tree of the investigated CC398 isolates (Figure ‎3.6) revealed identical structure, root position and the six different clades (A-F) as in the MST (Figure ‎3.5).    
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Figure ‎3.6. Maximum likelihood tree of the 195 investigated CC398 isolates based on 96 polymor-
phisms.  
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3.3.3.1 Phylogeny and the geographical distribution of CC398 The geographical distribution of the investigated CC398 isolate collection is represented in Figure ‎3.7. This CC398 isolate collection represented ten different countries. The countries of origin for the investigated CC398 isolates were plotted on the MST in different colours. Clades A (n = 10), E (n = 9), and D (n = 13) with excep-tion of one isolate (the previously published strain S0385 from the Netherlands in clade D) consisted of isolates that were collected from Germany. In addition, clade F harboured 11 isolates; three of them were collected from Denmark, while the remain-ing eight isolates were from Germany. Clade B contained five isolates, which were originated from four different countries (Denmark, n =2; Germany, n = 1; Italy, n = 1; the Netherlands, n = 1). Clade C composed of 52 isolates with different geographical backgrounds (Austria, n = 15; Belgium, n = 2; Germany, n = 29; and the Netherlands, n = 6).  BaTS analysis was used to resolve the association of the geographical origin of the investigated CC398 isolates with their phylogeny. The BaTS analysis is summa-rised in Table ‎3.2 and revealed that certain countries of origin (Austria, Denmark, Germany, Italy, the Netherlands, and UK) were significantly associated with the phy-logenetic traits.  
Table ‎3.2. BaTS analysis results show the association of the geographical distribution of the in-
vestigated CC398 isolates with the phylogeny  
 
Country of origin MC value p-value Austria** 13.72 0.009 Belgium 10.39 1 Canada 1 1 Denmark** 31.38 0.009 Germany** 10.58 0.009 Italy** 2 0.009 Thailand 1 1 The Netherlands* 20.39 0.029 UK** 4.06 0.009 USA 14.95 1 
AI=8.89; p=0   
PS=59.80;p=0   *, p < 0.05; **, p < 0.01 
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Figure ‎3.7. Minimum spanning tree represents the geographical distribution of the investigated 
195 CC398 isolates. The different colours represent the different countries of origin.  
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3.3.3.2 Phylogeny and spa types Mapping the 14 different spa types onto the MST shows that clades A (n = 10), E (n = 9) and F (n = 11) consisted of isolates characterised by spa type t034, with ex-ception of one isolate within clade F that was represented by spa type t011 (Figure ‎3.8). Similarly, all isolates in clade A (n =5) shared the same spa type (t108). Clades D (n = 12) and C (n = 52) comprised isolates characterised by spa type t011 (Figure ‎3.8), with exception of three isolates in clade C (t6867 (n =2) and t779 (n = 1)) (Table ‎A.1).  Interestingly, isolates with spa type t899 (n = 2) were the most divergent hap-lotype in comparison with the remaining CC398 isolates (Figure ‎3.8). These t899 iso-lates had ten point of mutations compared to the root (au200-2, au200-3, au201-1, au201-2, au201-3, au202-1, au202-2, au202-3, au202-4 and au202-5). These SNPs were located on the isolates chromosomes within a region of ≥ 111,139 bp (between 23,209 - 134,348) (Table ‎A.7). Hence, the SNPs from these t899 isolates were exclud-ed from the phylogenetic analysis. In total, seven of the investigated CC398 isolates were represented by spa type t571; six of them were belonging to the most ancestral lineage of CC398 (Figure ‎3.8).    
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BaTS analysis revealed that spa types t011, t034, t108, t571, t899, and t1457 were significantly associated with the phylogeny (p < 0.01; Table ‎3.3). 
Table ‎3.3. BaTS analysis results show the association of the investigated CC398 isolates’ spa 
types with the phylogeny    Spa-type MC value p-value t011** 1.92 0.009 t034** 10.69 0.009 t108** 5 0.009 t571** 20.49 0.009 t899** 2 0.009 t1197 1 1 t1344 1 1 t1451 1 1 t1457** 2 0.009 t2576 1 1 t2876 1 1 t2974 1 1 t5972 1 1 t6867 1 1 
AI=5.74; p=0   
PS = 42; p = 0   **, p < 0.01 
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Figure ‎3.8. Minimum spanning tree shows the various spa types that represented the inves-
tigated CC398 isolates’ collection. 
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3.3.3.3 Phylogeny and SCCmec types Figure ‎3.9 represents the distribution of the detected SCCmec types onto the phylogenetic tree of the investigated CC398 isolates. The MST revealed that clades A (with exception of three isolates), B (with exception of one isolate), D, E and F (with exception of three isolates) carried SCCmec V. Clade C composed of isolates that har-boured SCCmec IV with exception of four isolates which had SCCmec V. In total, 17 MSSA isolates out of 37 were located in the ancestral clade, while the remained 20 MSSA isolates were distributed across the phylogenetic tree (Figure ‎3.9). BaTS analysis demonstrated that the MSSA isolates, and the CC398 isolates with SCCmec types IV and V were significantly associated with the phylogeny (p < 0.01, Table ‎3.4).  
Table ‎3.4. BaTS analysis results show the association of the detected SCCmec types with the 
phylogeny           
SCCmec-type MC value p-value MSSA** 43.96 0.009 II 1 1 III 1 1 IV** 21.43 0.009 V** 13.72 0.009 VII 1 1 IX 1 1 X 1 1 n.t. 12.67 1 
AI=5.97; p=0   
PS = 4.06; p = 0   **, p < 0.01   
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Figure ‎3.9. Minimum spanning tree represents the distribution of MSSA and various SCC-
mec types among the CC398 isolates’ collection. 
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3.3.4 Correlation of the phylogeny and host origin  The phylogenetic analysis indicated that all isolates from turkey meat (n = 4) clustered together and shared the same point mutations (Figure ‎3.10). These isolates were collected from Germany and were MSSA (Table A.1). In contrast, CC398 isolates recovered from human were distributed over the phylogenetic tree (Figure ‎3.10). Clades A, B, D and F consisted mainly of human isolates (n = 7, n = 4, n =9, n = 7; re-spectively). However, isolates from other host species were found in these clades. For instance, isolates from pigs (n = 2) and cat (n = 1) were located in clade A, while in clade B was one isolate collected from goat. In addition, three isolates from pigs and chicken (n = 2, n = 1; respectively) were found in clade D, whereas clade F had four isolates from pigs (Figure ‎3.10). Interestingly, clade C (n = 52) consisted primarily of isolates that were collect-ed from horses under veterinary care (n = 41) (Figure ‎3.10). Of note, human isolates in the same clade (n = 6; 07-00334, 07-00471, 07-01238, 07-01239, 07-01335, 07-01730) were from veterinary personnel of an equine clinic in a large Austrian veteri-nary hospital (Stationary Care 1) who had close contact to infected horses (Table ‎A.1). Furthermore, 5 isolates from various hosts (dog, n = 2; bovine, n = 2; pig, n = 1) were situated in clade C (Figure ‎3.10); these animals were in contact with one horse (09-02432) and shared the same farm (Farm 1) (Table ‎A.1). The CC398 isolates in clade C (n = 52) were collected from four different countries (Austria, Belgium, Germany, and the Netherlands) between 2006 and 2011 (Figure ‎3.7); the German iso-lates within this clade (n = 29) had been collected from 13 equine clinics and veteri-nary practitioners distributed over seven different federal states. The majority of iso-lates in clade C were characterised by spa type t011 and SCCmec IV (Figure ‎3.8, Fig-ure ‎3.9, Table ‎A.1). In total, 53 horse isolates were included in this study; four horse isolates characterized by spa type t034 and SCCmec V shared the same point muta-tions and were located near the root of the CC398 phylogenetic tree (Figure ‎3.10). In addition, estimating the TMRCA of clade C shows that this sub-lineage has emerged between horses since ≈ 2002 (95% confidence interval, 1998 to 2005). At the same time, clade C was extremely rare among S. aureus CC398 isolates from human infections in Germany. Among > 6,700 isolates that had been submitted to the German National Reference Centre for Staphylococci in RKI between 2010 and 
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2011, there were 48 MRSA isolates from human infections that displayed spa type t011 (Table ‎A.8). Among these, only four isolates carried the synonymous base sub-stitution that defines clade C (i. e., they carried a thymidine residue at genomic posi-tion 2,533,404; SNP au309-2; Table ‎A.7 and Table ‎A.8), as revealed by targeted PCR and sequencing. Hence, the association of clade C with infections in horses was highly significant (p<0.0001; chi2 test). BaTS analysis indicated that CC398 isolates from turkey meat and from horses each displayed a significant association with the phylogenetic structure of the inves-tigated CC398 isolates (p < 0.01; Table ‎3.5). In contrast, other host species including humans and pigs were more dispersed on the phylogenetic tree (Figure ‎3.10), not significantly different from a random distribution (p > 0.1; Table ‎3.5). 
Table ‎3.5. BaTS analysis results show the association of isolates’ host origin with the phylogeny             
Host MC value p-value Broiler thaw 1.2 1 Cat 1 1 Cattle 1.03 1 Chicken 1 1 Dog 1.04 1 Environment 1 1 Goat 1 1 Goose 1 1 Horse** 6.61 0.009 Human 4.58 0.19 Pig 2.37 0.47 Turkey** 4 0.009 
AI=10.31; p=0   
PS = 65.36; p = 0   **, p < 0.01 
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Figure ‎3.10. Minimum spanning tree represents the host origin of the 195 investigated CC398 
isolates. 
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3.4 CC398 virulence factors and bacteriophages  
The immune evasion cluster (IEC) genes carried on the β- converting φSa3 prophage (sak, chp and scn) were detected in 17 CC398 isolates (Figure ‎3.11.A). Elev-en isolates were recovered from human (06-03005, 07-01429, 09-01311, 09-01312, 09-03229, 09-03231, 09-03234, 10-02048, 11-00078, and 11-02211), while six were of animal origin (11-00501, 11-00530, 11-01553, 11-02281, 11-02801, and 11-02802) (Table ‎A.9). All the human isolates that carried φSa3 were MSSA, with excep-tion of one (Table ‎A.9). In contrast, all animal isolates that harboured the IEC genes were MRSA. Three of the animal isolates (11-02281, 11-02801, and 11-02802) were located in clade C, while the remaining three (11-00501, 11-00530, and 11-01553) were located in clade E (Figure ‎3.11.A). 
 e detected the φAvβ prophage-related sequences only in isolates from tur-key meat samples (n = 4) (Table ‎A.9). This φAvβ prophage, another member of the β-converting phage family, was detected first in avian strains belonging to CC5 [163]. In addition, the phylogenetic tree of the investigated CC398 isolates indicated that the MSSA isolates from the turkey meat samples shared the same point mutations and haplotype (Figure ‎3.10) and were significantly associated with the phylogeny (Table ‎3.5). Panton-Valentine Leukocidin (PVL) is a cytotoxin, which is encoded by genes (lukS/F-PV) carried on bacteriophage. PVL positive S. aureus strains are known to cause leukocyte destruction and tissue necrosis [133]. Among the 195 investigated CC398 isolates, only seven isolates harboured the PVL genes (Figure ‎3.11.A). In addi-tion, these isolates were recovered from infected human (Table ‎A.9). We detected bacteriophages φSa2S0385 and φSa6S0385 in 82 and 113 iso-lates, respectively (Figure ‎3.11.B). Furthermore, only 29 among the 195 investigated isolates were positive to both (φSa2S0385 and φSa6S0385) bacteriophages (Figure ‎3.11.B). Both bacteriophages (47 Kb) were detected first in the CC398 refer-ence genome (strain S0385) [225], and shared common domains, which consisted of mainly genes encoding phage regulatory, tail and capsule proteins [225]. Only one virulence gene (NWMN0280) was previously identified in both phages [225]. Howev-
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er, we detected these phages in clinical and commensal isolates, which were recov-ered from various host species.  
Figure ‎3.11. Minimum spanning tree shows the distribution of different bacteriophages that 
were harboured by the investigated CC398 isolates. A) φAvβ, φSa3, PVL bacteriophages detected in 
the 195 CC398 isolates and B) shows isolates positive for φSa2 and φSa6 bacteriophages. 
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3.5 Adhesion of CC398 to human and equine fibronectin 
The significance of bacterial adherence followed by invasion has been previ-ously demonstrated [228,229]. Bacteria must first adhere to the host cells before col-onisation and invasion can occur. In addition, it was previously shown that the S. au-
reus fibronectin binding proteins play an important role in the invasion of mammali-an cells [215]. Fibronectin (FN) is a glycoprotein and member of host extracellular matrix proteins. It is essential for different mechanisms carried out by the host cells such as tissue differentiation and wound healing. Using an in vitro binding assay, the adhesion ability of representative CC398 isolates to human and equine FN was stud-ied. Six CC398 isolates were used in this assay; five isolates were recovered from eq-uine infections, while one isolate was from pig (Table ‎3.6). The FN binding assay revealed that the adherence ability of the investigated CC398 isolates (n = 6) to human and equine FN did not differ significantly (p = 0.23) (Figure ‎3.12). Furthermore, among the six investigated CC398 only one isolate recov-ered from a horse (10-02693) showed significantly increased adhesion (p = 0.003) to the equine FN compared to the human FN (Figure ‎3.13).  
Table ‎3.6. CC398 isolates used in the adhesion assay. 
Isolate ID Country Isolation Date Spa type Host Clade 06-02016 Austria 13.04.2006 t011 Horse C 08-00301 Germany 03.09.2007 t011 Pig D 10-02693 Germany  05.11.2010 t034 Horse N.A. 11-00833 Germany  12.01.2011 t6867 Horse C 11-01925 Germany  13.05.2011 t1451 Horse N.A. 11-02806 Germany  23.08.2011 t011 Horse N.A.     
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Figure ‎3.12. Adhesion of CC398 isolates (n = 6) to human and equine fibronectin (FN). The data represent the mean value of six independent experiments with each host’s FN, while the error bars representing standard deviation.  
 
Figure ‎3.13. Binding of the six investigated CC398 isolates that were recovered from 
different hosts to human and equine fibronectin (FN). The data represent the mean val-ues of six independent experiments with each host’s FN, while the error bars representing standard deviation. Levels of significance were determined by the Mann–Whitney U test; *, p < 0.05. 
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3.6 Phagocytosis of CC398 by the host’s innate immune system 
Phagocytosis reflects the main process for combating pathogen infections. Neutrophils or blood leucocytes are considered as the key cells of the innate immune system. Neutrophils are short-lived cells and need to be continuously generated in steady-state conditions from the bone marrow.  The innate immune response of various hosts (pig, horse and human) to the S. 
aureus CC398 infection was investigated. In this assay, we measured the phagocytosis of the six CC398 isolates (Table ‎3.6) via hosts’ lymphocytes, monocytes and granulo-cytes at three different time points (5, 30 and 60 min) (Figure ‎3.14).  This analysis revealed that the phagocytosis of CC398 (n = 6) by the different 
host’s lymphocytes, monocytes and granulocytes was significantly increased over the incubation time, with exception of human lymphocytes (p = 0.24) (Figure ‎3.14).    
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Figure ‎3.14. Phagocytosis of CC398 (n = 6) by various hosts’ lymphocytes, monocytes 
and granulocytes over different time points. A) pig blood , B) horse blood, and C) human 
blood. The data represent the mean values of ten independent experiments with each hosts’ blood, while the error bars representing standard deviation. Levels of significance were de-termined by the Mann–Whitney U test; *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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In total, after 60 min of incubation, the horse lymphocytes and monocytes en-gulfed significantly greater number of CC398 compared to their pig and human coun-terparts (p < 0.001) (Figure ‎3.15). The measured phagocytosis of CC398 by pig granu-locytes was significantly lower than that for both horse and human granulocytes (p < 0.001) (Figure ‎3.15). In addition, the phagocytosis of CC398 by human and horse granulocytes did not differ significantly (P = 0.1) (Figure ‎3.15).     
     
Figure ‎3.15. Phagocytosis of CC398 by various hosts lymphocytes, monocytes, and 
granulocytes after 60 min incubation time. The data represent the mean values of ten in-
dependent experiments with each hosts’ blood, while the error bars representing standard deviation. Levels of significance were determined by the Mann–Whitney U test; ***, p < 0.001. 
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Figure ‎3.16 demonstrates the comparison of the phagocytosis of the six differ-ent CC398 isolates by host leukocytes after 60 min incubation, which revealed that monocytes and granulocytes from pig showed significantly increased phagocytosis of clade C isolates (06-02016 and 11-00833) compared to the remaining isolates (p < 0.001). In contrast, pig lymphocytes ingested isolates 11-02806 and 08-00301 signif-icantly less than the remaining isolates (p < 0.01) (Figure ‎3.16.A). The phagocytosis by horse lymphocytes did not differ between isolates. Despite the fact that horse monocytes had significant reduction in the phagocytosis of the isolate recovered from pig (08-00301) compared with other isolates (p < 0.001). Granulocytes from horse ingested significantly higher amount of isolates 06-02016, 11-00833 and 10-02693 than the remained three isolates (p < 0.01) (Figure ‎3.16.C). Of note, phagocytosis by human lymphocytes, monocytes and granulocytes was not isolate dependent (Figure ‎3.16). 
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Figure ‎3.16. Phagocytosis of the six different CC398 isolates by lymphocytes (A), mon-
ocytes (B) and granulocytes (C) of pig, horse and human, after 60 min incubation time. **, p < 0.01; ***, p < 0.001. 
 Results 
78  
3.6.1 Immune evasion cluster and phagocytosis of CC398 The S. aureus immune evasion cluster (IEC), located on β-haemolysin-converting bacteriophages, encodes the immune-modulating proteins chemotaxis in-hibitory protein (CHIP), staphylococcal complement inhibitor (SCIN), staphylococcal enterotoxin A (SEA) and staphylokinase (SAK). This IEC mediates the S. aureus inva-sion by escaping the host innate immunity. Previous study demonstrated that CC398 originated in human where it acquired the prophage ΦSa3, which carried genes en-coding the IEC (Price et al, 2012). To study influence of the IEC genes on the host innate immunity, two groups of CC398 isolates (with and without the IEC genes) were used to measure their phago-cytosis by human leukocytes (lymphocytes, monocytes and granulocytes). These CC398 were mainly recovered from infection sites from both animal and human (Table ‎3.7).  
Table ‎3.7. CC398 isolates used for investigating the influence of acquisition the IEC on phagocy-
tosis. 
Isolate Country Isolation date Spa type SCCmec Host Characteristic Clade φSa3 11-02281 Germany  30/06/11 t779 II Horse Clinical isolate C Positive 11-02801 Germany  14/08/11 t011 IV Horse Clinical isolate C Positive 11-02802 Germany  14/08/11 t011 IV Horse Clinical isolate C Positive 06-03005 Germany 01/12/06 t571 MSSA Human Wound infection Not defined Positive 11-00501 Germany  10/02/11 t034 V Thaw water No information E Positive 11-00530 Germany  14/02/11 t034 V Thaw water No information E Positive 11-01553 Germany  26/04/11 t034 V Horse Clinical isolate E Positive 11-02407 Germany  03/08/11 t1451 MSSA Human Wound infection Not defined Positive 09-03591 Germany  03/12/09 t011 MRSA Human Clinical isolate Not defined Positive 09-01897 Germany  11/05/09 t034 MRSA Human Clinical isolate Not defined Positive 10-01386 Germany  18/06/10 t034 MRSA Human Clinical isolate Not defined Positive 07-01429 Germany 01/06/07 t571 MSSA Human Wound infection Not defined Positive 11-02804 Germany  19/08/11 t011 IV Horse Clinical isolate C Negative 11-02560 Germany  18/07/11 t011 IV Horse Clinical isolate C Negative 11-01189 Germany  04/04/11 t011 IV Horse Clinical isolate C Negative 07-01494 Germany 01/06/07 t034 V Human Wound infection A Negative 11-01119 Germany  21/03/11 t034 V Horse Clinical isolate E Negative 09-00709 Germany 01/06/09 t034 V Human Commensal E Negative 07-01653 Germany 01/06/07 t034 V Human Wound infection E Negative 09-00393 Germany 01/06/09 t034 V Human Commensal Not defined Negative 07-00415 Germany 01/06/07 t034 MSSA Human No information Not defined Negative 09-00444 Germany 01/06/09 t011 V Human Commensal E Negative 07-02239 Germany 01/06/07 t108 V Human Wound infection B Negative 08-02710 Germany 06/10/08 t034 MSSA Human No information A Negative 
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Acquisition of the IEC by CC398 isolates did not influence the phagocytosis by human lymphocytes and monocytes after 60 min incubation time (Figure ‎3.17). In contrast, human granulocytes showed significant reduction in the phagocytosis of CC398 isolates with IEC after 30 and 60 min (p = 0.002, P = 0.001; respectively) com-pared to IEC negative CC398 isolates (Figure ‎3.18). 
 
Figure ‎3.17. Human neutrophils after 60 min and the phagocytosis of CC398 with and without 
immune evasion cluster (IEC). **, p < 0.01. 
 
Figure ‎3.18. Phagocytosis of CC398 with and without immune evasion cluster (IEC) by human 
granulocytes. **, p < 0.01. 
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3.7 Whole genome sequence analysis 
The evolution and epidemiology of CC398 was elucidated using a dHPLC-based mutation discovery method. This dHPLC approach covered 1.4% of the CC398 genome, and delivered higher discriminatory power compared to the standard spa and MLST typing methods. However, to assess the molecular genetic basis that lead to successful spread of clade C between horses with improved discriminatory resolu-tion, we sequenced the genomes of six representative CC398 isolates (Table ‎3.8). These isolates were distributed over the CC398 phylogenetic tree, and their genomes were 454 pyrosequenced using Roche genome sequencer Titanium. In addition, raw Illumina sequence data of two CC398 isolates from horse (IMT25053, wound infec-tion, t011, SCCmec V; IMT26596, wound infection, t6867, SCCmec IV) were obtained from the Institute of Microbiology and Epizootics at the Free University Berlin as a 
part of the MedVet Staph project’s cooperation (Table ‎3.8). All eight genome se-quences were de novo assembled; the six 454 pyrosequenced genomes were assem-bled using Newbler software; while the two Illumina sequenced genomes were as-sembled using Velvet software.   
Table ‎3.8. CC398 isolates used for whole genome sequencing. 
Isolate ID 
Sequencing 
technology 
Number of 
reads 
Average 
read length 
(bp) 
Total bases 
(bp) 
Coverage 
Number of 
contigs 
Number of ba-
ses in contigs 
(bp) 06-02016 454/ Roche 340109 608.63 207,001,138 69 132 2,828,647 08-00301 454/ Roche 400641 611.49 244,988,774 82 74 2,806,552 10-02693 454/ Roche 214392 598.18 128,244,254 43 51 2,740,366 11-00833 454/ Roche 202229 591.43 119,605,158 40 58 2,764,070 11-01925 454/ Roche 184929 592.26 109,525,161 37 40 2,769,179 11-02806 454/ Roche 154281 602.73 92,990,274 31 50 2,848,200 IMT25053 Illumina 3734559 101 377,190,459 131 50 2,756,033 IMT26596 Illumina 3887464 101 392,633,864 137 53 2,802,118    
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3.7.1 Comparative genomics The eight sequenced genomes (06-02016, 08-00301, 10-02693, 11-00833, 11-01925, 11-02806, IMT25053, and IMT26596) (Table ‎3.8) were compared to the se-quenced LA-MRSA CC398 reference genome (strain S0385; accession no. AM990992), which characterized by spa type t011, SCCmec V, and recovered from human infec-tion in the Netherlands. In addition, we included in this comparison three previously published CC398 genome sequences [192,230], which were isolated from human in-fections. Among these three complete genomes, two were MSSA from USA with spa type t571 (ST398NM01, accession number CP003045; ST398NM02, accession num-ber AIDT00000000 [192]), while the third genome was for a Canadian representative LA-MRSA isolate with spa type t034 (08BA02176, accession number CP003808 [230]) (Figure ‎3.19, Table ‎3.9).  The genomic comparisons represented in Figure ‎3.19 revealed that the inves-tigated CC398 genomes and the reference genomes (strain S0385) were diverse in terms of mobile genetic elements such as prophages, transposons and SaPIs. Similar to the reference (strain S0385) and other CC398 complete genomes, the eight inves-tigated genomes lacked various virulence factors present in other epidemic MRSA strain types, such as enterotoxin and exfoliative toxin genes [225,230,231]. Further-
more, the genomic islands νSaα and νSaβ were identified in all genomes (Table ‎3.9). These islands were detected in the reference genome (strain S0385) and carried type I restriction-modification (R-M) system, which is essential for preventing horizontal gene transfer into the bacterial genome [225]. Only isolates 11-00833 and IMT26596 carried stretches of the integrative conjugative elements (ICESa1A, ICESa1B and ICE-Sa2) (Figure ‎3.19), which were detected previously in the reference strain (S0385) [225].     
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Figure ‎3.19. Comparison of different CC398 genomes. Each circle represents different genome, from inside: LA-MRSA reference genome (S0385, inner ring), while the outer ring represents isolate 06-02016 genome. 
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Table ‎3.9. Genomic content of the investigated CC398 isolates. 
   Isolate (clade) 
Mobile genetic ele-
ments a Locus tag 
Position in the reference genome (strain 
S0385, accession no. AM990992) Size in bp 
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SCCmec SAPIG0028- SAPIG0085 34531- 88218 53,687 V V - - V V V V V IV IV IV SaPI Pig (S0385) SAPIG0469-SAPIG0483 484555- 496868 12,313 X X - - - - - - - X X X SaPIbov4-Like   13,606 - - - - - X X X - - - - 
νSaα (R-M & hsdS genes) SAPIG0499-SAPIG0500 511859- 514586 2,727 X X X X X X X X X X X X Type II R-M SAPIG2545-SAPIG2546 2625780- 2627998 2,218 X X X X X X X X X X X X ICESa1A SAPIG0070- SAPIG0084 75635- 87783 12,148 X - - - - - - - - X X - IECSa1B SAPIG1847- SAPIG1866 1956685- 1971358 14,673 X - - - - - - - - - - - ICESa2 SAPIG2030-SAPIG2046 2108820- 2121908 13,088 X - - - - - - - - X X - Transposase SAPIG1293 1356636-1357583 947 X X X - - - - - - - - - Tn916-like transpos-on  SAPIG0953-SAPIG0969 997945- 1016147 18,202 X X - - X X X X X X X X Tn554 like transpos-on SAPIG2023-SAPIG2025 2102165- 2105717 3,552 X X X X X X X X X X X X Transposon Tn559-like Inserted in SAPIG1715 (DNA re-pair protein RadC)  4,214 - - - - - - - - X X X X Tn7_like transposon SAPIG2202- SAPIG2208 2276988- 2283585 6,597 X X X X X X X X X X X X Sa2S0385 Prophage SAPIG1489-SAPIG1554 1597005- 1643185 46,180 X - - X X X X X - - - X Sa6S0385 Prophage SAPIG0334-SAPIG0399 370475- 417309 46,834 X X - - - - X  X  X X Phage1    ≈44,000 - - - - - - - - - X X - Phage2   ≈47,000 - - - - - - - X - - - - a, the presence of a mobile genetic element is represented by (X), while its absence is represented by (-)   
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3.7.1.1 Surface proteins  
S. aureus adheres to components of the extracellular matrix (ECM) of the host to facilitate colonisation and infection. This adherence is mediated by so-called mi-crobial surface proteins, which are anchored to the S. aureus cell wall. A previous study, based on whole genome sequencing, reported variation in genes encoding sur-face proteins in the LA-MRSA CC398 reference genome (strain S0385) compared with the human MSSA CC398 strains (ST398NM01 and ST398NM02) [192]. For instance, a number of surface proteins in the LA-MRSA CC398 (strain S0385) harboured prema-ture stop codons that lead to generation of protein truncation [192]. In contrast, the human MSSA CC398 isolates had no truncations in these surface proteins “dubbed wild type” [192].  In order to assess the genetic variation of the surface proteins from horse, human and LA-CC398 isolates, we compared the gene sequences of 14 surface pro-teins that are listed in Table ‎3.10. In contrast to the human and the horse CC398 iso-lates, the reference strain S0385 lacked the sdrE gene (Table ‎3.10). Variations ranged between point mutation to insertions or deletions (Indels) were detected among 12 surface proteins gene sequences (Table ‎3.10).  Interestingly, clfA gene from clades C isolates had an insertion of 18 bp com-pared with its counterpart from the remaining isolates (Table ‎3.10). In contrast to the reference strain (S0385), there was no truncation of clfB gene in the eight investigat-ed isolates, but it harboured Indels in the variable repeat region ranged between 18 to 42 bp (Table ‎3.10). Among the horse CC398 isolates, only isolate 10-02693 har-boured the genes encoding fnbB and sdrC that were similar to the human CC398 (ST398NM01) (Table ‎3.10).   
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Table ‎3.10. Variation of CC398 isolates surface proteins 
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Clumping factor A clfA WT/6 SNPs WT/6 SNPs Truncated/ 6 SNPs WT/6 SNPs  T/Δ 24 bp /Δ 139/6 SNPs bp  T/Δ 24 bp /Δ 139/6 SNPs bp  T/Δ 24 bp /Δ 139/6 SNPs bp  T/Δ 24 bp /Δ 139/6 SNPs bp  T/Δ 24/Δ 139/4 SNPs  T/Δ 18/6 SNPs  T/Δ 24/Δ 139/6 SNPs 
 T/Δ 24/Δ 
139/Δ 18/6 SNPs Clumping factor B clfB  WT Δ 456 bp Truncated WT  T/Δ 18 bp  T/Δ 18 bp  T/Δ 18 bp  T/Δ 42/Δ 19 bp  T/Δ 18 bp  T/Δ 18 bp  T/Δ 18 bp  T/Δ 18 bp Collagen cna ΔB do-main ΔB do-main WT Δ 561 Δ 561 Δ 561 Δ 561 Δ 561 Δ 561 Δ 561 Δ 561 Δ 561 Coagulase coa WT WT Δ81 bp Δ243 bp WT WT WT WT WT WT WT WT Elastin-binding pro-tein of S. aureus ebps WT WT WT WT WT WT WT WT WT WT WT WT Extracellular com-plement-binding protein ecb WT WT WT WT WT WT WT WT WT WT WT WT Fibronectin binding protein A fnbA WT Δ42 bp WT WT WT WT WT WT WT WT WT WT Fibronectin binding protein B fnbB WT WT Truncated Truncated Truncated Truncated Truncated Truncated WT Truncated Truncated Truncated Iron-regulated sur-face determinants B isdB WT WT 1 SNP/Δ9 bp WT 1 SNP/Δ9 bp 1 SNP/Δ9 bp 1 SNP/Δ9 bp 1 SNP/Δ9 bp WT/1 SNP 1 SNP/Δ9 bp 1 SNP/Δ9 bp 1 SNP/Δ9 bp Iron-regulated sur-face determinants C isdC WT WT WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP WT/ 1 SNP Serine aspartate re-peat protein C sdrC WT WT Δ174 bp WT Δ174 bp Δ174 bp Δ174 bp Δ174 bp WT Δ174 bp Δ174 bp Δ174 bp Serine aspartate re-peat protein D sdrD Δ54 bp WT 3 SNPs WT WT WT WT WT WT WT WT WT Serine aspartate re-peat protein E sdrE  T/Δ 54 Δ138 bp Absent WT WT WT WT WT  T/Δ 18 WT WT  T/Δ 18 Serine aspartate re-peat protein H sdrH Δ39 bp WT WT WT WT WT WT WT WT WT WT WT * WT, wild type 
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3.7.1.2 Mobile genetic elements Previous studies have shown that certain mobile genetic elements contribute to the successful spread of CC398 between human and livestock [190,192]; therefore, we determine the presence of transposons, pathogenicity islands, and prophages in the investigated CC398 genomes. 3.7.1.2.1 Transposons The entire investigated genomes harboured the transposons Tn916, Tn552 and Tn7-like (Table ‎3.9), which were previously identified in the reference LA-MRSA CC398 genome (strain S0385) [225]. The Tn916 was found to carry the tetracycline resistance element tet(M), while Tn552 carries regulator components that involve in 
tetracycline and β-lactam resistance [225].  Among the investigated isolates, only isolate 10-02693 and the entire clade C isolates (11-00833, IMT26596 and 06-02016) harboured a transposon similar to Tn559 in their chromosomes (Table ‎3.9). This Tn559 was found to carry gene encod-ing trimethoprim resistance (dfrK) [232].     
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3.7.1.2.2 Pathogenicity islands Similar to the LA-CC398 reference strain (S0385) and 08BA02176 genomes, isolates from clade C (06-02016, 11-00833 and IMT26596) harboured the SaPI (SaPIpig S0385) (Figure ‎3.19, Table ‎3.9). This SaPIpig carry genes encoding two puta-tive extracellular proteins homologous to the staphylococcal complement inhibitor (scn) and von Willebrand factor-binding protein (vwb), which were previously re-ported for their association with host specificity in ruminant [52,225,230]. In con-trast, isolates 08-00301 (spa type t011, from pig) and 10-02693 (spa type t034, from horse) lacked any SaPI (Figure ‎3.19, Table ‎3.9). Interestingly, the horse isolates 11-01925, 11-02806 and IMT25053 har-boured a novel SaPI ≈ 13 kb in length (dubbed SaPIbov4-like), which showed a high level of sequence similarity to the SaPIbov4 (accession number HM211303) rather than to SaPIpig (S0385) (Figure ‎3.20). This SaPIbov4-like carried a set of typical SaPI genes such as integrase (int), vwb and scn, which were similar to their counterparts from SaPIbov4 by 98%, 94% and 94%; respectively (Figure ‎3.21). In contrast to SaPIbov4, SaPIbov4-like carried three additional genes encoding hypothetical pro-teins (Figure ‎3.22). Although isolates 11-01925, 11-02806 and IMT25053 harboured the SaPIbov4-like, however, genetic variation was observed between these isolates con-cerning the vwb gene (Figure ‎3.23). In SaPIbov4-like, the vwb gene was 1,491 bp in length and encoded 496 amino acid residues. The vwb sequences from isolates 11-02806, IMT25053 and 11-01925 were found to be completely identical in all but one nucleotide, leading to the substitution of an asparagine by a lysine (Figure ‎3.23).  
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Figure ‎3.20. Similarity of the novel SaPI (SaPIbov4-like) with SaPIGS0385 and SaPIbov4 
(accession number AM990992 and HM211303; respectively). The different degrees of DNA sequences similiarities 80%, 50%, 20% are represented by the colours red, blue and green; respectively. 
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Figure ‎3.21. Comparison of the shared genes between SaPIbov4 (blue) and SaPIbov4-like 
(red). 
Figure ‎3.22. Comparison of SaPIbov4-like and SaPIbov4 genetic contents. 
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Figure ‎3.23. Line-up of the von Willebrand factor-binding protein (vwb) sequences (residues 1-500) obtained from SaPIbov4, SaPIG (strain 
385) and SaPIbov4-like, which were harboured by different CC398 isolates. This figure is adapted from line-up generated by PRALINE tool. The different colours represent the relative sequence conservation at each position, and the conservation scoring was performed by PRALINE. The scoring scheme works from 0 for the least conserved alignment position, up to 10 (*) for the most conserved alignment position. 
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3.7.1.2.3 Prophages Among the investigated isolates, 06-02016, 08-00301, 11-01925, 11-02806 and IMT25053 carried prophage φSa2S0385 (Figure ‎3.19), while the genes present in prophage φSa6S0385 were detected only in three isolates (06-02016, 10-02693 and IMT26596) (Figure ‎3.19) (Table ‎A.9). These φSa2S0385 and φSa6S0385 pro-phages were previously described for the LA-CC398 reference strain (S0385) [225].  Three horse CC398 genomes (11-00833, IMT26596 and 11-02806) contained 
stretches of ≈44 and ≈47 kb of novel prophages DNA sequences (Phage1 and Phage2, respectively). Both prophages (Phage1 and Phage2) had a mosaic structure and con-sisted mainly of genes encoding phage regulatory proteins (head, tail and capsule proteins) (Figure ‎3.24), which were similar to previously detected prophages se-quences from other S. aureus genomes (Figure ‎3.25). The two phages differed at the terminal end, which included the integrase gene (Figure ‎3.25). The integrase gene of Phage1 found in isolates 11-00833 and IMT26596 was highly similar (99%) to the in-tegrase gene (SA2981_0802) from previously published S. aureus genome 04-02981 (accession no. CP001844) [106]. Similarly, the integrase gene of Phage2 in isolates 11-02806, was 98% similar to the integrase gene in genomes ED133 (SAV_1817) and LGA251 (SARLGA251_17130) (accession no. CP001996 and FR821779, respectively) [33,233]. However, no virulence determinants were detected for both phages (Phage1 and Phage2).     
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Figure ‎3.25. Comparison of the novel phages (phage 1 and 2) with previously published pro-
phages DNA sequences. 
Figure ‎3.24. Structure of phage1 and phage2 
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3.7.2 CC398 Phylogeny based on whole genome sequencing The phylogenetic tree was constructed based on the whole genome sequences alignment of the 28 CC398 isolates (the eight genome sequences (Table ‎3.8), and 20 further genome sequences from previously published study [190] (Table ‎A.6). For SNPs calling, the 28 genome sequences were aligned against the published CC398 chromosome reference genome (strain S0385; accession no. AM990992). In addition, SNPs located in repetitive regions and mobile genetic elements such as (prophages, transposons, SaPIs and the SCCmec elements) were discarded. Hence, the SNPs alignment represented only the polymorphism within the core genomes of the inves-tigated CC398 isolates. The phylogenetic tree was rooted using the S. aureus ST36 ge-nome (accession no. BX571856) as outgroup (Figure ‎3.26). We detected 1,656 SNPs, including 352 parsimony informative SNPs. Among these 1,656 SNPs, 1,604 were from coding regions (434 synonymous and 1,170 non-synonymous) and 194 insertions or deletions ranging from 1 to 10 bp. Figure ‎3.26 represents the phylogenetic tree of the 29 CC398 (including the reference genome ST398_S0385) based on whole genome sequencing. The most ancestral lineage of CC398 composed of two MSSA isolates (LY19990171 and ST20091526) recovered from human and characterized by spa type t571 (Figure ‎3.26).  Of note, clade C was represented by six isolates (IMT26596, 11-00833, M2009_10004208, 06-02016, AV4 and 29139) (Figure ‎3.26); four of them were iso-lated from horses, while the remaining two isolates were environmental samples “pig (dust) [190]” (Figure ‎3.26, Table ‎A.6). All these six isolates were characterised by SCCmec IVa. Clade C was defined by 14 SNPs (5 synonymous and 9 nonsynonymous) (Table ‎3.11).      
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Figure ‎3.26. Maximum likelihood tree of 29 CC398 isolates (including the reference strain S0385) 
based on 1,656 SNPs, including 352 parsimony informative SNPs. Clade C is highlighted in lighten blue, reference strain genome (ST398_S0385) is dark blue, red labels represent isolates from Robert Koch Institute collection, while green labels represent isolates received from the Free University Berlin. All black-labelled isolates were included from previous study of Price et al. [190]. 
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Table ‎3.11. Point mutations that define clade C based on whole genome sequencing. 
SNP(s) position(s) in CC398 
genome (strain S0385, ac-
cession number AM990992) 
Ancestral Derived Quality Locus Product 
Ancestral  
codon 
Ancestral  
amino acid 
Derived  
codon 
Derived  
amino acid 
34270 G A Synonymous SAPIG0027 Hypothetical protein GAG Glutamine GAA Glutamine 34273 T A Synonymous SAPIG0027 Hypothetical protein GCT Alanine GCA Alanine 111809 A T Non- Synonymous  No CDS is defined AAG Lysine ATG Methionine 1204607 C A Synonymous SAPIG1148 Phosphodiesterase, family GGC Glycine GGA Glycine 1302177 G A Non- Synonymous SAPIG1246 Succinate-CoA ligase, alpha subunit subfamily GTT Valine ATT Isoleucine 1320027 C T Non- Synonymous SAPIG1264 RIP metalloprotease RseP ACA Threonine ATA Isoleucine 1326057 T C Synonymous SAPIG1266 DNA polymerase III, alpha subunit, Gram-positive type GTT Valine GTC Valine 1477472 A C Non- Synonymous SAPIG1402 Transcriptional regulator AAT Asparagine CAT Histidine 1517268 G T Non- Synonymous SAPIG1434 EbhA protein AGC Serine ATC Isoleucine 1837869 G T Non- Synonymous SAPIG1748 Isocitrate dehydrogenase, NADP-dependent TAG Stop codon TAT Tyrosine 1918655 C T Non- Synonymous SAPIG1809 LPXTG-motif cell wall anchor domain GCC Alanine GTC Valine 2533404 A T Non- Synonymous SAPIG2453 Nitrite-reductase [NAD(P)H], large subunit AAC Asparagine TAC Tyrosine 2724179 C T Synonymous SAPIG2634 NAD-binding site protein GTC Valine GTT Valine 2843598 G A Non- Synonymous SAPIG2732 Polysaccharide deacetylase domain protein GTC Valine ATC Isoleucine    
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4 DISCUSSION  
4.1 Molecular epidemiology of CC398 
In this study, a collection of 195 S. aureus CC398 isolates was investigated. This isolate collection was isolated between 1993 and 2011; recovered from 11 vari-ous host species and represented 10 different countries. Hence, this isolate collection represented a broad range of the CC398 population.  Pulsed Field Gel Electrophoresis (PFGE) using is considered to be the gold standard for the molecular typing of S. aureus isolates. However, CC398 was non-typeable by conventional SmaI-PFGE due to methylation of the SmaI site. Therefore, 
spa, MLST and SCCmec typing methods were considered as standardised tool for the epidemiological characterization of CC398 and other S. aureus lineages [234–236]. The molecular typing results suggest that the genetic diversity among the spa and SCCmec types of CC398 is limited. In addition, these findings are in good agree-ment with previous studies, which demonstrated that the spa types t011 and t034, and SCCmec types (IV and V) were the most common among CC398 isolates [145,149,237,238].  The antimicrobial resistance analysis of the 195 CC398 isolates showed that most of the isolates were mainly resistant to penicillin, tetracycline and oxacillin (Figure ‎3.3, Table ‎A.1). Previous studies have reported that all LA-MRSA CC398 were tetracycline resistance [145,239]. Therefore, it has been suggested that the use of an-timicrobial agents, mainly tetracycline, might be one of the reasons for the emergence of MRSA CC398 [240]. Furthermore, it was previously speculated that the tetracycline resistance phenotype could be used as an epidemiological marker for the LA-MRSA CC398 isolates [190,241]. However, the two tetracycline resistance genes tet(K) and 
tet(M) are located on plasmid (pT181) and transposon (Tn916), respectively; which was detected in methicillin-susceptible S. aureus [242], suggesting that tetracycline resistance cannot be the only factor responsible for the successful spread of CC398 between livestock. In addition, another study has demonstrated that tetracycline re-sistance phenotype is a misleading marker for the molecular genotyping of CC398 
 Discussion 
97  
[241]. Previous studies have shown that the CC398 isolates carried novel multidrug resistance genes that were located on plasmids; including the trimethoprim and oxa-zolidinones resistance genes [187,243]. Taken together, these data might emphasise the high rate of horizontal transfer of genetic material, such as plasmids and trans-posons, from other bacteria to CC398.  
4.2 Microevolution of CC398 
The mutation rate of CC398 isolate collection was relatively faster compared to a previously reported evolutionary rate for other S. aureus clonal complexes [94,108]. These comparisons emphasise the variation of mutation rates among close-ly related S. aureus clones that may reflect variations in selective pressures faced in diverse ecological niches.  Based on the calculated mutation rate, the sequences variations and the isola-tion date of the 195 investigated CC398 isolates dataset (1993 – 2011); the time to most recent common ancestor was traced back to ≈ 1974 (95% confidence interval, 1955 to 1991). Of note, CC398 was non-typeable by SmaI-PFGE, so it is reasonable that CC398 has spread between animals for several years before they were first de-scribed to cause clinical infections between farmers [169]. Therefore, retrospective studies on the ancient non-typeable S. aureus strains using the recent molecular typ-ing methods (e.g. MLST and spa typing) can lead to identify the basal CC398 isolates. Based on whole genome sequencing (WGS), a previous study showed that CC398 has originated in human and later transmitted to livestock [190]. However, this study did not estimate the date of the most-recent human ancestor of CC398. Although the CC398 isolates investigated here were collected over 18 years, they represented mainly the time period from 2006 to 2011 and some years were represented only by few isolates (e.g. 1993, n = 1; 2001, n = 1; 2002, n = 2). Applying WGS on a wider CC398 isolate collection that includes ancient and recent serially sampled isolates will precisely estimate the time to most recent common ancestor of CC398, and re-duce the estimated confidence interval (1955 - 1991). 
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4.3 Phylogeny and population structure of CC398 
The 96 detected SNPs within the screened 97 housekeeping loci of the 195 in-vestigated CC398 isolates were used to construct the MST and to elucidate the phy-logeny of CC398. The 195 CC398 isolate collection showed very limited diversity over the MST (Figure ‎3.5). However, the phylogenetic tree resolved CC398 into six distinct clades (Figure ‎3.6). 
4.3.1 Phylogeography of CC398 The investigated 195 CC398 isolates represented ten different countries. Among these ten countries, origin from six European countries was significantly as-sociated with phylogeny (Table ‎3.2), which suggests the wide dissemination of CC398 in various countries. Of note, CC398 has first been detected in Europe [169], and later reported in several other geographic regions worldwide such as North and Central America, Singapore, China, Australia and New Zealand [170,171,244–246]. In addi-tion, it was shown that CC398 isolates from different countries were similar in terms of their genetic content [247]. Of note, food animals are exported around the world and CC398 may have deposited away inside them. Similarly, a previous study has re-vealed that the spread of the poultry S. aureus ST5 lineage was strongly consistent with the globalized nature of the poultry industry [163]. Taken together, these data emphasize the potential impact of globalization and the livestock trade routes for the emergence and spread of CC398 worldwide.  However, the investigated CC398 isolate collection contained few countries that were inadequately represented such as Canada (n = 1), Thailand (n = 1) and Italy (n = 3). For in-depth investigation of the CC398 phylogeography, it would be neces-sary to include demographically and geographically representative isolates of further geographical origins (e.g. China, Australia, New Zealand and African countries).  
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4.3.2 The phylogenetic analysis emphasise the limitations of spa and SCCmec 
typing approaches Rooting the CC398 phylogenetic tree using the concatenated sequences of the investigated isolates and N315 as an out-group showed that a cluster of two isolates, characterised by the spa type t899, was the most divergent compared to the remain-ing CC398 isolates (Figure ‎3.8). The SNPs discovery using dHPLC revealed that t899 isolates had 10 SNPs in three different housekeeping loci (au200, au201 and au202), 
which were located on the isolates chromosomes with a region of ≥ 111,139 bp (be-tween 23,209 – 134,348) (Table ‎A.7). These findings are in agreement with a study based on whole genome sequencing, suggested that CC398 with spa type t899 had acquired a fragment of 123,000 bp from ST9 through horizontal gene transfer. This fragment included the spa gene and the SCCmec insertion site [190].  The S. aureus clone (ST9) was detected in pigs and other livestock worldwide [184]. In S. aureus, variation of spa types has been described previously as a result of replacement of a large chromosomal DNA fragment from other lineages. For instance, the epidemic S. aureus clone ST239 has emerged likely after such recombination event between ST8-like and ST30-like chromosomes [121]. Hence, spa typing has lim-itations, and MLST typing is required for accurate identification of the t899 isolates. In addition, homoplasy within the spa gene might lead to discrepancies between the phylogeny of CC398 and spa types. Previous study demonstrated that spa typing can misclassify specific S. aureus lineages due to recombination events and homoplasy and might occasionally lead to misinterpretation [94,106,190].  In this study, MRSA CC398 isolates characterised by SCCmec types IV and V and the methicillin-susceptible CC398 isolates were significantly associated with phy-logeny (Table ‎3.4). Most MSSA CC398 isolates were traced adjacent to the root of the phylogenetic tree. These findings are in agreement with previous CC398 study, which suggested that CC398 had originated as MSSA and afterward acquired the resistance to methicillin [190]. In addition, these data may suggest that CC398 encountered se-lective pressure through the antibiotic usage that led to the acquisition of SCCmec el-ement.  
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The horizontally transferred region observed among the t899 of ST9 and CC398 isolates also carries the SCCmec element, which suggests an alternative mech-anism for SCCmec dissemination between S. aureus clones. Taken together, these data strongly support previous findings that the dissemination of SCCmec elements in MRSA lineages has occurred on several occasions [94,248]. 
4.4 Human-to-livestock host jumps 
The 195 CC398 isolate collection investigated in this study was collected from 11 host species (Table ‎A.1). Human (n = 80) and animals (n = 115) CC398 isolates were isolated from colonisation and infection sites. CC398 was previously detected in multiple host species [141]. Previously, Price et al [190] has shown that CC398 origi-nated in human as MSSA and subsequently spread to livestock, where it acquired re-sistance to methicillin and tetracycline. In addition, human MSSA isolates with spa type t571 were the most ancestral lineage on the CC398 phylogenetic tree that was based on whole genome sequencing [190]. In this study, the phylogenetic tree based on dHPLC approach revealed that the entire MSSA CC398 isolates from human with 
spa type t571 (n = 5) were located near to the root (Figure ‎3.8). In addition, MSSA CC398 isolates from both human and animals with spa type t034 were also located near to the root. Nevertheless, the dHPLC-based mutation discovery method applied in this study covered 1.4% of the CC398 genome; therefore, the CC398 phylogenetic tree did not reflect the human-to-animal host jumps that accomplished CC398. In ad-dition, human CC398 isolates were distributed on the phylogenetic tree (Figure ‎3.10) and were not significantly different from a random distribution (p > 0.1; Table ‎3.5). In contrast to the LA-MRSA-CC398 isolate, the human-associated MSSA CC398 
isolates harboured the β- converting φSa3 prophage, which carries genes (sak, chp and scn) associated with human innate immunomodulation [190]. It was shown that 
φSa3 prophage plays an important role in the adaptation of S. aureus to the human niche [79,192]. The loss of φSa3 prophage in LA-associated isolates, hence, suggests adaptation of CC398 to the animal-niche [190]. In agreement with the observation of Price et al., the immune evasion genes (sak, chp and scn) carried by the φSa3 pro-phage were detected in 17 CC398 isolates (Figure ‎3.11.A). However, only eleven iso-lates were of human origin, while six were of animal origin (Table ‎A.9). All the human 
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isolates that carried φSa3 with exception of one were MSSA, while the animal isolates 
were all M SA. These findings suggest that φSa3 prophage was acquired by CC398 through horizontal gene transfer. We observed that MSSA CC398 isolated from turkey meat (n = 4) shared the same point mutations (Figure ‎3.10), and they were significantly associated with phy-logeny (Table ‎3.5). The φAvβ prophage sequences were detected in these four CC398 isolates using PCR approach (Table ‎A.9). This φAvβ prophage was previously detect-ed in S. aureus CC5 from various bird species, and in industrially fattened broiler chickens [163]. The φAvβ prophage carries avian-niche-specific genes, which sug-gests that MSSA CC398 in turkey flocks have adapted to the host through acquisition of an avian-specific prophage, similar to S. aureus CC5 in industrially fattened broiler chickens [163]. This explanation is in agreement with previous CC398 study based on whole genome sequencing [190]. Only handful of breeder companies is responsible for turkey production worldwide [249]. Furthermore, the antimicrobials abuse at farms is considered as a risk factor for the wide dissemination of MRSA between animals [250]. In the United States, the Union of Concerned Scientists demonstrated that more than 70% of all sold antibiotics were given during fattening to the livestock; including swine, cattle and poultry [251]. MRSA CC398 was detected between turkey flocks, and people in frequent contact with them [252,253]. Both ST5 and CC398 were the most dominant 
S. aureus between chicken and turkey [254], which possibly enhanced the horizontal gene transfer between both lineages. 
4.5 Immune evasion cluster genes protect CC398 against phagocytosis  
As revealed previously, there is increasing evidence for an evolutionary trend of increasing pathogenicity of CC398 for humans. One example of this is the acquisi-tion of the φSa3 prophage, which carries so-called immune evasion cluster (sak, chp and scn) genes [190,192].  In this study, the CC398 positive to the immune evasion cluster genes were significantly less engulfed by human granulocytes, after 30 and 60 min, compared with their negative counterparts (Figure ‎3.18). These findings indicate the significant 
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contribution of the immune evasion cluster genes to the protection of CC398 from the human immune response. This would explain the ability of CC398 to invade the hu-man immune system and then disseminating systemically to cause severe infection. It was shown that the immune evasion cluster genes produce proteins that hamper the phagocytosis of other S. aureus strains by human neutrophils [255]. In addition, pre-vious studies revealed selection against the immune evasion cluster in animal hosts, which was suggested as a part of CC398 adaptation to non-human hosts [190,247]. However, all the investigated CC398 isolates were collected from both human and an-imal hosts (Table ‎3.7). A recent study revealed that CC398 isolates with spa type t108 were significantly less engulfed by human granulocytes compared with t011, t034 and other CA-MRSA isolates [256]. Nevertheless, only one CC398-t108 isolate (07-02239) was included here that carried the immune evasion cluster genes (Table ‎3.7). Hence, CC398-t108 is unlikely to have played a part in the significant reduction in the phagocytosis of CC398 that was observed in our study.  Several studies revealed that S. aureus strains harboured the PVL genes were able to evade the human immune system causing severe infections [74–77]. PVL tox-in is able to lyse the mammalian leukocytes, which are involved in the phagocytosis of 
S. aureus, by forming pores in their cell membrane. To exclude the effect of PVL as pu-tative immune evasion factor, all the investigated CC398 isolates were PVL negative. 
Hence, the difference observed in the CC398 isolates’ evasion capacity to the human granulocytes could not be explained by the expression of PVL toxins. Taken together, these data show for the first time that CC398 can hamper the phagocytosis by human granulocytes. However, these findings might not translate di-rectly to human adaption of CC398. In contrast to well-studied intracellular patho-gens and other S. aureus lineages, nothing is yet known about how CC398 can survive phagocytosis. For instance, it was previously shown that the presence of iron-regulated surface determinant protein might reduce the uptake of S. aureus by human neutrophils [257]. In addition, some S. aureus strains can survive in the human mac-rophages by secreting proteins such as metalloprotease, which resist the human an-timicrobial peptide [258]. Further research needs to be performed to investigate the expression levels of the immune evasion cluster genes in the CC398 isolates from dif-
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ferent host species, which might be a promising approach for explaining this observa-tion in more details.  
4.6 Emergence of equine-associated CC398 sub-clone 
Interestingly, clade C consisted mainly of isolates from horses under veteri-nary care (n = 41). In total, 53 CC398 isolates from horses were included in the pre-sent study. Isolates from other host species (Figure ‎3.10) had been also allocated in clade C; however, the epidemiological data shown that those hosts were in close con-tact with infected horses (Table ‎A.1). Isolates in clade C (n = 53) were collected from four different countries (Figure ‎3.7) between 2006 and 2011. These findings suggest that clade C is a distinct sub-clone within CC398, which is disseminated among hospi-talised horses and veterinary personnel all over Germany and in several European countries. Of note, the majority of clade C isolates were characterized by spa type t011 (95%) and SCCmec IV (91%) (Table ‎A.1).  Several studies showed that MRSA CC398 with spa type t011 and SCCmec type IV was the most dominant strain among the MRSA infections and carriage in horses in Europe. For instance, in the Veterinary University of Vienna, several cases (n = 9) have been detected [244]. In Belgium, screening of horses on admission to a Belgian equine clinic revealed a high colonization percentage with MRSA-CC398-t011-IV [259]. The same MRSA CC398 sub-clone was detected among horses in a veterinary hospital in Finland between 2007 and 2009; subsequently, it caused infection in one employee of the stuff members [260]. The first report of CC398 from England was in 2009; there the MRSA-CC398-t011-IV was detected in two horses admitted to the Equine Referral Hospital at the Royal Veterinary College [261]. Furthermore, a previ-ous study, based on MLST, spa- and SCCmec typing, has shown that MRSA-CC398-t011-IV caused nosocomial infections in horses in an equine clinic in Switzerland [262]. The authors reported that the same CC398 strain was initially detected in one of the personnel members who formerly worked in an equine clinic in Belgium. Later, this MRSA-CC398-t011-IV was detected in infected horses and subsequently replaced ST1-t2863, which was dominant in wound infections in this equine clinic [262]. These data suggest that all the detected CC398 strains from those studies [244,259–262] were likely affiliated to clade C. In addition, isolates from clade C commonly 
 Discussion 
104  
showed resistance to gentamicin, which is the first choice antibiotic and frequently used in the treatment of infections in horses [263–265]. This finding suggests that CC398 encountered selective pressure for gentamicin resistance in equine settings, which is comparable to the epidemic EMRSA-15 strains that encountered selective pressure for clindamycin and erythromycin resistance in veterinary and human healthcare settings in the United Kingdom; respectively [266]. In addition, the au-thors suggested that the reason for this selection in EMRSA-15 strains was due to the wide use of clindamycin and erythromycin in veterinary practice and human medi-cine in the United Kingdom; respectively [266]. Worth mentioning that clade C was extremely rare among S. aureus isolates from human infections in Germany, and its association with infections in horses was highly significant (p < 0.0001). Taken to-gether, these findings raised the debate whether the emergence of that MRSA-CC398-t011-IV reflects epidemic spread or host adaptation? 
4.6.1 Equine CC398-host interactions In order to test the hypothesis whether the equine CC398 sub-clone is better adapted to horses than to other host species, we studied phenotypic characters of this equine CC398 isolates, including their adhesion capacity to host fibronectin. The abil-ity of S. aureus to interact with the host’s plasma fibronectin is essential for host colo-nization and infection. The CC398 isolates set, including the equine CC398 isolates (MRSA-CC398-t011-IV), demonstrated no significant differences in the adherence ability to both human and equine fibronectin, suggesting that differences in the host origin of fibronectin do not play a significant role in the adhesion of CC398. These ob-servations are in agreement with a previous study, which showed no significant dif-ferences between the binding ability of CC398 to the human and bovine plasma fi-bronectin [256]. Another study showed that the adhesion capacity of LA-CC398 to the human and porcine keratinocytes did not differ [192]. However, only isolate 10-02693 (horse-t034-V) adhered significantly more efficient to the equine fibronectin compared with its human counterpart (Figure ‎3.13). Since it was reported that LA-CC398 isolates harboured point mutations in several genes that encode adhesion fac-tors [192], therefore, we compared the sequences of the genes encoding the fibron-ectin-binding proteins (fnbA and fnbB). This comparison revealed that all the investi-gated CC398 isolates, with exception of isolate 10-02693, harboured a point mutation 
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in fnbB gene similar to that found in the CC398 reference genome (strain S0385), which lead to truncation in the encoded protein [192] (Table ‎3.10). This may likely explain the adhesion differences of isolate 10-02693 to both human and equine fi-bronectin. Furthermore, these findings indicate that the equine MRSA-CC398-t011-IV sub-clone is likely able to initiate colonization in exposed human and equine. Howev-er, further investigations are needed to determine the fnbB gene expression of these individual CC398 isolates. Several S. aureus surface proteins mediate its adhesion to the host tissue; therefore, investigating the adhesion of the CC398 to the human and equine nasal mucosa and keratinocytes might deliver a better understanding of the emergence of MRSA-CC398-t011-IV sub-clone between different hosts. 
4.6.2 Equine CC398 sub-clone is not generally protected against phagocytosis Another approach for studying the attributes of equine CC398 was to investi-gate its ability to invade different host species by escaping their innate immune re-sponses. We observed that human and horse granulocytes had similar capacity to phagocyte CC398 isolates, which may reflect the narrow spectrum of virulence char-acteristics of CC398 and its limited level of host specificity. In addition, the results showed significant increased phagocytosis toward equine CC398 isolates and isolate 10-02693 by horse granulocytes, which may suggest that the phagocytosis of CC398 by horse granulocytes is isolate dependent. One can speculate that equine CC398 sub-clone is not generally protected against the phagocytosis by horse granulocytes. In-terestingly, the horse monocytes showed significantly higher uptake of CC398 com-pared with its human and pig counterparts, which might suggest that horse mono-cytes plays an important role in the elimination of invading pathogens. However, lit-tle is known about the putative role of horse monocytes in phagocytosis and it re-mains to be elucidated.  Pig neutrophils had significantly lower uptake capacity of CC398 compared to their human and horse counterparts, which may likely suggest the enhanced clear-ance capacity of CC398 by pig neutrophils. Previous studies showed that the porcine genes encoding toll-like receptors, key components of the host innate recognition system, harboured polymorphisms compared to their human counterparts [267,268]. Furthermore, It was suggested that this maintenance of diversity in the toll-like re-
ceptors genes might have some advantages for the pig’s immune system to eliminate 
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pathogens efficiently [267–269]. Another explanation could be the use of antibiotics as a growth promoter in conventionally raised pigs such as tetracycline, which was previously shown to decrease the efficiency of neutrophils phagocytic activities [270,271]. However, the degree of uncertainty in these estimates is considerable, and no firm conclusions should be drawn. The phagocytosis assay used in this study can only reflect an approximation to in vivo phagocytosis and cannot clarify the observed reduction in the uptake of CC398 by pig neutrophils, especially since there are several factors involved in the host innate immune response. For instance, the hosts’ neutro-phils employ several oxygen-dependent and oxygen-independent strategies to elimi-nate the invading pathogens. Although achievements have been made concerning un-derstanding mechanisms used by CC398 to evade host’s innate system, particularly those including neutrophils, our understanding in this area still incomplete. 
4.7 Whole genome sequencing and the nosocomial spread of equine CC398 
lineage 
The dHPLC-based mutation discovery approach applied in this study delivered improved discriminatory power compared to spa typing and the MLST typing meth-ods, and provided several novel insights into S. aureus population structure [94,107,135]. However, it covered only 1.4% of the CC398 genome, and clade C was defined by one synonymous base substitution. Hence, the resolution of analyses and the strength of any inferences would be much improved by whole-genome-sequencing [35,108]. The phylogenetic tree of the 28 CC398 isolates based on whole genome se-quencing, presented in this study, confirmed the emergence of clade C among horses and was defined by 14 point mutations. The isolates that formed clade C on this phy-logenetic tree were all isolated from horses, with exception of two isolates (29139 and M2009_10004208) that were originating from pig (dust). These two sequences were included from a previous study [190], which did not provide any further epi-demiological data concerning the previous contact with horses. The fact that spa type t011 and SCCmec IV characterized those environmental isolates, likely suggests their previous contact with horses.  
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As the equine MRSA-CC398-t011-IV sub-clone appears to have become estab-lished within the equine settings; however, our understanding of the genetic deter-minants of this equine CC398 sub-clone remains incomplete. In addition, a better un-derstanding of the features that make this equine CC398 sub-clone successful within and among equine settings, from several countries, was urgently required. To ad-dress this issue we used a comparative genomics approach that involved whole ge-nome sequencing of eight CC398 isolates, including three isolates from clade C. The isolates chosen here for sequencing were phylogenetically divergent, thus raising the amount of informative data produced. The most striking finding of the comparative genomics approach is that three CC398 horse isolates, which do not belong to clade C, harboured a novel pathogenicity island that share DNA sequences similarities with SaPIbov4. These data emphasise the importance of horizontal gene transfers in the genetic diversity of CC398. In addition, the observed divergence of vwb genes se-quences carried by SaPIbov4-like might reflect an additional strategy for the viru-lence of CC398.  The detection of novel phages that are harboured by different isolates that were belonging to different clades suggests that several phages are associated to CC398, and they may have played a role for its evolution. The DNA sequences of these phages encode functional gene products that are required for the phage propagation. Extensive experiments need to be performed to investigate whether these two pro-phages might influence the virulence of CC398. However, it was claimed that bacteri-ophages might influence the adaptation of CC398 to different host-niches through several mechanisms; including the carriage of genes that encode immune evasion modulators [190]. As these novel phages had approximately similar size and were closely related across their genome, so one can speculate that these phages were ac-quired independently by each isolate through horizontal gene transfer. One of the most significant findings here is that clade C isolates genomes showed high levels of similarities to the LA-CC398 reference genome (strain S0385), including the majority of surface proteins, the mobile genetic elements and the lack of virulence factors such as enterotoxin and exfoliative toxin genes. These findings sug-gest that the equine CC398 sub-clone had not encountered better adaptation to eq-uine. Furthermore, one can speculate that the genomic content of this equine CC398 
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sub-clone is adequate for successful dissemination of this isolates between different host species. Similarly, a recent study, based on whole genome sequencing, has shown that EMRSA-15 strains isolated from human did not differ compared to their counterparts from companion animals concerning their genomic content [266]. In addition, the authors suggested that the ability of S. aureus lineages to infect an ex-tended host spectrum might be distinctive for their long-term evolutionary history [266]. Taken together, the emergence of this MRSA CC398 sub-clone in horses from several European equine clinics is likely due to an epidemic spread, which is compa-rable to several epidemic MRSA strains that rapidly spread within and between med-ical care hospitals and cause a large number of healthcare-associated infections in humans [35,272,273]. The spread of this equine CC398 sub-clone might be due to in-sufficient hygiene practices in veterinary settings. Several studies have reported that the nasal carriage rate of MRSA among veterinary practitioners is much greater than in medical staff in human hospital [274–277]. Furthermore, the nosocomial spread of MRSA in equine clinics and among veterinary personnel was previously demonstrat-ed [144,182,278–283]. Hence, personnel in veterinary settings may play an im-portant role in the introduction and spread of MRSA into equine clinics. In addition, humans with frequent contact with horses can represent a reservoir for MRSA and then transmit it to their household. A metapopulation model showed that the occur-rence of a relatively large proportion of MRSA-CC398 carriers between susceptible human populations might result in an outbreak [284]. One can speculate that the di-rect transmission between horses should be easier to eliminate in equine compared with human hospitals, as horses are commonly not allowed to move freely in the eq-uine hospitals. Insufficient hand hygiene is a key route for MRSA transmission within equine hospitals [147]; therefore, the implementation of good hand hygiene practice is the significant measure for preventing nosocomial infections.     
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4.8 Conclusions and future perspectives 
In this study, we demonstrated a new insight into the phylogeny of CC398 based on genome-wide mutation discovery. We revealed the dissemination of a spe-cific MRSA-CC398 sub-clone “dubbed clade C” within and between different equine settings, which caused infections in horses and nasal colonisation of humans. Based on the phenotypic characterisation of this CC398 sub-clone, we could demonstrate the lack of host adaptation. Moreover, the genomic analysis presented here together with the epidemiological data, provide evidence that the spread of this equine CC398 sub-clone is due to epidemic spread. The spread of this equine CC398 sub-clone can be traced through testing for the presence/ absence of the SNPs defining the clade C (canonical SNPs) using diagnostic PCR followed by sequence analysis. Improvements in the infection control programmes by checking the efficacy of the methods of disin-fection or sterilization may reduce the frequency of infection. Veterinarians play an important role in controlling the transmission of this sub-clone by taking precautions with staff hygiene, and implementation of risk reduction strategies for infection pre-vention. In the last years, the comparative genomics studies provided important in-sights into genetic variation in the populations of S. aureus and demonstrated its power to address issues of evolution and host adaptation. The comparison of the ge-nome sequences of CC398 isolates has led to some unpredicted discoveries about the number of pathogenicity islands that differ between closely related isolates, and the prevalence dynamics of phages. Overall, these findings were not only enhancing our understanding of the equine CC398 genomic contents, but also provided an insight in-to the evolution of CC398. It will now be exciting to investigate the role of these novel mobile genetic el-ements in the virulence of CC398. This can be achieved by performing in vitro assays that measure the invasion of different host cells (e.g. epithelial and endothelial cells) by CC398 strains. Furthermore, one can make use of the available genome sequence data of CC398 to construct whole-genome microarrays. These microarrays will allow us to investigate the gene expression, and the interactions between thousands of genes in CC398 strains under different environmental growth conditions.  
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Alternatively the transcriptome of CC398 can be inferred and quantified by us-ing the high-throughput next-generation RNA sequencing (RNA-seq). This RNA se-quencing approach has several advantages over the microarray-based method; in-cluding the higher genome coverage, higher-sensitivity and it can capture nearly all of the expressed transcripts. The first functional genomics study on S. aureus N315, based on RNA sequencing, revealed approximately 200 novel transcripts [285]. Therefore, RNA sequencing is considered as a revolutionary tool for functional ge-nomic research. Various methods can be used to investigate how CC398 might spread among veterinary settings and across the borders. For instance, we could mine the epidemio-logical data together with phylogeographic analysis for additional insights relating to the identification of the international transmission routes for CC398. In addition, us-ing wireless sensor implants combined with the Global Positioning System coordi-nates to track pets and livestock interactions and contact nodes will be a promising method for elucidating the transmission dynamics of CC398. Several studies, based on metagenomic analysis, revealed that shifts in the composition of gut microbiota is associated with several diseases such as inflamma-tory bowel diseases, ulcerative colitis, and Clostridium difficile infections [286–289]. It will now be exciting to use metagenomic approaches for investigating whether the nasal microbiome composition differs in humans colonised and infected with CC398 compared with non-carriers. Such studies will allow us to better understand the in-teraction between CC398 and other bacterial species, and the relative abundance of certain bacterial species might help to develop new treatment strategies. For in-stance, probiotic-based approaches that restore the balance in the nasal microbiome composition might be promising strategies for the decolonization and treatment of CC398 positive patients; similar to those used to treat Clostridium difficile infections [290,291]. We should keep in mind that the frequent exposure of CC398 to antimicrobial agents, in livestock, increases the selection pressure for antibiotic resistance. Hence, an international multidisciplinary effort is needed to slow the development of antibi-otic resistance through avoiding the overuse of antibiotics in livestock. 
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A. APPENDIX 
Table ‎A.1. CC398 Investigated Isolates 
Isolate ID Synonym Country Farm/Stationary 
or Ambulatory 
Care** 
Isolation 
date 
Spa type SCCmec Host Characteristic Resistance* Clade 
04-03094† MRSA Germany N.A. 01.06.2004 t034 V Human  PEN,ERY, OXA, CLI, TET,  A 05-02057†  Germany N.A. 01.06.2005 t034 V Dog  PEN; ERY; CLI; TET N.A. 06-00262† E 64 Austria S.C. 1 01.06.2006 t011 IV Horse Wound infection PEN; OXA; GEN; ERY; CLI; TET; SXT N.A. 06-00880†  Austria S.C. 1 01.06.2006 t011 IV Horse Infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 06-00903† BK 201770 Germany N.A. 13.04.2006 t011 V Human Bacteremia / Sepsis PEN; ERY; CLI; TET; CIP N.A. 06-02016† Shila Austria S.C. 1 13.04.2006 t011 IV Horse Infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 06-02985† M1960 Austria N.A. 10.04.2006 t011 V Human Infection PEN; TET; SXT N.A. 06-03005† 242003 Germany N.A. 01.12.2006 t571 MSSA Human Wound infection ERY N.A. 06-03034† VA 318796 Germany N.A. 10.12.2006 t034 V Human Commensal PEN; OXA; ERY; CLI; TET; SXT N.A. 07-00334† M 25 Austria S.C. 1 10.12.2006 t011 IV Human Commensal PEN; OXA; GEN; TET; SXT C 07-00415† 1000 4239 Germany N.A. 01.06.2007 t034 MSSA Human  PEN; TET  N.A. 07-00471† M 34 Austria S.C. 1 01.06.2007 t011 IV Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-00755† W 372/06 Austria S.C. 1 01.06.2007 t011 IV Horse Wound infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-00757† W 1129/06 Austria S.C. 1 01.06.2007 t011 IV Horse Wound infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01238† H 99 Austria S.C. 1 01.06.2007 t011 IV Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01239† H 101 Austria S.C. 1 01.06.2007 t011 IV Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01274† 159 Germany N.A. 26.04.2007 t034 V Pig  PEN; OXA; ERY; CLI; TET; SXT A 07-01335† H 73 Austria S.C. 1 26.04.2007 t011 IV Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01337† R 109 Austria S.C. 1 01.06.2007 t011 IV Horse Infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01388† E 120 Austria S.C. 1 01.06.2007 t011 IV Horse Infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01429† 2451294 Germany N.A. 01.06.2007 t571 MSSA Human Wound infection ERY N.A. 07-01494† 235633 Germany N.A. 01.06.2007 t034 V Human Wound infection PEN; OXA; ERY; CLI; TET  A 07-01640† 235633 Germany N.A. 25.05.2007 t034 V Human Wound infection PEN; OXA; ERY; CLI; TET A 
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07-01653† VA 9476872-WA Germany N.A. 24.05.2007 t034 V Human Wound infection PEN; OXA; ERY; CLI; TET; CIP; SXT; MFL E 07-01730† H120 Austria S.C. 1 01.06.2007 t011 IV Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-01826† 81 Germany N.A. 01.06.2007 t1197 MSSA Human Wound infection TET; CIP; SXT; MFL N.A. 07-01949† E 130 Austria S.C. 1 01.06.2007 t011 IV Horse Infection PEN; OXA; GEN; ERY; CLI; TET; SXT C 07-02239† VA 312822 Germany N.A. 01.06.2007 t108 V Human Wound infection PEN; OXA; TET; CIP; MFL B 07-02347† 88 732B 755 Germany N.A. 01.06.2007 t034 nt Human Commensal PEN; OXA; ERY; CLI; TET A 07-02415† 1 Denmark N.A. 01.06.2007 t2974 V Pig  PEN; OXA; TET  N.A. 07-02424† 11 Denmark N.A. 03.09.2007 t011 V Pig  PEN; OXA; GEN; ERY; CLI; TET; SXT D 07-02431† H2 Germany N.A. 03.09.2007 t011 V Human  PEN; OXA; GEN; ERY; CLI; TET; SXT D 07-02432† H3 Germany N.A. 03.09.2007 t011 V Human  PEN; OXA; GEN; ERY; CLI; TET; SXT D 07-02433† H4 Germany N.A. 03.09.2007 t011 V Human  PEN; OXA; GEN; ERY; CLI; TET; SXT D 07-02464† H12 Germany N.A. 03.09.2007 t034 MSSA Human  PEN; ERY; CLI; TET; SXT F 07-02558† 88 735B 930 Germany N.A. 03.09.2007 t034 V Human Abscess PEN; OXA; ERY; CLI; TET A 07-02632† H 824 Germany N.A. 03.09.2007 t034 V Human  PEN; OXA; ERY; CLI; TET; SXT A 07-02642† H 827 Germany N.A. 10.09.2007 t034 V Human  PEN; OXA; ERY; CLI; TET; SXT F 07-03026† 25533 Germany N.A. 03.09.2007 t011 V Human Wound infection PEN; OXA; TET N.A. 07-03443†  Germany N.A. 03.09.2007 t034 V Pig  PEN; OXA; ERY; CLI; TET A 08-00301† B 11 Germany N.A. 03.09.2007 t011 V Pig  PEN; OXA; GEN; ERY; CLI; TET; SXT; TGC D 08-00306† H 2 Germany N.A. 30.01.2008 t011 V Human  PEN; OXA; ERY; CLI; TET; TGC D 08-00307† H 3 Germany N.A. 30.01.2008 t011 V Human  PEN; OXA; ERY; CLI; TET; TGC D 08-00308† H 4 Germany N.A. 30.01.2008 t011 V Human  PEN; OXA; GEN; ERY; CLI; TET; SXT; TGC D 08-00360† H 6 Germany N.A. 30.01.2008 t034 MSSA Human  PEN; TET; SXT; TGC F 08-00401† 16 Germany N.A. 30.01.2008 t034 V Pig  PEN; OXA; ERY; CLI; TET; SXT; TGC N.A. 08-00537†  Germany N.A. 30.01.2008 t034 MSSA Turkey Skeletal infection PEN; ERY; CLI; TET; CIP N.A. 08-00543†  Germany N.A. 01.06.2008 t034 MSSA Turkey Skeletal infection PEN; TET N.A. 08-00700† H1 Germany N.A. 01.06.2008 t011 MSSA Human  PEN; ERY; CLI; TET N.A. 08-00798†  Germany N.A. 01.06.2008 t034 MSSA Turkey Skeletal infection PEN; ERY; CLI; TET N.A. 08-00888†  Germany N.A. 01.06.2008 t034 MSSA Turkey Skeletal infection PEN; TET; CIP N.A. 
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08-00907† H 1 Germany N.A. 01.06.2008 t011 V Human  PEN; OXA; ERY; CLI; TET  N.A. 08-00912† S 5 Germany N.A. 01.06.2008 t034 V Pig  PEN; OXA; ERY; CLI; TET; SXT E 08-01058† H 4 Germany N.A. 01.06.2008 t034 MSSA Human  PEN; TET; SXT N.A. 08-01223† H 4,1 Germany N.A. 01.06.2008 t034 MSSA Human  PEN; TET; SXT N.A. 08-01388† VA 309257 Germany N.A. 01.06.2008 t011 V Human Wound infection PEN; OXA; TET N.A. 08-01605† H 800/2 Germany N.A. 01.06.2008 t011 MSSA Human  PEN; ERY; CLI; TET; SXT N.A. 08-01712† S 1a Germany N.A. 01.06.2008 t011 V Pig  PEN; OXA; TET; SXT N.A. 08-01737† H 28 S 3 Germany N.A. 01.06.2008 t011 V Pig  PEN; OXA; TET; SXT N.A. 08-01849†  Germany N.A. 01.06.2008 t011 V Human  PEN; OXA; TET  N.A. 08-02208†  Germany N.A. 06.10.2008 t034 V Human  PEN; OXA; ERY; CLI; TET E 08-02418† E 855 Germany N.A. 06.10.2008 t034 V Human Wound infection PEN; OXA; ERY; CLI; TET F 08-02710† 339 Germany N.A. 06.10.2008 t034 MSSA Human  PEN; ERY; CLI; TET A 08-02807† 579 Germany N.A. 06.10.2008 t034 V Human  PEN; ERY; CLI; TET F 09-00339† 2006S318 Belgium N.A. 06.10.2008 t011 V Human  PEN; OXA; ERY; CLI; TET; CIP; SXT; MFL N.A. 09-00340-1† 2006S488 Belgium N.A. 06.10.2008 t011 IV Horse  PEN; OXA; GEN; ERY; CLI; TET; SXT C 09-00341† 2007S256 Belgium N.A. 06.10.2008 t011 V Pig  PEN; OXA; TET; CIP; MFL N.A. 09-00342† 2007S174 Belgium N.A. 06.10.2008 t011 V Chicken (thaw wa-ter) 
 PEN; OXA; ERY; CLI; TET N.A. 
09-00343† 2007S413 Belgium N.A. 06.10.2008 t011 V Horse  PEN; OXA; TET N.A. 09-00393† 1 Germany N.A. 01.06.2009 t034 V Human Commensal PEN; OXA; ERY; CLI; TET N.A. 09-00443† H2 Germany N.A. 01.06.2009 t011 V Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT D 09-00444† H3 Germany N.A. 01.06.2009 t011 V Human Commensal PEN; OXA; GEN; ERY; CLI; TET; SXT D 09-00445† H4 Germany N.A. 01.06.2009 t011 V Human Commensal PEN; OXA; ERY; CLI; TET; SXT D 09-00709† 1 Germany N.A. 01.06.2009 t034 V Human Commensal PEN; OXA; ERY; CLI; TET E 09-00711†  Germany N.A. 01.06.2009 t034 V Pig Commensal PEN; OXA; ERY; CLI; TET N.A. 09-01308† SW 61.2 USA N.A. 01.06.2009 t034 V Pig  PEN; OXA; TET N.A. 09-01309† SW 181.1 USA N.A. 01.06.2009 t034 V Pig  PEN; OXA; ERY; CLI; TET N.A. 09-01310† SW 31.1 USA N.A. 01.06.2009 t034 V Pig  PEN; OXA; TET N.A. 
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09-01311† 05.9498.K UK N.A. 22.10.2005 t034 MSSA Human Sepsis PEN N.A. 09-01312† NY.ST398 USA N.A. 01.06.2009 t571 MSSA Human  PEN; ERY N.A. 09-01313† 07.6579.J UK N.A. 23.08.2007 t034 V Environment  PEN; OXA N.A. 09-01314† 07.8588.D UK N.A. 12.11.2007 t034 V Human Wound infection PEN; OXA N.A. 09-01315† 07.2736.J UK N.A. 05.03.2007 t034 V Human Infection PEN; OXA N.A. 09-01316† HU 01010T USA N.A. 01.06.2009 t034 V Human  PEN; OXA; TET N.A. 09-01318† 07.7640.J  UK N.A. 04.10.2007 t034 V Human Infection PEN; OXA N.A. 09-01840  Germany  N.A. 01.06.2009 t034 V Pig  PEN, OXA, ERY, TET, CIP i, OXaSu N.A. 09-02165† 1 Germany N.A. 01.06.2009 t034 V Pig  PEN; OXA; CLI; TET F 09-02423†  Germany N.A. 01.06.2009 t011 III Human Commensal PEN; OXA; ERY; CLI; TET N.A. 09-02427† 1 Netherlands N.A. 01.06.2009 t034 MSSA Dog Commensal PEN; TET N.A. 09-02428† 2 Netherlands F 1 01.06.2009 t011 IV Dog Commensal PEN; OXA; GEN; ERY; CLI; TET  C 09-02429† 8 Netherlands F 1 01.06.2009 t011 IV Dog Commensal PEN; OXA; GEN; ERY; CLI; TET  C 09-02431† 4 Netherlands N.A. 01.06.2009 t1197 V Horse Commensal PEN; OXA; ERY; CLI; TET; CIP; MFL N.A. 09-02432† 5 Netherlands F 1 01.06.2009 t011 IV Horse Commensal PEN; OXA; GEN; ERY; CLI; TET; CIP; MFL C 09-02434† 16 Netherlands N.A. 01.06.2009 t011 V Horse Commensal PEN; OXA; TET N.A. 09-02435† 3 Netherlands N.A. 01.06.2009 t011 V Pig Commensal PEN; OXA; TET N.A. 09-02436† 7 Netherlands F 1 01.06.2009 t011 IV Pig Commensal PEN; OXA; GEN; ERY; CLI; TET C 09-02437† 12 Netherlands N.A. 01.06.2009 t1457 V Pig Commensal PEN; OXA; TET N.A. 09-02438† 27 Netherlands N.A. 01.06.2009 t011 V Pig Commensal PEN; OXA; TET N.A. 09-02439† 28 Netherlands N.A. 01.06.2009 t1457 V Pig Commensal PEN; OXA; TET N.A. 09-02440† 9 Netherlands F 1 01.06.2009 t011 IV Bovine Commensal PEN; OXA; GEN; ERY; CLI; TET C 09-02441† 10 Netherlands N.A. 01.06.2009 t571 V Bovine Commensal PEN; OXA; ERY; CLI; TET N.A. 09-02442† 11 Netherlands F 1 01.06.2009 t011 IV Bovine Commensal PEN; OXA; GEN; ERY; CLI; TET C 09-02444† 13 Netherlands N.A. 01.06.2009 t108 V Goat Commensal PEN; OXA; TET B 09-02476† 44 Italy F 3 30.07.2007 t899 IV Human Abscess PEN; OXA; TET; SXT N.A. 09-02477† 45 Italy F 3 01.08.2007 t108 V Human Commensal PEN; OXA; ERY; CLI; TET; CIP; SXT; MFL B 09-02478† 46 Italy F 3 01.08.2007 t899 MSSA Human Commensal PEN; TET N.A. 09-02611† 7 Germany N.A. 01.06.2009 t034 V Human Commensal PEN; OXA; TET F 
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09-02615† 15 Germany N.A. 01.06.2009 t034 V Pig Commensal PEN; OXA; TET F 09-03220 62931 Denmark N.A. 21.10.2008 t011 V Human  PEN, OXA, ERY, CLI, TET, SXT i, OX-aSu F 09-03221 40850 Denmark N.A. 11.03.2004 t034 Iva Human  PEN, OXA, ERY, CLI, TET, OXaSu N.A. 09-03222 47772 Denmark N.A. 16.12.2005 t034 IV Human  PEN, OXA, TET, OXaSu N.A. 09-03223 40315 Denmark N.A. 26.01.2004 t034 V Human  PEN, OXA, ERY, CLI, TET, SXT i, OX-aSu N.A. 09-03224 40555 Denmark N.A. 10.02.2004 t034 V Human  PEN, OXA, ERY, CLI, TET, CIP i, SXT i, OXaSu N.A. 09-03225 43511 Denmark N.A. 26.01.2004 t034 V Human  PEN, OXA, TET, SXT i, OXaSu N.A. 09-03226 62939 Denmark N.A. 21.10.2008 t034 IV Human  PEN, OXA, ERY, CLI, TET, OXaSu N.A. 09-03227 51225 Denmark N.A. 28.04.2006 t108 V Human  PEN, OXA, TET, OXaSu B 09-03229 52615 Denmark N.A. 17.09.2006 t011 MSSA Human  CIP i N.A. 09-03230 45068 Denmark N.A. 08.04.2005 t034 MSSA Human  PEN, TET, CIP i, OXaSu N.A. 09-03231 55241 Denmark N.A. 27.01.2007 t571 MSSA Human  ERY, CIP i N.A. 09-03232 66369 Denmark N.A. 23.05.2009 t1451 MSSA Human  ERY, CIP i N.A. 09-03233 62942 Denmark N.A. 21.10.2008 t011 V Human  PEN, OXA, GEN, ERY, CLI, TET, OX-aSu N.A. 09-03234 50148 Denmark N.A. 18.01.2006 t034 V Human  PEN, OXA, ERY, CIP, MFL, OXaSu N.A. 09-03235 58476 Denmark N.A. 18.10.2007 t108 V Human  PEN, OXA, TET, OXaSu B 09-03236 66801 Denmark N.A. 03.07.2009 t571 V Human  PEN, OXA, TET, OXaSu N.A. 09-03237 53783 Thailand N.A. 01.09.2007 t034 IX Human  PEN, OXA, TET, SXT i, OXaSu N.A. 09-03238 53790 Canada N.A. 28.09.2007 t034 X Human  PEN, OXA, GEN, TET, OXaSu N.A. 09-03323† VB963847 Germany N.A. 28.09.2007 t1344 nt Dog  PEN; OXA; TET N.A. 09-03324† VB972261 Austria N.A. 28.09.2007 t011 IV Horse Infection PEN; OXA; GEN; TET C 09-03325-1† VB 972715.3 Germany N.A. 28.09.2007 t011 IV Horse Clinical isolate PEN; OXA; GEN; TET; CIP; SXT; MFL C 09-03326† VB976023.2 Austria N.A. 28.09.2007 t011 IV Horse Infection PEN; OXA; GEN; TET; SXT C 09-03327† VB976086.1 Germany N.A. 28.09.2007 t034 nt Cat  PEN; OXA; ERY; CLI; TET A 09-03329 73-11242-1 Denmark N.A. 01.06.2001 t034 MSSA Pig  ERY, CLI, TET N.A. 09-03330 74-13727-1 Denmark N.A. 01.06.2002 t034 MSSA Pig  PEN, ERY, CLI, TET N.A. 
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09-03331 74-13714-1 Denmark N.A. 01.06.2002 t034 MSSA Pig  PEN, TET, SXT F 09-03332 75-12166-1 Denmark N.A. 01.06.2003 t034 MSSA Pig  PEN, ERY, CLI, TET, SXT i N.A. 09-03333 76-11472-1 Denmark N.A. 01.06.2004 t034 MSSA Pig  PEN, OXA, TET, CIP, SXT, MFL, OX-aSu N.A. 09-03334 76-11995-1 Denmark N.A. 01.06.2004 t034 MSSA Pig  PEN, ERY, CLI, TET, SXT i N.A. 09-03335 77-11730-1 Denmark N.A. 01.06.2005 t034 MSSA Pig  PEN, SXT N.A. 09-03336 2007-70-95-9 Denmark N.A. 01.06.2007 t2876 MSSA Pig  PEN, ERY, CLI, TET, SXT i N.A. 09-03337 USA42 USA N.A. 01.06.1993 t034 MSSA Bovine Mastitis PEN, ERY, CLI, TET N.A. 09-03339 21441-4S Denmark N.A. 01.06.2007 t034 V Pig  PEN, OXA, ERY, CLI, TET, SXT i, OX-aSu N.A. 09-03340 23221-1B2 Denmark N.A. 01.06.2007 t034 V Pig  PEN, OXA, TET, SXT, OXaSu N.A. 09-03343 98699-M-23-B-1 Denmark N.A. 01.06.2007 t034 MSSA Pig  PEN, CLI, TET, SXT N.A. 09-03345 2007-70-52-4 Denmark N.A. 01.06.2007 t034 V Pig  PEN, OXA, TET, SXT, OXaSu N.A. 09-03347 10(72398) Denmark N.A. 01.06.2007 t034 V Pig  PEN, OXA, ERY, CLI, TET, CIP, SXT, MFL, OXaSu F 10-01698  Germany  S.C. 6 22.07.2010 t011 V Horse Clinical isolate PEN, OXA, GEN, ERY, CLI, TET, OX-aSu C 10-02048  Germany  N.A. 22.07.2010 t034 MSSA Human Furuncle PEN, ERY, CLI, TET N.A. 10-02213-1  Germany  S.C. 6 20.09.2010 t011 V Horse Wound infection PEN, OXA, GEN, ERY, CLI, TET, OX-aSu C 10-02592  Germany  N.A. 26.10.2010 t011 V Goose  PEN, OXA, TET, CIP, OXaSu N.A. 10-02593  Germany  N.A. 26.10.2010 t011 V Goose  PEN, OXA, TET, CIP, OXaSu N.A. 10-02655  Germany  N.A. 09.11.2010 t034 V Chicken (thaw wa-ter) 
 PEN, OXA, ERY, CLI, TET, OXaSu E 
10-02658  Germany  N.A. 09.11.2010 t2576 V Chicken (thaw wa-ter) 
 PEN, OXA, GEN, ERY, CLI, TET, SXT i, OXaSu N.A. 
10-02693 1025102 Germany  A.C. 12 05.11.2010 t034 V Horse Clinical isolate PEN, OXA, ERY, CLI, TET, OXaSu N.A. 11-00014  Germany  N.A. 14.12.2010 t011 V Bovine Mastitis PEN, OXA, GEN, TET, OXaSu N.A. 
 Appendix  
141  
11-00078  Germany  N.A. 14.12.2010 t034 MSSA Human Abscess PEN, ERY, CLI N.A. 11-00080  Germany  N.A. 14.12.2010 t571 MSSA Bovine Mastitis Sens. N.A. 11-00501  Germany  N.A. 10.02.2011 t034 V Chicken (thaw wa-ter) 
 PEN, OXA, ERY, CLI, TET, OXaSu E 
11-00530  Germany  N.A. 14.02.2011 t034 V Chicken (thaw wa-ter) 
 PEN, OXA, ERY, CLI, TET, OXaSu E 
11-00569  Germany  N.A. 17.02.2011 t011 V Chicken (thaw wa-ter) 
 PEN, OXA, GEN, ERY, CLI, TET, OX-aSu D 
11-00571  Germany  N.A. 17.02.2011 t011 V Chicken (thaw wa-ter) 
 PEN, OXA, ERY, CLI, TET, OXaSu N.A. 
11-00830 1028487 Belgium S.C. 2 14.12.2010 t011 IV Horse Clinical isolate PEN, OXA, GEN, ERY, CLI, TET, RAM, OXaSu C 11-00833 1101194 Germany  A.C. 13 12.01.2011 t6867 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01113-1 1102964 Germany  A.C. 13 28.01.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01119 1108771 Germany  A.C. 2 21.03.2011 t034 V Horse Clinical isolate PEN, OXA, ERY, CLI, TET, OXaSu E 11-01120 1108947 Germany  A.C. 12 21.03.2011 t034 V Horse Clinical isolate PEN, OXA, GEN, ERY, CLI, TET, OX-aSu N.A. 11-01123 1109769 Germany  S.C. 5 28.03.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-01124 1109802 Germany  A.C. 12 29.03.2011 t034 V Horse Clinical isolate PEN, OXA, ERY, CLI, TET, OXaSu N.A. 11-01125 1109932 Germany  S.C. 5 31.03.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-01188 1110544 Germany  A.C. 3 05.04.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01189 1110582 Germany  S.C. 5 04.04.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-01190 1110692 Germany  A.C. 1 05.04.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01191 1110739 Germany  A.C. 4 06.04.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX- C 
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aSu 11-01192 1110845 Germany  A.C. 5 07.04.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-01550 1114446 Germany  A.C. 1 10.05.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01553 1112803 Germany  S.C. 3 26.04.2011 t034 V Horse Clinical isolate PEN, OXA, ERY, CLI, TET, OXaSu E 11-01925 1114648 Germany  A.C. 1 13.05.2011 t1451 V Horse Clinical isolate PEN, OXA, TET, OXaSu N.A. 11-01929 1115092 Germany  A.C. 1 17.05.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01931 1115795 Germany  A.C. 6 27.05.2011 t011 V Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01932 1115872 Germany  S.C. 5 26.05.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-01937 1116588 Germany  A.C. 1 04.06.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-01940 1117093 Germany  A.C. 14 10.06.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02211  Germany  N.A. 07.07.2011 t034 MSSA Human Abscess PEN, ERY, CLI N.A. 11-02277 1117232 Germany  A.C. 1 14.06.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02281 1118615 Germany  S.C. 4 30.06.2011 t779 II Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-02283 1118823 Germany  A.C. 13 01.07.2011 t6867 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02285 1119501 Germany  A.C. 7 11.07.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02287 1119504 Germany  A.C. 8 11.07.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02558 1119783 Germany  A.C. 9 16.07.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02560 1119963 Germany  A.C. 10 18.07.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, SXT i, OXaSu C 11-02561 1119983 Germany  A.C. 6 19.07.2011 t011 V Horse Clinical isolate PEN, OXA, GEN, TET, OXaSu C 11-02564 1120152 Germany  A.C. 12 23.07.2011 t034 V Horse Clinical isolate PEN, OXA, ERY, CLI, TET, OXaSu N.A. 11-02801 1121483 Germany  S.C. 5 14.08.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-02802 1121495 Germany  A.C. 1 14.08.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-02804 1121988 Germany  S.C. 5 19.08.2011 t011 IV Horse Clinical isolate PEN, OXA, GEN, TET, CIP, MFL, OX-aSu C 11-02806 1122115 Germany  A.C. 11 23.08.2011 t011 V Horse Clinical isolate PEN, OXA, GEN, ERY, CLI, TET, SXT i, OXaSu N.A. 
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*Resistance against the following antibiotics was tested: PEN, penicillin G; OXA, oxacillin; TPL, teicoplanin; VAN, vancomycin; GEN, gentamicin; TET, tetracycline; CIP, ciprofloxacin; MFL, moxifloxacin; SXT, trime-thoprim/sulfamethoxazole (cotrimoxazole; SXTi, intermediate resistance to SXT); ERY, erythromycin; CLI, clindamycin; RAM, rifampicin; DAP, daptomycin; MUP, mupirocin; LNZ, linezolid and TGC, tigecycline. **The veterinary care or facilities in this study were divided into stationary care (S.C., where the animals must be hospitalized for at least one night in order to receive medical treatment) or ambulatory care (A.C., medical care is provided to animals without being admitted to a hospital for treatment). Numbers in (Farm/Stationary or Ambulatory Care) represent the various Farms (F), Stationary, or Ambulatory Care. N.A. in Fedral state = Not Available; in Clade = Not Assigned; and in Farm/Stationary or Ambulatory Care = No information Available. †All the 112 CC398 isolates that were analysed by Anne Wittenberg using the same method (dHPLC). 
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Table ‎A.2. Primers used for Multilocus Sequence Typing (MLST). 
Housekeeping loci Primer Sequence 5´-3 
Carbamate kinase (arcC) arcC-F TTGATTCACCAGCGCGTATTGTC 
arcC-R AGGTATCTGCTTCAATCAGCG Shikimate dehydrogenase (aroE) aroE-F ATCGGAAATCCTATTTCACATTC 
aroE-R GGTGTTGTATTAATAACGATATC Glycerol kinase (glpF) glpF-F CTAGGAACTGCAATCTTAATCC 
glpF-R TGGTAAAATCGCATGTCCAATTC Guanylate kinase (gmk) gmk-F ATCGTTTTATCGGGACCATC 
gmk-R TCATTAACTACAACGTAATCGTA Phosphate acetyltransferase (pta) pta-F GTTAAAATCGTATTACCTGAAGG 
pta-R GACCCTTTTGTTGAAAAGCTTAA Triosephosphate isomerase (tpi) tpi-F TCGTTCATTCTGAACGTCGTGAA 
tpi-R TTTGCACCTTCTAACAATTGTAC Acetyl coenzyme A acetyltransferase (yqiL) yqiL-F CAGCATACAGGACACCTATTGGC 
yqiL-R CGTTGAGGAATCGATACTGGAAC  
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Table ‎A.3. Primers used for Staphylococcal Cassette Chromosome mec (SCCmec) typing. 
Primer Specific for Amplified stretches Sequence (5′-3′) Size (bp) 
α2, 2 SCCmec I ccrA1/β2 CCTATATCATCAATCAGTACGT 690 
β2, 2-1 ccrA1/β2 GCCTTGATAATAGCCTTC 
α3, 2 SCCmec II, IV ccrA2/β AGGCATCAATGCACAAACACT 920 
β2, 2-1  ccrA2/β2 CGAATGAAGTGAAAGAAAGTGG MECI P2 SCCmec II MECI P2 ATCAAGACTTGCATTCAGGC 209 MECI P3  MECI P3 GCGGTTTCAATTCACTTGTC  DCS F2 SCCmec III DCS F2 CATCCTATGATAGCTTGGTC 342 DCS R1  DCS R1 CTAAATCATAGCCATGACCG  RIF4 F3 SCCmec V RIF4 F3 GTGATTGTTCGAGATATGTGG 243 RIF4 R9  RIF4 R9 CGCTTTATCTGTATCTATCGC  RIF5 F10  RIF5 F10 TTCTTAAGTACACGCTGAATCG 414 RIF5 R13  RIF5 R13 GTCACAGTAATTCCATCAATGC  IS431 P4  IS431 P4 CAGGTCTCTTCAGATCTACG 381 pUB110 R1  pUB110 R1 GAGCCATAAACACCAATAGCC  IS431 P4  IS431 P4 CAGGTCTCTTCAGATCTACG 303 pT181 R1  pT181 R1 GAAGAATGGGGAAAGCTTCAC  MECA P4  MECA P4 TCCAGATTACAACTTCACCAGG 162 MECA P7  MECA P7 CCACTTCATATCTTGTAACG  
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Table ‎A.4. Primers used for screening of Mobile genetic elements (MGEs). 
MGE Primer Sequence 5´-3 Reference 
φAvβ1 φAvβ-F1 GCTTTGACATTTTCGGCATT Lowder v, 2009 φAvβ-R1 CTGGCTTGCTTTCTTCTGCT 
φAvβ2 φAvβ-F2 TTAACCCACTCCGCAAATTC Lowder v, 2009 φAvβ-R2 ATCGCAAGAGACCAAGCAGT 
φSa2 intSa2-F TCAAGTAACCCGTCAACTCGGAGA Schijffelen J M, 2010 intSa2-R TGAAA´CCCTCTGTCAACATAGCTCGAA 
φSa3 intSa3-F ATGAAGCTCTAGCTAAT Price et al, 2012 IntSa3-R CACAACGCTCCCAATGTT 
φSa6 intSa6-F GCCATCAATTCAAGGATAG Schijffelen J M, 2010 IntSa6-R TCTGCAGCTGAGGACAAT PVL PVL-F ATCATTAGGTAAAATGTCTGGACATGATCCA Lina G, 1999 PVL-R GCATCAAGTGTATTGGATAGCAAAAGC 
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Table ‎A.5. Genetic loci and PCR primers for dHPLC. 
Locus ORF Annotation Left Primer (5´-3´) Right Primer (5´-3´) Position in 
(S0385 Genome) 
Product 
size (bp) 
Temperature 
(°C) au200 SA0016 adenylosuccinate synthase TTCGTTTCGAAGGTAATTGG CGTGCATTTTCAGGTAATTCTT 23216 23628 371 56.3 au201 SA0098 hypothetical protein, similar to aminoacylase TGAAGATGAAACGGCGAAAT CCTGTTTTCATTGTGCTCAT 110529 110948 380 57.3 au202 SA0113 hypothetical protein, similar to ornithine cyclodeami-nase (EC 4.3.1.12) AAACGCGTGTTTGTTTACGA TTTTGTTGTTGTGCCTGTTGA 130244 130731 447 56.3 au204 SA0171 NAD-dependent formate dehydrogenase TGCGCATGAATTACAACACA TCTTCAATGCGTTTTTGTGC 194555 194982 428 55.4 au205 SA0182 hypothetical protein, similar to indole-3-pyruvate de-carboxylas TTAGTTGCAATGAGCCATCA TTCAGCAACAGCAGGATTTT 213236 213690 415 54.3 au206 SA0202 hypothetical protein, similar to gamma-glutamyltranspeptidase precursor TCTTGCGGCTAAAATTGGTAA TGGCGCGAATATTTTTCAGT 239439 239855 376 56.3 au207 SA0220 hypothetical protein, similar to glycerophosphodiester phosphodiesterase TGAAAAGCGCATTGTTCTTC TCCATTTTGACGCATTTTCA 263008 263471 424 54.6 au208 SA0256 6-phospho-beta-glucosidase CCGCAAATCAATTTGAAGGT GCGCAAAATGCACAAAATAA 310060 310488 389 55.6 au209 SA0299 hypothetical protein, similar to carbohydrate kinase, PfkB family TTGCAGAAACATCAAATCCTG TCATTTTTGGGGAAGAAACC 355123 355563 400 56.0 au210 SA0311 hypothetical protein, similar to trimethylamine dehy-drogenase (EC 1.5.99.7) TCGAAATTTCCACACCATCA CCGTAAACGCATCAACAAAA 369364 369789 386 57.7 au212 SA0346 hypothetical protein, similar to cystathionine beta-lyase TGACAGCACCAGCAATTAAA ATTCGCTTTTGCTTTTGCAT 405743 406170 388 56.2 au213 SA0376 GMP synthase AAGTTGAACGTGCCAATGAA TTGATCCCCAATTGCTTTATG 434800 435239 399 57.2 au214 SA0419 cystathionine gamma-synthase CAAACATGGCTTTGCGTTTA ATGCCACCTGTTGAATTTGA 480802 481293 452 56.5 au215 SA0431 NADH-glutamate synthase small subunit AAGCGGGCATTACTTTCATT AACGCATTGTTTGAACACCA 495821 496294 434 55.8 au218 SA0507 hypothetical protein, similar to N-acyl-L-amino acid amidohydrolase TCAAATTTGGGATTATGGTGTG CAAACCTCATGAAACCATTGA 592338 592835 455 54.9 au219 SA0512 branched-chain amino acid aminotroansferase homo-logue AAATTTCACCTGCTGCACAA TGCAACTTTTGCAAAGCCTA 599411 599841 391 56.6 au220 SA0537 hypothetical protein, similar to phosphomethylpyrim-idine kinase, thiD homologue AAGCTTTGCCACCTTTAATGA TGCAAGCAGATTTGAAAACG 631634 632116 442 56.3 au222 SA0697 hypothetical protein, similar to glycerate kinase CAGTTGCAAGCCAAATTGAA TCGACTTGAAAAATCCGACA 795048 795547 460 55.6 au223 SA0730 2, 3-diphosphoglycerate- independentphosphoglycer-ate mutase CGGAAATTTTTGCGAACAGA TTCGATTGCTTTGATTGTCG 836703 837148 406 55.3 au224 SA0791 hypothetical protein, similar to glycerate dehydrogen-ase TGACGTTGTTATGTGGCAAAA TTAAACCCTTGCAACCTTCTT 896974 897414 399 56.8 au225 SA0859 thimet oligopeptidase homologue TACTGAATTGCGCAAAGAATTG ATGCAACTTCAGCGACAAAA 974341 974741 359 55.4 au226 SA0945 dihydrolipoamide S-acetyltransferase component of pyruvate dehydrogenase complex E2 AAAGAAATCGCAGCTGAACAA TTTTGAGCAATACGGCCAAT 1073758 1074161 363 56.2 au227 SA1044 dihydroorotase ATGAAGGGAAACGCAGTAAA CAATTCCGAATGGTGCTTTT 1181330 1181731 362 56.4 au228 SA1115 riboflavin kinase / FAD synthase ribC CAATGGCATTCGGATTTTTC CATTCGCTTTTTGCAACTCA 1264780 1265262 443 53.8 au229 SA1177 transketolase TTGGTTCACCGAATAAAGCA TGGATTTGTTTGAACCAGCA 1339372 1339785 374 54.8 au230 SA1226 asd, aspartate semialdehyde dehydrogenase AAAAAGCTGGTGCAATCGTT TCGTTTCTTTGTCAAGCGTTA 1401265 1401747 442 56.1 au231 SA1308 30S ribosomal protein S1 ATGCACCAAAGTTTGCCAAT TTCCGGCTTCACTAATTTCAA 1513993 1514478 445 54.8 au232 SA1412 oxygen-independent coproporphyrinogen oxidase III TTCATGGCCATCTAATGCAA CATTTGAAGCAAATCCTGATGA 1617553 1618016 422 54.6 
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au233 SA1496 glutamyl-tRNA reductase ATTTCCCCTGCACCAATAAT CGAATTGCCCATGAAGATTT 1704604 1705096 453 56.1 au234 SA1545 D-3-phosphoglycerate dehydrogenase TGCAGTGAATGCACCTAAAA TAACAATGCGCCAGTTTTTC 1766721 1767216 456 54.2 au236 SA1814 hypothetical protein, similar to succinyl-diaminopimelate desuccinylase ATGTTGCACCCATGTTCAAA CATCGATTTGATGTGCCATT 2053853 2054311 419 55.6 au237 SA1924 hypothetical protein, similar to aldehyde dehydrogen-ase GCAAATGCTGCTGCTAATTTT TTAATGGCGAATGGGTAGAAA 2173216 2173675 418 56.7 au238 SA1991 6-phospho-beta-galactosidase TTTTGTTGGCAATGCGTGTA ATTTCAATTGCATGGTCACG 2263407 2263853 407 55.1 au239 SA2120 hypothetical protein, similar to amino acid amidohy-drolase GCAATTGCTTTATGCGTCAAT TCAAAACAGGGGCAATTACA 2383969 2384377 368 57.3 au240 SA2214 adenosylmethionine-8-amino-7-oxononanoate ami-notransferase ACCCTGCGATTTCATCATTT TAAAATTGCCCATTCTACGC 2485384 2485811 388 55.7 au242 SA2410 nrdD, anaerobic ribonucleoside-triphosphate reduc-tase ACTCGTGCGCAAATTTCTTT ACGGATCGTTTTTGTCGTTT 2701426 2701886 421 56.5 au243 SA2470 hypothetical protein, similar to histidinol dehydrogen-ase TGTTTGAATCGACGCATGTT TTGCTGCATTGACTTATGGAA 2781905 2782326 381 57.2 au244 SA0177 argJ, arginine biosynthesis bifunctional protein homo-logue TGGCAAATCACCAAGTTGAA TGCGTTAATACGCACATAATCA 206898 207388 449 57.0 au245 SA0240 sorbitol dehydrogenase homologue TTGAAAGTGCGAATGACGTT CAAATATTCGTGCCCATTGA 291411 291896 446 57.9 au247 SA0361 truncated hypothetical protein, similar to phospho-glycerate mutase; Gpm3p CATGGCGAATCAAAATCGAA CCATCAAACAACGAATGACAA 418661 419144 443 55.2 au248 SA0527 probable glucosamine-6-phosphate isomerase AAGAGATGGCATTTAATCAGCA AATGGCTTGCTTTGGAACAT 622181 622659 437 54.6 au250 SA0572 hypothetical protein, similar to esterase/lipase TTTAAACGATCACGTTGAGGA AAAGGATCATGTTCCCCATT 665507 665947 400 54.2 au251 SA0671 hypothetical protein, similar to urea amidolyase GAAATTGTGCCATCAGAATCA TTTAAGCGTGCGAAATCTGA 764197 764696 459 54.2 au252 SA0821 argH, argininosuccinate lyase TGCATTTTCAACTGGCTCAT TTGACGTCGTTTCAAGCAA 926525 925992 494 54,8 au253 SA0896 menD, menaquinone biosynthesis protein GGTTAGAAAAATGGCAATGCT GCCAAACAACCGTTCAAAAT 1017529 1017968 399 54.1 au254 SA0924 purN, phosphoribosylglycinamide formyltransferase CGATTTTTGCATCAGGTTCA TTTTGAATCGTCCGGTCTAA 1049523 1050001 439 54.8 au255 SA1089 sucD, succinyl-CoA synthetase AAAAATGAAACTGGGGCAAC CCGATTTCACCAATCATAACAA 1232627 1233078 410 56.9 au256 SA1150 glnA, glutamine-ammonia ligase TGAAAAAGGGGAACCAACTT AATCCGCGTGCATTTTTAAG 1307593 1308024 392 56.1 au257 SA1366 glycine dehydrogenase subunit 1 TCGCATTGCAAGCAAGAATA CAATTGAACCGTAAAAGTTTGG 1575017 1575507 449 55.6 au258 SA1487 folC, folylpolyglutamate synthase TTTACGTCGCCGTTTATTGA CAATTGGCTTTGCATGTTGT 1693267 1693720 414 55.8 au259 SA1524 malate dehydrogenase homologue CGCAATTTTTGAAGGACGTT CTTTAGCAACATTACGAGCAA 1739355 1739845 450 56.2 au260 SA1554 acsA, acetyl-CoA synthetase ATTGTTGGGCCGTTATTTGA TTTGTAGCGCCATTTAACCA 1781281 1781729 409 55.8 au261 SA1585 proline dehydrogenase homologue TTTAGGGGAATTTGTCGGTA GAAATTGCGTGCGTTTAACA 1824023 1824497 435 54.7 au262 SA1669 citG, fumarate hydratase, class-II ACACATTTACAAGATGCAACG TGCAACCATTGTTAACATTTCA 1905900 1906352 410 57.2 au263 SA1735 manganese-dependent inorganic pyrophosphatase CCTGAAATTGCCGGTTTAAT TTTTTCGAGAAACAACACCAGA 1987761 1988244 442 55.1 au264 SA1864 3-isopropylmalate dehydratase large subunit TGCATTGGAATTGGAACAA TGATTTCAGGGAATGGTTCA 2105530 2105983 454 56,1 au265 SA1965 glmM, femD, phosphoglucosamine-mutase ACAAAGCGCTTGAACAAGAA TTGTGCAAATCTTTCAGCATC 2225913 2226346 393 55.4 au267 SA2071 moeB, molybdopterin biosynthesis protein moeB TGCGTTGATTATTGGTATGG TTTAATGCTGGCAATTGTGG 2332305 2332760 416 56.0 au268 SA2099 hypothetical protein, similar to monooxygenase ATCCGGATTGTGCAAAAGAA TGGGCAATTTTACCGATTTT 2359332 2359800 429 54.7 au269 SA2240 hypothetical protein, similar to para-nitrobenzyl ester-ase chain A TGCACGCAATAAAGCACAAT TGCAAATTCAGCAAGCCATA 2517061 2517511 411 55.0 au270 SA2260 hypothetical protein, similar to glucose 1-dehydrogenase TGCGTGGGACAATTTTAATG TTCCACGAATCATCACTTAAC 2537713 2538172 419 57.6 au271 SA2327 hypothetical protein, similar to pyruvate oxidase ATGTACGATGCCAAAATGGA TCATCCGGCAAGATTGTTTT 2612925 2613400 436 54.9 au272 SA2348 crtN, squalene desaturase TTAATGCCAGATTTTGCACCT TTTCGCATGATACGTTTGCT 2638403 2638864 421 54.3 au273 SA2393 hypothetical protein, similar to 2-dehydropantoate 2- AGACACGCCAAAACAATAACA ATGCATGATTGCAACTGTCT 2680864 2681340 436 55.7 
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reductase au274 SA2490 pckA, phosphoenolpyruvate carboxykinase TTTCAACTTTCGACGACACAA TGCTTTAAAATGTGGTGCAGA 1844849 1845280 390 54.4 au275 SA0969 hypothetical protein, similar to glycerophosphoryl diester phosphodiesterase CGCACCACAAATTATGTTTGA TTCGGGATTGTTTGTTTGAA 1099466 1099873 367 55.6 au276 SA1334 hypothetical protein, similar to pyrroline-5-carboxylate reductase AACACGCATCAACCACATA TTTTTCTTAATTGAGCCATGC 1540756 1541157 402 55,7 au277 SA2439 sasF, conserved hypothetical protein (Cooper + Feil) AATGCCTCAACGCAACATTA CAACGATTTGGCGATTTGAT 2743068 2743554 447 54.9 au279 SA0740 hypothetical protein (Cooper + Feil) TTGGAACATTTATTATGGCTTT ACGGTCGATTTGACCTTTTA 847062 847504 401 54.0 au280 SA0817 hypothetical protein, similar to NADH-dependent fla-vin oxidoreductase (Cooper + Feil) TGAAGAAGTGCTTAAAGCGAAA AATTTCATCTTCCCGTCCAT 921075 921477 361 57.0 au281 SA2445 hypothetical protein (Cooper + Feil) TTAAAATGGCCGGATGATGT TTTCGCTGGAATATGATTGG 2753158 2753616 419 55.4 au282 SA2121 hutI, imidazolonepropionase (cooper + Feil) CCCATTTAACATTTGGTGGA GCTTCTTTGGCTTTTTGCAT 2385678 2386152 435 56.0 au284 SA0015 dnaC, replicative DNA helicase (Cooper + Feil) AAAGTTGCAACGCATGAAGA TTGCTCAATCGAACCAGATT 21445 21939 455 56.8 au285 SA0119 hypothetical protein, similar to diaminopimelate TTGAATGTGGGCGCTTTATT TCCTCCTTTGTTTGCGTTAAA 138812 139214 362 56.3 au286 SA0223 hypothetical protein, similar to UDP-glucose 4-epimerase TGCAATCGTTTGAGAAGCAA TGGTCGGTTCAAAGATGAAA 267449 267872 384 57.7 au287 SA0416 hypothetical protein, similar to carboxylesterase ATTAAAATTGGCGCAGCACT GCATTGAAAAAGCGAATAACA 477346 477781 395 55.0 au288 SA0545 phosphotransacetylase GCGCAAAAACTTGATCTTGA TGCCAAAGCTTAATGCTGATT 638508 638919 371 56.4 au289 SA0656 probable N-acetylglucosamine-6-phosphate deacety-lase ATTGTTGCAATTGGAGAAGG ACGTTTCAAGCGCTTCTTTT 750368 750863 456 54.9 au290 SA0843 3-oxoacyl- synthase TATGGCAATTGCAGGTTTCA TTGCTTCAATTCCACCTGTT 956696 957156 421 57.8 au291 SA0881 hypothetical protein, similar to nucleotidase GGCATCAAAACGTTGGATTA GCGAAAATGGATGTGTTTGA 1001452 1001936 445 54.6 au292 SA0902 HisC homologue TGGAACGATTGCTAAATGTGTT TCCTTCGCTGAATTTGAAGA 1023317 1023721 363 54.8 au293 SA0958 myo-inositol-1(or 4)-monophosphatase homologue TTTATGGATTTGCCCAAGGA TTCAATGGTTTCAAGGGTTG 1084827 1085247 381 54.8 au294 SA1121 hypothetical protein, similar to processing proteinase AAGAAATGGCCAACCGATAA TTGCCGACAACATAAACAGAA 1273973 1274433 420 53.2 au295 SA1163 aspartate kinase homologue AACAAAAATACCCGCTTCCTT AAAGTTTCCAAATTCGGTGGT 1324852 1325298 405 53.9 au296 SA1199 hypothetical protein, similar to anthranilate synthase AAATCCAACCATTCATGCCTA TTCGCTGCATTCTTTTGGAT 1373094 1373518 384 55.3 au298 SA1349 dihydrolipoamide dehydrogenase TTGATCCAACATGTGCCAAT TGGTGTTATCGGAATGGAAT 1559232 1559653 382 54.6 au299 SA1377 glucokinase TCAAATTGAGCAGGTGCAAA GCGCAGAAATAGGTCATTTT 1582274 1582676 363 54.7 au300 SA1652 uroporphyrinogen decarboxylase AAGCAAACCATGTTGCTTCA TTCGCAACCAGAATATCGAA 1886778 1887220 403 55.3 au301 SA1685 hypothetical protein, similar to A/G-specific adenine AATTGCCACATACCATGCAA TCCCAAAGATCCTGATCAATTT 1932656 1933123 426 54.6 au302 SA1724 adenylosuccinate lyase ACGGAAAGGTGTTTTCGTTT AAATTTGCCGTTGAAATTCG 1974092 1974559 428 55.6 au303 SA1749 hypothetical protein, similar to aspartate transaminase GCCCAAAGCTTAAATGAACAA ATGTTTGAAGGTTTGCACCA 2001475 2001949 434 55.4 au304 SA1858 dihydroxy-acid dehydratase TTGGTTTGACGGCGTATTTT ATGCATCATCAATTGCTTCG 2097921 2098372 412 57.5 au305 SA1874 alanine racemase TCGCATTGATGACCATTTACA CTTGTATTTGAAGGCGTGTTT 2122020 2122457 396 55.8 au306 SA1963 mannitol-1-phosphate 5-dehydrogenase TTGCAGACGTCAATGAAGAAA TCTTTTTCAACAACCCATTCG 2216805 2217249 403 55.2 au307 SA2001 hypothetical protein, similar to oxidoreductase TTCTTCTTGTTGATGGAATGGA AAACAGCAGAAGCGGTTAAA 2272199 2272623 383 55.1 au308 SA2140 hypothetical protein, similar to esterase TGCCATTAATTGGCGATATG TTCCATTGGAGATTGTTGGA 2404832 2405246 375 55.8 au309 SA2188 nitrite reductase TGCATTTCCATCAACCATTC TAACCGCATCATGCTTTCAA 2459852 2460274 383 55.7  
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Table ‎A.6. CC398 isolates used in the whole genome sequencing approach. 
Isolate Country Isolation year Host Case spa SCCmec tet(M) Reference 06-02016 Austria 2006 Horse Infection t011 IVa Positive RKI, this study 08-00301 Germany 2007 Pig Colonisation t011 V Positive RKI, this study 10-02693 Germany 2010 Horse Infection t034 V Positive RKI, this study 11-00833 Germany 2011 Horse Infection t6867 IVa Positive RKI, this study 11-01925 Germany 2011 Horse Infection t1451 V Positive RKI, this study 11-02806 Germany 2011 Horse Infection t011 V Positive RKI, this study IMT25053 Germany 2011 Horse Infection t011 V Positive FUB, this study IMT26596 Germany 2011 Horse Infection t6867 IVa Positive FUB, this study 9B Denmark 2007 Pig Colonisation t034 Vc (5C2&5) Positive Price et al, 2012 55488 Denmark 2007 Human Colonisation t034 Vc (5C2&5) Positive Price et al, 2012 PR7/08 Portugal 2007 Pig (dust)  t011 Vc (5C2&5) Positive Price et al, 2012 Veo8/003845st Spain 2008 Pig (dust)  t011 Vc (5C2&5) Positive Price et al, 2012 UB08187 France 2008 Pig (dust)  t011 Vc (5C2&5) Positive Price et al, 2012 23824 Austria 2008 Pig (dust)  t011 Vc (5C2&5) Positive Price et al, 2012 AV6 Belgium 2008 Horse Colonisation t011 Vc (5C2&5) Positive Price et al, 2012 AV4 Belgium 2008 Horse Colonisation t1451 IVa (2B&5) Positive Price et al, 2012 29139 Italy 2008 Pig (dust)  t011 IVa (2B) Positive Price et al, 2012 M2009_10004208 Hungary 2009 Pig (dust)  t011 IVa (2B) Positive Price et al, 2012 ST398SO385 The Netherlands 2006 Human Infection t011 Vc (5C2&5) Positive Price et al, 2012 51225 Denmark 2006 Human Colonisation t108 Vc (5C2&5) Positive Price et al, 2012 F20 USA 2008 Pig (meat)  t034 MSSA Positive Price et al, 2012 P23-03_SW181.1 USA 2008 Pig Colonisation t034 Vc (5C2&5) Positive Price et al, 2012 F38 USA 2008 Pig Colonisation t034 MSSA Positive Price et al, 2012 F10 USA 2008 Pig (meat)  t034 MSSA Positive Price et al, 2012 P23-11_HF-446 China 2007 Human Infection t034 MSSA Negative Price et al, 2012 P23-9_WZ-1 China 2002 Human Infection t571 MSSA Negative Price et al, 2012 ST20091526 France 2009 Human Infection t571 MSSA Negative Price et al, 2012 LY19990171 France 1999 Human Infection t571 MSSA Negative Price et al, 2012 
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Table ‎A.7. The investigated genetic loci and their detected polymorphisms. 
Locus Polymorphisms Quality Ancestral Derived Position in CC398 ge-nome au200 au200-1 Non- Synony-mous C T 23542  au200-2 Synonymous A G 23313  au200-3 Synonymous C T 23466 au201 au201-1 Synonymous A G 116488  au201-2 Synonymous C T 116566  au201-3 Synonymous T A 116596  au201-4 Non- Synony-mous C T 116694 au202 au202-1 Non- Synony-mous G A 133896  au202-2 Synonymous C T 134025  au202-3 Synonymous T C 134127  au202-4 Synonymous T A 134217  au202-5 Synonymous A G 134232  au202-6 Non- Synony-mous C A 133893  au202-7 Non- Synony-mous  Deletion 14 bp CACACGCTTCAGAG 133887-133900  au203-1 Non- Synony-mous C T 146630 au204 au204-1 Non- Synony-mous T C 198844 au206 au206-1 Non- Synony-mous T A 239258 au207 au207-1 Non- Synony-mous G A 263000  au207-2 Non- Synony-mous T C 262976 au208 au208-1 Synonymous G A 313878 au209 au209-1 Non- Synony-mous C T 358137 au210 au210-1 Non- Synony-mous C T 419613 au212 au212-1 Non- Synony-mous T A 456070  au212-2 Non- Synony-mous G A 456279 au214 au214-1 Non- Synony-mous A T 539521  au214-2 Non- Synony-mous C A 539264 au215 au215-1 Synonymous C T 554340  au215-2 Synonymous A T 508003 au223 au223-1 Non- Synony-mous A G 901302 au227 au227-1 Non- Synony-mous C T 1251377 au228 au228-1 Non- Synony-mous T C 1333553 au230 au230-1 Non- Synony-mous T G 1470360 au231 au231-1 Non- Synony-mous C A 1583161 au232 au232-1 Non- Synony-mous T G 1731536 au234 au234-1 Synonymous G A 1872909  au234-2 Non- Synony-mous C T 1872581  au234-3 Non- Synony-mous A T 1872820 au236 au236-1 Non- Synony-mous C A 2137364  au236-2 Synonymous G A 2137214 au237 au237-1 Synonymous T C 2241862 au239 au239-1 Synonymous T A 2455456  au239-2 Non- Synony-mous G A 2455634 
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au240 au240-1 Non- Synony-mous G A 2558218 au243 au243-1 Non- Synony-mous G C 2840526  au243-2 Non- Synony-mous C T 2840670 au244 au244-1 Synonymous G A 207306  au244-2 Non- Synony-mous A Deletion of one A 210973 au245 au245-1 Non- Synony-mous G A 292470 au247 au247-1 Non- Synony-mous A C 467424 au251 au251-1 Non- Synony-mous T A 827455  au251-2 Non- Synony-mous G A 827793 au252 au252-1 Non- Synony-mous T A 982524  au252-2 Synonymous C T 982720  au252-3 Non- Synony-mous G A 982789 au254 au254-1 Non- Synony-mous C T 1122187 au255 au255-1 Synonymous T C 1302242  au255-2 Synonymous A G 1302390 au256 au256-1 Non- Synony-mous G A 1377726  au256-2 Synonymous T C 1377565  au256-3 Synonymous C T 1377735 au257 au257-1 Non- Synony-mous C A 1688944  au257-2 Non- Synony-mous A G 1688994 au260 au260-1 Synonymous A T 1887201 au261 au261-1 Synonymous T C 1929639 au262 au262-1 Non- Synony-mous C T 2012944 au264 au264-1 Synonymous G A 2174508 au265 au265-1 Synonymous T C 2299872 au267 au267-1 Non- Synony-mous C T 2403403 au269 au269-1 Non- Synony-mous G A 2589905  au269-2 Non- Synony-mous  Insertion of one A 2589898 au270 au270-1 Non- Synony-mous G A 2609589 au273 au273-1 Synonymous G A 2735776  au273-2 Non- Synony-mous T C 2735604  au273-3 Non- Synony-mous A G 2735517 au279 au279-1 Non- Synony-mous G A 911481  au279-2 Non- Synony-mous T C 911544  au279-3 Synonymous A C 911498 au282 au282-1 Synonymous G A 2457315 au284 au284-1 Non- Synony-mous G T 21662 au286 au286-1 Non- Synony-mous G A 267557 au289 au289-1 Non- Synony-mous T G 813835 au291 au291-1 Non- Synony-mous G A 1074694 au294 au294-1 Non- Synony-mous C T 1342929  au294-2 Non- Synony-mous A C 1342883  au294-3 Non- Synony-mous C T 1342720 
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au296 au296-1 Non- Synony-mous  Insertion of 6 bp TATTTT 1441728-1441733 au298 au298-1 Synonymous C T 1673345  au298-2 Non- Synony-mous A T 1673293  au298-3 Synonymous A G 1673244 au300 au300-1 Synonymous C T 1993865  au300-2 Non- Synony-mous G A 1993929  au300-3 Non- Synony-mous G A 1994130 au304 au304-1 Non- Synony-mous G A 2166786 au307 au307-1 Synonymous T C 2346800 au309 au309-1 Non- Synony-mous T C 2533073  au309-2 Synonymous A T 2533404     
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Table ‎A.8. Additional human isolates screened for the SNP au309-2 Isolate ID Country Federal state  Hospital* Isolation date Spa type Host Characteristic Nucleotide at position 2,533,404 (SNP au309-2) 10-00069 Germany Hesse 1 28/12/09 t011 Human Clinical isolate A 10-00190 Germany North Rhine-Westphalia 2 2010 t011 Human Clinical isolate A 10-00289 Germany Bavaria 3 02/02/10 t011 Human Clinical isolate A 10-00307 Germany Brandenburg 4 08/02/10 t011 Human Clinical isolate A 10-00345 Germany Schleswig-Holstein 5 25/01/10 t011 Human Clinical isolate A 10-00825 Germany Bavaria 3 05/04/10 t011 Human Clinical isolate A 10-00856 Germany Lower Saxony 6 26/03/10 t011 Human Clinical isolate A 10-00901 Germany Hesse 7 12/04/10 t011 Human Clinical isolate A 10-01083 Germany Bavaria 8 04/05/10 t011 Human Clinical isolate A 10-01322 Germany Lower Saxony 9 04/08/09 t011 Human Clinical isolate A 10-01346 Germany Saxony 10 31/05/10 t011 Human Clinical isolate A 10-01433 Germany Lower Saxony 11 2010 t011 Human Clinical isolate A 10-01458 Germany Bavaria 12 21/06/10 t011 Human Clinical isolate T 10-01814 Germany Saxony 10 20/07/10 t011 Human Clinical isolate A 10-01920 Germany Schleswig-Holstein 13 02/08/10 t011 Human Clinical isolate A 10-01949 Germany Bavaria 3 18/08/10 t011 Human Clinical isolate A 10-01972 Germany North Rhine-Westphalia 14 03/08/10 t011 Human Clinical isolate A 10-02072-1 Germany Bavaria 3 30/08/10 t011 Human Clinical isolate A 10-02423-1 Germany Saxony 10 28/09/10 t011 Human Clinical isolate A 10-02477 Germany Schleswig-Holstein 5 07/10/10 t011 Human Clinical isolate A 10-02565 Germany Saxony-Anhalt 15 23/10/10 t011 Human Clinical isolate A 10-02573 Germany Bavaria 3 22/10/10 t011 Human Clinical isolate A 10-02581 Germany Brandenburg 16 15/10/10 t011 Human Clinical isolate A 10-02855 Germany Schleswig-Holstein 17 25/11/10 t011 Human Clinical isolate A 11-00322 Germany North Rhine-Westphalia 18 21/01/11 t011 Human Clinical isolate A 11-00496 Germany Saxony-Anhalt 15 05/02/11 t011 Human Clinical isolate A 11-00666 Germany Schleswig-Holstein 17 23/02/11 t011 Human Clinical isolate A 11-00708 Germany Bavaria 3 28/02/11 t011 Human Clinical isolate A 11-00720 Germany Bavaria 3 01/03/11 t011 Human Clinical isolate T 11-00776 Germany Lower Saxony 11 25/02/11 t011 Human Clinical isolate A 11-00893 Germany Schleswig-Holstein 17 17/03/11 t011 Human Clinical isolate A 11-00896 Germany Lower Saxony 11 23/02/11 t011 Human Clinical isolate A 11-01155 Germany Lower Saxony 19 03/04/11 t011 Human Clinical isolate A 11-01170 Germany Hamburg 20 02/04/11 t011 Human Clinical isolate A 11-01298 Germany Brandenburg 21 2011 t011 Human Clinical isolate A 11-01869 Germany Berlin 22 2011 t011 Human Clinical isolate A 11-02050 Germany Schleswig-Holstein 5 25/05/11 t011 Human Clinical isolate A 11-02153 Germany Hesse 1 14/06/11 t011 Human Clinical isolate A 11-02310 Germany North Rhine-Westphalia 2 28/03/11 t011 Human Clinical isolate A 11-02359 Germany Mecklenburg-Western Pomerania 23 22/07/11 t011 Human Clinical isolate A 11-02636 Germany Lower Saxony 19 18/08/11 t011 Human Clinical isolate T 11-02735 Germany Schleswig-Holstein 24 26/08/11 t011 Human Clinical isolate T 
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11-03257 Germany Schleswig-Holstein 25 04/11/11 t011 Human Clinical isolate A 11-03267 Germany Baden-Württemberg 26 2011 t011 Human Clinical isolate A 11-03381 Germany North Rhine-Westphalia 27 2011 t011 Human Clinical isolate A 11-03422 Germany Schleswig-Holstein 28 11/11/11 t011 Human Clinical isolate A 11-03616 Germany Hesse 1 07/12/11 t011 Human Clinical isolate A 11-01712 Germany Hesse 29 19/05/11 t011 Human Clinical isolate A *Numbers in Column E (Hospital) represent the various Hospitals that the isolates were collected from 
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Table ‎A.9. The 195 investigated CC398 and their acquisition to various bacteriophages. 
Isolate ID Host Spa type SCCmec φAvβ φSa2 φSa3 φSa6 lukPV 04-03094 Human t034 V Negative Negative Negative Positive Negative 05-02057 Dog t034 V Negative Negative Negative Positive Negative 06-00262 Horse t011 IV Negative Positive Negative Positive Negative 06-00880 Horse t011 IV Negative Positive Negative Positive Negative 06-00903 Human t011 V Negative Positive Negative Negative Negative 06-02016 Horse t011 IV Negative Positive Negative Positive Negative 06-02985 Human t011 V Negative Positive Negative Negative Negative 06-03005 Human t571 MSSA Negative Negative Positive Negative Negative 06-03034 Human t034 V Negative Negative Negative Positive Negative 07-00334 Human t011 IV Negative Positive Negative Positive Negative 07-00415 Human t034 MSSA Negative Positive Negative Negative Negative 07-00471 Human t011 IV Negative Positive Negative Positive Negative 07-00755 Horse t011 IV Negative Positive Negative Positive Negative 07-00757 Horse t011 IV Negative Positive Negative Positive Negative 07-01238 Human t011 IV Negative Positive Negative Positive Negative 07-01239 Human t011 IV Negative Positive Negative Positive Negative 07-01274 Pig t034 V Negative Negative Negative Positive Negative 07-01335 Human t011 IV Negative Positive Negative Positive Negative 07-01337 Horse t011 IV Negative Positive Negative Positive Negative 07-01388 Horse t011 IV Negative Positive Negative Positive Negative 07-01429 Human t571 MSSA Negative Negative Positive Negative Negative 07-01494 Human t034 V Negative Negative Negative Negative Negative 07-01640 Human t034 V Negative Negative Negative Positive Negative 07-01653 Human t034 V Negative Negative Negative Positive Negative 07-01730 Human t011 IV Negative Positive Negative Positive Negative 07-01826 Human t1197 MSSA Negative Negative Negative Negative Negative 07-01949 Horse t011 IV Negative Positive Negative Positive Negative 07-02239 Human t108 V Negative Positive Negative Negative Negative 07-02347 Human t034 nt Negative Negative Negative Positive Negative 07-02415 Pig t2974 V Negative Negative Negative Negative Negative 07-02424 Pig t011 V Negative Positive Negative Negative Negative 07-02431 Human t011 V Negative Positive Negative Negative Negative 07-02432 Human t011 V Negative Positive Negative Negative Negative 07-02433 Human t011 V Negative Negative Negative Negative Negative 07-02464 Human t034 MSSA Negative Negative Negative Positive Negative 07-02558 Human t034 V Negative Positive Negative Positive Negative 07-02632 Human t034 V Negative Negative Negative Positive Negative 07-02642 Human t034 V Negative Negative Negative Positive Negative 07-03026 Human t011 V Negative Positive Negative Negative Negative 07-03443 Pig t034 V Negative Negative Negative Positive Negative 08-00301 Pig t011 V Negative Positive Negative Negative Negative 08-00306 Human t011 V Negative Positive Negative Negative Negative 08-00307 Human t011 V Negative Positive Negative Negative Negative 08-00308 Human t011 V Negative Positive Negative Negative Negative 08-00360 Human t034 MSSA Negative Positive Negative Negative Negative 08-00401 Pig t034 V Negative Negative Negative Positive Negative 08-00537 Turkey t034 MSSA Positive Negative Negative Positive Negative 08-00543 Turkey t034 MSSA Positive Negative Negative Positive Negative 08-00700 Human t011 MSSA Negative Positive Negative Negative Negative 08-00798 Turkey t034 MSSA Positive Negative Negative Positive Negative 08-00888 Turkey t034 MSSA Positive Negative Negative Positive Negative 08-00907 Human t011 V Negative Positive Negative Negative Negative 08-00912 Pig t034 V Negative Negative Negative Positive Negative 08-01058 Human t034 MSSA Negative Negative Negative Positive Negative 08-01223 Human t034 MSSA Negative Positive Negative Positive Negative 08-01388 Human t011 V Negative Positive Negative Negative Negative 08-01605 Human t011 MSSA Negative Negative Negative Positive Negative 08-01712 Pig t011 V Negative Positive Negative Negative Negative 08-01737 Pig t011 V Negative Negative Negative Negative Negative 08-01849 Human t011 V Negative Negative Negative Negative Negative 08-02208 Human t034 V Negative Negative Negative Positive Negative 08-02418 Human t034 V Negative Negative Negative Positive Negative 08-02710 Human t034 MSSA Negative Negative Negative Positive Negative 08-02807 Human t034 V Negative Negative Negative Positive Negative 09-00339 Human t011 V Negative Positive Negative Negative Negative 09-00340-1 Horse t011 IV Negative Negative Negative Positive Negative 09-00341 Pig t011 V Negative Positive Negative Negative Negative 09-00342 Chicken (thaw water) t011 V Negative Positive Negative Negative Negative 09-00343 Horse t011 V Negative Positive Negative Negative Negative 
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09-00393 Human t034 V Negative Negative Negative Negative Negative 09-00443 Human t011 V Negative Positive Negative Negative Negative 09-00444 Human t011 V Negative Positive Negative Negative Negative 09-00445 Human t011 V Negative Positive Negative Negative Negative 09-00709 Human t034 V Negative Negative Negative Positive Negative 09-00711 Pig t034 V Negative Negative Negative Positive Negative 09-01308 Pig t034 V Negative Positive Negative Negative Negative 09-01309 Pig t034 V Negative Positive Negative Negative Negative 09-01310 Pig t034 V Negative Positive Negative Positive Negative 09-01311 Human t034 MSSA Negative Negative Positive Negative Negative 09-01312 Human t571 MSSA Negative Negative Positive Negative Negative 09-01313 Environment t034 V Negative Negative Negative Negative Negative 09-01314 Human t034 V Negative Negative Negative Positive Negative 09-01315 Human t034 V Negative Negative Negative Positive Negative 09-01316 Human t034 V Negative Positive Negative Positive Negative 09-01318 Human t034 V Negative Negative Negative Positive Negative 09-01840 Pig t034 V Negative Negative Negative Positive Negative 09-02165 Pig t034 V Negative Negative Negative Positive Negative 09-02423 Human t011 III Negative Positive Negative Negative Negative 09-02427 Dog t034 MSSA Negative Negative Negative Negative Negative 09-02428 Dog t011 IV Negative Negative Negative Positive Negative 09-02429 Dog t011 IV Negative Negative Negative Positive Negative 09-02431 Horse t1197 V Negative Negative Negative Negative Negative 09-02432 Horse t011 IV Negative Negative Negative Positive Negative 09-02434 Horse t011 V Negative Positive Negative Negative Negative 09-02435 Pig t011 V Negative Negative Negative Positive Negative 09-02436 Pig t011 IV Negative Negative Negative Negative Negative 09-02437 Pig t1457 V Negative Positive Negative Negative Negative 09-02438 Pig t011 V Negative Positive Negative Negative Negative 09-02439 Pig t1457 V Negative Positive Negative Negative Negative 09-02440 Bovine t011 IV Negative Positive Negative Negative Negative 09-02441 Bovine t571 V Negative Positive Negative Positive Negative 09-02442 Bovine t011 IV Negative Negative Negative Positive Negative 09-02444 Goat t108 V Negative Positive Negative Negative Negative 09-02476 Human t899 IV Negative Positive Negative Negative Negative 09-02477 Human t108 V Negative Positive Negative Negative Negative 09-02478 Human t899 MSSA Negative Positive Negative Negative Negative 09-02611 Human t034 V Negative Negative Negative Positive Negative 09-02615 Pig t034 V Negative Negative Negative Positive Negative 09-03220 Human t011 V Negative Positive Negative Positive Negative 09-03221 Human t034 Iva Negative Negative Negative Positive Negative 09-03222 Human t034 IV Negative Negative Negative Positive Negative 09-03223 Human t034 V Negative Negative Negative Negative Negative 09-03224 Human t034 V Negative Positive Negative Positive Negative 09-03225 Human t034 V Negative Negative Negative Positive Negative 09-03226 Human t034 IV Negative Negative Negative Positive Negative 09-03227 Human t108 V Negative Negative Negative Negative Negative 09-03229 Human t011 MSSA Negative Positive Positive Negative Negative 09-03230 Human t034 MSSA Negative Negative Negative Positive Negative 09-03231 Human t571 MSSA Negative Negative Positive Negative Negative 09-03232 Human t1451 MSSA Negative Negative Negative Negative Negative 09-03233 Human t011 V Negative Negative Negative Negative Positive 09-03234 Human t034 V Negative Positive Positive Positive Positive 09-03235 Human t108 V Negative Positive Negative Negative Positive 09-03236 Human t571 V Negative Positive Negative Positive Positive 09-03237 Human t034 IX Negative Negative Negative Positive Negative 09-03238 Human t034 X Negative Negative Negative Positive Negative 09-03323 Dog t1344 nt Negative Positive Negative Negative Negative 09-03324 Horse t011 IV Negative Positive Negative Negative Negative 09-03325-1 Horse t011 IV Negative Negative Negative Positive Negative 09-03326 Horse t011 IV Negative Negative Negative Negative Negative 09-03327 Cat t034 nt Negative Negative Negative Positive Negative 09-03329 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03330 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03331 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03332 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03333 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03334 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03335 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03336 Pig t2876 MSSA Negative Positive Negative Positive Negative 09-03337 Bovine t034 MSSA Negative Negative Negative Positive Negative 09-03339 Pig t034 V Negative Negative Negative Positive Negative 09-03340 Pig t034 V Negative Negative Negative Positive Negative 
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09-03343 Pig t034 MSSA Negative Negative Negative Positive Negative 09-03345 Pig t034 V Negative Negative Negative Positive Negative 09-03347 Pig t034 V Negative Positive Negative Positive Negative 10-01698 Horse t011 V Negative Negative Negative Negative Negative 10-02048 Human t034 MSSA Negative Positive Positive Negative Positive 10-02213-1 Horse t011 V Negative Positive Negative Negative Negative 10-02592 Goose t011 V Negative Positive Negative Negative Negative 10-02593 Goose t011 V Negative Positive Negative Negative Negative 10-02655 Chicken (thaw water) t034 V Negative Positive Negative Positive Negative 10-02658 Chicken (thaw water) t2576 V Negative Negative Negative Positive Negative 10-02693 Horse t034 V Negative Negative Negative Positive Negative 11-00014 Bovine t011 V Negative Positive Negative Negative Negative 11-00078 Human t034 MSSA Negative Positive Positive Negative Positive 11-00080 Bovine t571 MSSA Negative Positive Negative Negative Negative 11-00501 Chicken (thaw water) t034 V Negative Negative Positive Positive Negative 11-00530 Chicken (thaw water) t034 V Negative Negative Positive Positive Negative 11-00569 Chicken (thaw water) t011 V Negative Negative Negative Negative Negative 11-00571 Chicken (thaw water) t011 V Negative Positive Negative Negative Negative 11-00830 Horse t011 IV Negative Positive Negative Positive Negative 11-00833 Horse t6867 IV Negative Negative Negative Negative Negative 11-01113-1 Horse t011 IV Negative Negative Negative Positive Negative 11-01119 Horse t034 V Negative Negative Negative Positive Negative 11-01120 Horse t034 V Negative Negative Negative Positive Negative 11-01123 Horse t011 IV Negative Negative Negative Positive Negative 11-01124 Horse t034 V Negative Negative Negative Positive Negative 11-01125 Horse t011 IV Negative Positive Negative Positive Negative 11-01188 Horse t011 IV Negative Negative Negative Positive Negative 11-01189 Horse t011 IV Negative Negative Negative Positive Negative 11-01190 Horse t011 IV Negative Negative Negative Positive Negative 11-01191 Horse t011 IV Negative Negative Negative Positive Negative 11-01192 Horse t011 IV Negative Negative Negative Positive Negative 11-01550 Horse t011 IV Negative Negative Negative Positive Negative 11-01553 Horse t034 V Negative Negative Positive Positive Negative 11-01925 Horse t1451 V Negative Positive Negative Negative Negative 11-01929 Horse t011 IV Negative Negative Negative Positive Negative 11-01931 Horse t011 V Negative Positive Negative Negative Negative 11-01932 Horse t011 IV Negative Negative Negative Positive Negative 11-01937 Horse t011 IV Negative Negative Negative Positive Negative 11-01940 Horse t011 IV Negative Positive Negative Positive Negative 11-02211 Human t034 MSSA Negative Positive Positive Negative Positive 11-02277 Horse t011 IV Negative Negative Negative Positive Negative 11-02281 Horse t779 II Negative Negative Positive Positive Negative 11-02283 Horse t6867 IV Negative Negative Negative Negative Negative 11-02285 Horse t011 IV Negative Negative Negative Negative Negative 11-02287 Horse t011 IV Negative Negative Negative Negative Negative 11-02558 Horse t011 IV Negative Negative Negative Negative Negative 11-02560 Horse t011 IV Negative Negative Negative Negative Negative 11-02561 Horse t011 V Negative Positive Negative Negative Negative 11-02564 Horse t034 V Negative Negative Negative Positive Negative 11-02801 Horse t011 IV Negative Negative Positive Positive Negative 11-02802 Horse t011 IV Negative Negative Positive Positive Negative 11-02804 Horse t011 IV Negative Negative Negative Positive Negative 11-02806 Horse t011 V Negative Positive Negative Negative Negative  
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LIST OF ABBREVIATIONS 
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